Compounds > aspirin
Page last updated: 2024-10-23

aspirin and Auricular Fibrillation

aspirin has been researched along with Auricular Fibrillation in 1090 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)."10.27Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013)
"We sought to derive and internally validate a simple and easily applied clinical prediction rule to identify patients with nonvalvular atrial fibrillation (AF) whose stroke risk while taking aspirin is, irrespective of age, low enough that oral anticoagulation therapy is unnecessary."10.20A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. ( Gullov, AL; Hart, RG; Hellemons, BS; Koefed, BG; Koudstaal, PJ; Laupacis, A; Petersen, P; van Walraven, C; Wells, GA, 2003)
" Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE."9.51Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022)
"The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain."9.41A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021)
"The aim of this study was to investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) versus warfarin triple therapy in patients with atrial fibrillation and STEMI."9.41Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021)
"In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease."9.41Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021)
"It is the common clinical practice to prescribe indefinite aspirin for patients with non-valvular atrial fibrillation (NVAF) post left atrial appendage occlusion (LAAO)."9.41Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial. ( Chen, M; Chen, TZ; Li, W; Li, YG; Mo, BF; Sun, J; Tang, X; Wang, Q; Zhang, PP, 2021)
"To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes."9.34Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020)
"The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy)."9.34Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. ( Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020)
"In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)."9.30Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019)
"The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel."9.30Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019)
"Using the standard maintenance dose of prasugrel (10 mg/day) as part of triple therapy with aspirin and an oral anticoagulant (OAC) is not recommended in the current guidelines because it increases the risk of bleeding compared with clopidogrel."9.30Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention　- From the TWMU-AF PCI Registry. ( Arashi, H; Ebihara, S; Fujii, S; Hagiwara, N; Honda, A; Jujo, K; Kawamoto, T; Mori, F; Nakao, M; Ota, Y; Otsuki, H; Saito, K; Takagi, A; Tanaka, H; Tanaka, K; Yamaguchi, J; Yoshikawa, M, 2019)
"The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)."9.30Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019)
" This study investigated the effect of warfarin versus aspirin on WBV in patients presenting with non-valvular atrial fibrillation (NVAF) and acute cardioembolic stroke."9.30Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial. ( Cho, DJ; Jeong, SK; Jung, KH; Lee, CH, 2019)
"Concomitant aspirin (ASA) is often prescribed in anticoagulated patients with atrial fibrillation (AF)."9.27Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. ( Lip, GYH; Proietti, M, 2018)
"To compared the therapeutic effect of a Chinese patent medicine Naoxintong Capsule (, NXT) and aspirin with adjusted-dose warfarin in Chinese elderly patients (over 65 years) with nonvalvular atrial fibrillation (NVAF) and genetic variants of vitamin K epoxide reductase (VKORC1), who are at high-risk of thromboembolism."9.27Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. ( Chen, H; Wang, H; Wu, XY; Zheng, LF; Zhou, XK, 2018)
"To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk."9.24Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017)
"Trials investigating aspirin omission in patients taking oral anticoagulation (OAC) after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) were not powered to assess rates of major bleeding or ischemic events."9.22Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. ( Alvarez-Covarrubias, HA; Byrne, RA; Cassese, S; Colleran, R; Kastrati, A; Kuna, C; Mayer, K; Ndrepepa, G; Rai, H, 2022)
" In the AVERROES trial, we performed serial brain magnetic resonance imaging (MRI) scans in a subgroup to explore the effect of apixaban, compared with aspirin, on clinical and covert brain infarction and on microbleeds in patients with atrial fibrillation."9.22Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. ( Avezum, A; Connolly, S; Dias, R; Diener, HC; Eikelboom, JW; Flaker, G; Gladstone, DJ; Hart, RG; Lewis, G; O'Donnell, MJ; Sharma, M; Smith, EE; Yusuf, S; Zhu, J, 2016)
"The AVERROES trial name is the following: The Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial demonstrated that apixaban reduced the risk of stroke relative to aspirin, without significantly increasing major bleeding risk in patients with atrial fibrillation (AF) considered unsuitable for warfarin therapy."9.20Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial. ( Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D, 2015)
"We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases."9.20Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015)
"Apixaban was associated with fewer strokes and systemic embolism versus aspirin across all subgroups; however, it caused more major bleeding events."9.20Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. ( Dorian, P; Kongnakorn, T; Lanitis, T; Lip, GY; Mardekian, J; Phatak, H, 2015)
"The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients."9.19The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014)
"Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use."9.19Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Alexander, JH; Alings, M; Atar, D; Aylward, P; Goto, S; Granger, CB; Hanna, M; Huber, K; Husted, S; Lewis, BS; Lopes, RD; McMurray, JJ; Pais, P; Pouleur, H; Steg, PG; Thomas, L; Verheugt, FW; Wallentin, L; Wojdyla, DM, 2014)
"We randomised 238 patients with non-valvular atrial fibrillation and a moderate stroke risk to aspirin or adjusted vitamin K antagonist therapy after TEE had ruled out thrombogenic features in the atria and aorta."9.19Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study. ( Baur, LH; Cheriex, EC; Crijns, HJ; Dinh, T; Heesen, WF; Kamp, O; Lindeboom, JE; Pisters, R; Prins, MH; Smeets, JL; Tieleman, RG; Verheugt, FW, 2014)
"A total of 973 patients aged≥75 years with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (n=488; target international normalized ratio, 2-3) or aspirin (n=485; 75 mg/d)."9.19Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). ( Fitzmaurice, D; Fletcher, K; Hobbs, FD; Lip, GY; Mant, J; Mavaddat, N; Roalfe, A, 2014)
"To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients."9.19Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014)
"Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences."9.19Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014)
"The safety and efficacy of combined low dose aspirin and warfarin therapy in patients with atrial fibrillation after mechanical heart valve replacement were evaluated."9.19Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement. ( Dong, MF; Ma, SJ; Ma, ZS; Song, GM; Wang, JT, 2014)
"The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated."9.17Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013)
"In AVERROES, 5599 patients (mean age 70 years) with atrial fibrillation who were at increased risk of stroke and unsuitable for vitamin K antagonist therapy were randomly assigned to receive apixaban (5 mg twice daily) or aspirin (81-324 mg per day)."9.16Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. ( Connolly, SJ; Diener, HC; Eikelboom, J; Hankey, GJ; Hart, RG; Hohnloser, SH; Joyner, CD; Lip, GY; O'Donnell, M; Shestakovska, O; Yusuf, S, 2012)
"Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation."9.16Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012)
"Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy."9.16Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012)
"In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior."9.15Apixaban in patients with atrial fibrillation. ( Afzal, R; Avezum, A; Budaj, A; Commerford, P; Connolly, SJ; Dans, AL; Diaz, R; Diener, HC; Eikelboom, J; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Hart, R; Hohnloser, SH; Jansky, P; Joyner, C; Kim, JH; Lanas-Zanetti, F; Lawrence, J; Lewis, BS; Lewis, G; Lip, GY; Munawar, M; O'Donnell, M; Pais, P; Parkhomenko, A; Sim, KH; Talajic, M; Tan, RS; Van Mieghem, W; Yusuf, S; Zhu, J, 2011)
"Oral anticoagulants are effective at reducing stroke compared with aspirin in atrial fibrillation patients older than 75 years."9.15Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. ( Bryan, S; Fitzmaurice, D; Fletcher, K; Hobbs, FD; Jowett, S; Lip, GY; Mant, J; Roalfe, A, 2011)
"001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)."9.15Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."9.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."9.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
" However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low."9.14Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). ( Kowey, PR; Myerburg, R; Naccarelli, GV; Packer, DL; Pratt, CM; Reiffel, JA; Reiter, MJ; Waldo, AL, 2010)
"Atrial fibrillation (AF) associated to rheumatic mitral valve disease (RMVD) increases the incidence of thromboembolism (TE), with warfarin being the standard therapy, in spite of difficulties in treatment adherence and therapeutic control."9.14Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. ( Bôer, BN; Grinberg, M; Lavitola, Pde L; Oliveira, WA; Sampaio, RO; Spina, GS; Tarasoutchi, F, 2010)
"The objective was to determine the main parameters taken into account for the decision of antithrombotic treatment of atrial fibrillation (AF) by vitamin K antagonist or aspirin."9.13Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. ( Delaunay, O; Doucet, J; Gréboval-Furstenfeld, E; M'bello, L; Moirot, P; Mouton-Schleifer, D; Pesqué, T; Tavildari, A, 2008)
"Aspirin offers modest reduction in stroke in patients with atrial fibrillation."9.13Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008)
"In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation."9.13Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008)
"To investigate the effects of aspirin-omitted dual antithrombotic therapy (DAT) on myocardial infarction and stent thrombosis in non-valvular atrial fibrillation (NVAF) patients presenting with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)."9.12Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. ( Li, GQ; Liu, SM; Luo, CF; Mo, P, 2021)
"In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI)."9.12Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo ( Wang, Q; Yang, K, 2021)
"For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe."9.12Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006)
"Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy."9.12Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006)
"To investigate whether warfarin is more effective and superior to aspirin for the prevention of thromboembolism in nonvalvular atrial fibrillation in Chinese."9.12[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. ( Hu, DY; Jiang, LQ; Sun, YH; Zhang, HP, 2006)
"2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day)."9.12Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. ( Fitzmaurice, D; Fletcher, K; Hobbs, FD; Lip, GY; Mant, J; Murray, E; Roalfe, A, 2007)
"This is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with atrial fibrillation (AF)."9.12Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). ( Ezekowitz, MD; Lionetti, DA; Nagarakanti, R; Nehmiz, G; Parcham-Azad, K; Pedersen, KE; Reilly, PA; Simmers, TA; Stangier, J; Wallentin, L, 2007)
"We evaluated the short-term safety and efficacy of aspirin-plus-clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation (AF)."9.11Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. ( Cocci, F; De Caterina, R; Lazzerini, G; Lorenzoni, R, 2004)
"This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin."9.10A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002)
"Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2."9.09Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. ( Asinger, R; Blackshear, JL; Fenster, P; Halperin, J; Pearce, LA; Pennock, G; Strauss, R; Zabalgoitia, M, 1999)
"We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2."9.09Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999)
"In inhibiting platelet function, aspirin seems to reduce the risk of cerebrovascular accidents, death, and acute coronary events in patients with nonrheumatic atrial fibrillation."9.09Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. ( Barriales, V; Posada, IS, 1999)
"In the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 2) Study, we studied the rate of bleeding events associated with the incidence of thromboembolic events in patients receiving warfarin sodium, 1."9.09Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1999)
"To investigate the effectiveness of aspirin and coumarin in preventing thromboembolism in patients with non-rheumatic atrial fibrillation in general practice."9.09Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. ( Hellemons, BS; Knottnerus, JA; Langenberg, M; Lemmens, T; Lodder, J; Schouten, HJ; van Ree, JW; Vermeer, F, 1999)
"A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years."9.09Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000)
"Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation."9.09Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
"Warfarin is effective in preventing thromboembolism in patients with atrial fibrillation, but aspirin is frequently used as an alternative treatment."9.09[Risk factors for thromboembolism in patients with atrial fibrillation during treatment with aspirin: a multicenter, cooperative retrospective study. Research Group for Antiarrhythmic Drug Therapy]. ( , 2000)
"The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients."9.09Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001)
"The Stroke Prevention in Atrial Fibrillation II study compared the efficacy and safety of aspirin and warfarin in patients with atrial fibrillation."9.08Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. ( Anderson, DC; Feinberg, WM; Hart, RG; Miller, VT; Pearce, LA; Rothrock, JF, 1996)
" Combined warfarin and aspirin therapy was associated with greater fecal hemoglobin excretion than standard warfarin therapy, suggesting the potential for increased gastrointestinal hemorrhage."9.08Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. ( Ahlquist, DA; Baker, VS; Blackshear, JL; Ellefson, R; Hart, RG; Holland, A; Koehler, J; Litin, SC, 1996)
"Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF)."9.08Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. ( , 1996)
"The Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled trial examining the following therapies: warfarin sodium, 1."9.08Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. ( Andersen, ED; Boysen, G; Godtfredsen, J; Gulløv, AL; Koefoed, BG; Pedersen, TS; Petersen, P, 1998)
"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand."9.07A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. ( Chaithiraphan, S; Opartkiattikul, N; Poungvarin, N; Viriyavejakul, A, 1994)
"Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation, but the value of this agent relative to aspirin in unclear."9.07Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. ( , 1994)
"The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) demonstrated that low-intensity warfarin anticoagulation can, with safety, sharply reduce the rate of stroke in patients with nonvalvular atrial fibrillation."9.07Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. ( Barzegar, S; Bauer, KA; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Millenson, MM; Oertel, LB; Sheehan, MA; Singer, DE, 1993)
"Although warfarin and perhaps aspirin may be effective in preventing thromboembolism in patients with nonvalvular atrial fibrillation, some patients develop cerebral infarction despite these therapies."9.07Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. ( Brace, LD; Helgason, CM; Hoff, JA; Kondos, GT, 1993)
"Recent randomized trials have consistently demonstrated the marked efficacy of warfarin in reducing the risk of stroke caused by nonrheumatic atrial fibrillation."9.07The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1992)
"Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring."9.06The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1990)
"From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo."9.06Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. ( Andersen, B; Andersen, ED; Boysen, G; Godtfredsen, J; Petersen, P, 1989)
"Recently, three randomized trials reported that dual antithrombotic treatments (DATs) including non-vitamin K antagonist oral anticoagulants (NOACs) and a P2Y12 inhibitor without aspirin were associated with significantly less bleeding than vitamin K antagonist (VKA)-based triple antithrombotic therapy (TAT) in atrial fibrillation (AF) patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)."9.05Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr ( Collet, JP; Dagres, N; Heidbuchel, H; Hindricks, G; Lip, GYH; Mujovic, N; Potpara, TS; Proietti, M; Valgimigli, M, 2020)
"A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety."9.05Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. ( Georgiopoulos, G; Korompoki, E; Leventis, I; Lip, GYH; Makaritsis, K; Milionis, H; Ntaios, G; Sagris, D; Vemmos, K, 2020)
"A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome."8.98Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018)
"Despite its lack of efficacy, aspirin is commonly used for stroke prevention in atrial fibrillation."8.91Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. ( Gándara, E; Gonzalez, JP; Vazquez, FJ, 2015)
"Until recently, pharmaceutical options for stroke prevention in atrial fibrillation were restricted to aspirin or vitamin K antagonist therapy."8.88Apixaban for the prevention of stroke in atrial fibrillation. ( Flaker, G; Littrell, R, 2012)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."8.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin."8.87Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011)
"Warfarin for stroke prevention in patients with atrial fibrillation (AF) is well documented."8.84Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. ( Andersen, LV; Deichgraeber, P; Frost, L; Lindholt, JS; Mortensen, LS; Vestergaard, P, 2008)
"To compare the effectiveness of aspirin, warfarin, and ximelagatran as thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF)."8.83Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. ( Edwards, SJ; Lip, GY, 2006)
"Current guidelines relating to the primary prevention of stroke in non-valvular atrial fibrillation are primarily based on randomised trials comparing warfarin with placebo."8.82[Choice of antithrombotic therapy in atrial fibrillation, a daily challenge. No convincing evidence that warfarin is better than acetylsalicylic acid]. ( Mooe, T, 2003)
"Individual patient data of patients who received aspirin or placebo after cerebral ischemia were obtained from 9 clinical trials."8.82Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. ( Algra, A; Ariesen, MJ; Koudstaal, PJ; Rothwell, PM; van Walraven, C, 2004)
"Warfarin has been in routine clinical use for more than 50 years; however, it was not proven to be of benefit in both primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (AF) until about a decade ago."8.82Warfarin for atrial fibrillation: the end of an era? ( Chambers, BR; Dewey, HM; Donnan, GA, 2004)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."8.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)."8.81Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002)
" Anticoagulant therapy with warfarin is now established as effective thromboprophylaxis against stroke in atrial fibrillation, in high-risk persons."8.79Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. ( Lip, GY; Lowe, GD, 1996)
" Although aspirin use seemed particularly effective in younger patients and in those with hypertension in the Stroke Prevention in Atrial Fibrillation 1 Study, this was not the case in the other studies."8.79The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. ( , 1997)
"AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospitalizations, and similar ischemic events than regimens including a vitamin K antagonist (VKA), aspirin, or both."8.02Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. ( Dhanda, D; Di Fusco, M; Kang, A; Kongnakorn, T; Polanco, C; Rivolo, S; Savone, M; Skandamis, A; Soto, J, 2021)
" The purpose of this study was to evaluate the incidence of major bleeding and thromboembolic events (TEs) in patients with atrial fibrillation (AF) receiving warfarin alone (monotherapy group) versus warfarin plus aspirin (combination therapy group)."8.02Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation. ( Afzal, M; Davidson, E; Li, J; Nagaraj, TA; Snider, MJ; Weiss, R, 2021)
"The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events."7.96Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020)
"In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone."7.96Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort. ( George, J; Hafeez, A; Halalau, A; Keeney, S; Matka, M; Said, A, 2020)
"In patients with atrial fibrillation, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care after percutaneous coronary intervention (PCI)."7.96Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. ( Aksoy, F; Altınbaş, A; Bağcı, A; Baş, HA; Varol, E, 2020)
"The biomarkers in the ABC-bleeding risk score (growth differentiation factor 15, hemoglobin, and troponin) were measured in blood samples collected at randomization between 2006 and 2010 in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial and between 2005 and 2009 in the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial, both of which were multinational randomized clinical trials."7.96Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. ( Alexander, JH; Alings, M; De Caterina, R; Eikelboom, JW; Ezekowitz, MD; Granger, CB; Held, C; Hijazi, Z; Huber, K; Hylek, EM; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Vinereanu, D; Wallentin, L, 2020)
"Comparative gastrointestinal bleeding (GIB) risk between rivaroxaban and low-dose aspirin is unknown in patients with atrial fibrillation (AF)."7.96Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study. ( Bell, JS; Chan, EW; Darzins, P; Fanning, L; Ilomaki, J; Lau, WCY; Leung, WK; Li, X; Man, KKC; Mongkhon, P; Wei, L; Wong, ICK, 2020)
"Despite international treatment guidelines currently advocating oral anticoagulants (OACs) as the only appropriate stroke prevention therapy for patients with atrial fibrillation (AF) and evidence that OACs can greatly reduce the risk of stroke with similar risk of bleeding compared with aspirin, the underuse of OACs in patients with AF is common globally, especially in Asia."7.96Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study. ( Chiu, PKC; Jamieson, E; Kng, CPL; Lam, MPS; Ng, VWS; Siu, CW; Wong, ICK, 2020)
" Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular atrial fibrillation (NVAF)."7.91Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. ( Arachchillage, DRJ; Farag, M; Gorog, DA; Gue, Y; Lip, GYH; Spinthakis, N; Srinivasan, M; Wellsted, D, 2019)
"Background As an alternative to vitamin K antagonist and low-dose aspirin (< 325 mg), non-vitamin K oral anticoagulants are available for the prevention of stroke in patients with atrial fibrillation."7.91Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. ( Burden, A; de Boer, A; de Vries, F; Gieling, E; Kramers, C; Ten Cate, V; van Onzenoort, HAW; Williams, R, 2019)
"This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan."7.91Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019)
"Compared with warfarin monotherapy, receipt of combination warfarin and aspirin therapy was associated with increased bleeding and similar observed rates of thrombosis."7.91Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. ( Almany, SL; Barnes, GD; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Sood, SL; Souphis, NM, 2019)
"We investigated whether the use of aspirin (irreversible COX1 inhibitor) in the preoperative period may prevent non-valvular atrial fibrillation, which is the most common rhythm problem in the postoperative period."7.91The Effect of Aspirin as an Irreversible COX1 Inhibitor in Preventing Non-Valvular Atrial Fibrillation After Coronary Bypass Surgery. ( Ates, A; Erkut, B, 2019)
"Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk."7.88Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018)
"This study sought to assess safety and effectiveness of low-dose aspirin in heart failure (HF) not complicated by atrial fibrillation."7.88Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study. ( Bjerre, J; D'Souza, M; Fosbøl, EL; Gislason, G; Gustafsson, F; Kober, L; Kristensen, SL; Madelaire, C; Schou, M; Torp-Pedersen, C, 2018)
"The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events."7.85Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. ( Eckman, MH; So, CH, 2017)
"To determine the clinical and cost effectiveness of apixaban compared to aspirin in the prevention of thromboembolic events for patients with atrial fibrillation for whom vitamin K antagonist (VKA) therapy (warfarin) has been considered unsuitable."7.85Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective. ( Ademi, Z; Liew, D; Pasupathi, K, 2017)
"Based on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon."7.85Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. ( Athanasakis, K; Bilitou, A; Boubouchairopoulou, N; Karampli, E; Kyriopoulos, J; Savvari, P; Tarantilis, F, 2017)
"Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K antagonists (VKA) and aspirin."7.85Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. ( Bos, J; Burden, AM; de Boer, A; de Vries, F; Gieling, EM; Kramers, C; van den Ham, HA; van Onzenoort, H, 2017)
"We conducted a post hoc ancillary analysis of clinically relevant bleeding and major bleeding events among 2293 patients receiving warfarin therapy in the AMADEUS trial."7.83Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. ( Lane, DA; Lip, GY; Proietti, M; Senoo, K, 2016)
"A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban."7.83Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016)
"Concomitant use of vitamin K antagonist (VKA) and aspirin (ASA) is becoming increasingly prevalent among atrial fibrillation (AF) patients."7.83Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. ( Atarashi, H; Chishaki, A; Inoue, H; Kiyono, K; Kodama, I; Kodani, E; Lip, GY; Okumura, K; Okuyama, Y; Origasa, H; Watanabe, E; Yamamoto, M; Yamashita, T, 2016)
"This model demonstrates that increased use of rivaroxaban in inadequately-managed NVAF patients could avoid 456 081 non-fatal ischemic strokes (IS) and 76 975 cardiovascular deaths over 10 years in Japan."7.83Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. ( Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E, 2016)
"Oral anticoagulation (OAC), rather than aspirin, is recommended in patients with atrial fibrillation (AF) at moderate to high risk of stroke."7.83Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. ( Gehi, AK; Hsu, JC; Katz, DF; Kennedy, K; Lubitz, SA; Maddox, TM; Marcus, GM; Marzec, LN; Turakhia, MP, 2016)
"To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control."7.83Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. ( Björck, F; Lip, GY; Renlund, H; Själander, A; Svensson, PJ; Wester, P, 2016)
"Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear."7.83Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016)
"Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD."7.83Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016)
" We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy."7.81Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015)
"Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)."7.81Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)
"Aspirin use increased among Chinese patients newly diagnosed with AF, with no relationship to the patient's stroke or bleeding risk."7.81Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. ( Guo, Y; Lip, GYH; Tian, Y; Wang, H; Wang, Y, 2015)
" We studied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc risk factor; 23,572 were not treated, 5,353 were initiated on aspirin, and 10,475 were initiated on warfarin."7.81Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2015)
"Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke."7.81Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015)
"We aimed to study differences in the prescribing of warfarin, aspirin and statins to patients with atrial fibrillation (AF) in socio-economically diverse neighborhoods."7.81Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. ( Carlsson, AC; Gasevic, D; Sundquist, J; Sundquist, K; Wändell, P, 2015)
"Long-term warfarin therapy has been used to decrease thromboembolic events in patients with atrial fibrillation (AF) following bioprosthetic mitral valve replacement (BMVR) and left atrial appendage obliteration (LAAO)."7.81Is long-term warfarin therapy necessary in Chinese patients with atrial fibrillation after bioprosthetic mitral valve replacement and left atrial appendage obliteration? ( Gao, C; Jiang, S; Ren, C; Zhang, L, 2015)
"The purpose of this study was to investigate whether aspirin use can be captured from the clinical notes in a nonvalvular atrial fibrillation population."7.81Medication Extraction from Electronic Clinical Notes in an Integrated Health System: A Study on Aspirin Use in Patients with Nonvalvular Atrial Fibrillation. ( An, J; Koblick, R; Rashid, N; Zheng, C, 2015)
"Atrial fibrillation (AF) increases risk of stroke, and although this stroke risk can be ameliorated by warfarin therapy, some patients decline to adhere to warfarin therapy."7.81Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. ( Arellano, AR; Bare, LA; Devlin, JJ; Louie, JZ; Perez, MV; Shiffman, D, 2015)
"An 80-year-old female with a history of hypertension and atrial fibrillation had been receiving warfarin anticoagulant therapy and had stably maintained an international normalized ratio (INR) within the 2."7.81Hemoptysis due to aspirin treatment alternative to warfarin therapy in a patient with atrial fibrillation. ( Cao, J; Cui, X; Han, Z; Song, W; Wen, H; Xu, Y, 2015)
"In patients with both stable coronary disease and atrial fibrillation, a baseline treatment of aspirin and an oral anticoagulant is often prescribed due to the proven benefits of each therapy on cardiovascular and thromboembolic events and mortality."7.81[Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?]. ( Lister, K; Louis Simonet, M, 2015)
" Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin."7.80Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014)
"To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective."7.80Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014)
"Apixaban was found to be a cost-effective alternative to warfarin and aspirin for stroke prevention in patients with AF in Sweden."7.80Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. ( De Geer, A; Jacobson, L; Kongnakorn, T; Lanitis, T, 2014)
"Inflammatory processes have been associated with an increased risk of atrial fibrillation (AF), potentially allowing for preventive therapy by anti-inflammatory agents such as aspirin."7.80Aspirin use and risk of atrial fibrillation in the Physicians' Health Study. ( Albert, CM; Djousse, L; Gaziano, JM; Hoffmeister, P; Ofman, P; Peralta, A; Petrone, AB; Rahilly-Tierney, CR, 2014)
"Evidence indicates that vitamin K antagonists (VKAs) and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non-valvular atrial fibrillation (AF), and patients who decline or cannot tolerate such treatment are often prescribed aspirin instead."7.80Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. ( Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014)
" The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities."7.80Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2014)
"To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal."7.80Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. ( Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S, 2014)
"A 73-yr-old Korean man with permanent atrial fibrillation visited outpatient clinic with severely increased International Normalized Ratio (INR) values after taking a usual starting dosage of warfarin to prevent thromboembolism."7.80Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. ( Jeong, HJ; Jun, JE; Kim, JH; Kim, JS; Lee, JE; Lee, SY; Ryu, DH, 2014)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."7.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"Aspirin is one of the preferred therapies in the primary prevention of ischemic stroke in paroxysmal atrial fibrillation (PAF)."7.79The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation. ( Colkesen, Y; Coskun, I; Muderrisoglu, H, 2013)
"the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin."7.78Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. ( O'Shea, D; Romero-Ortuno, R, 2012)
"Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable."7.78Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012)
"As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)."7.78A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012)
"Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF) patients unsuitable for warfarin by 63% but does not increase major bleeding."7.78Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. ( Anglade, MW; Coleman, CI; Hagstrom, K; Kluger, J; Lee, S; Meng, J, 2012)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."7.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"The authors investigated the use of warfarin at hospital discharge in 557 consecutive patients, mean age 76 years, with nonvalvular atrial fibrillation (AF) at a university hospital."7.76Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin. ( Aronow, WS; Bakerywala, S; Desai, HV; Gandhi, K; Laimuanpuii, J; Peterson, SJ; Sharma, M, 2010)
"The objective of this study was to evaluate the rate of stroke associated with aspirin and warfarin in routine clinical practice."7.75How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ( Gallagher, AM; Plumb, JM; Rietbrock, S; van Staa, TP, 2009)
"Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings."7.75Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009)
"Patients from SPORTIF III (n=3407) and SPORTIF V (n=3922) trials were categorized by prior stroke/TIA (21%) versus no prior stroke/TIA (79%) and by treatment group (ximelagatran vs warfarin)."7.74Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. ( Akins, PT; Albers, GW; Diener, HC; Feldman, HA; Newman, D; Spitzer, SG; Zoble, RG, 2007)
"To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage."7.74Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007)
"Using prescriptions for digoxin as a surrogate for atrial fibrillation, we identified its coprescription with antithrombotic therapy, aspirin or warfarin in a national prescribing database in 27 571 patients over 45 years old."7.74National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. ( Bennett, K; Feely, J; Mahmud, A; Okechukwu, I, 2007)
"Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year."7.74[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. ( Ataullakhanova, DM; Bykova, ES; Dobrovol'skiĭ, AB; Kropacheva, ES; Panchenko, EP; Titaeva, EV; Zharkova, TV, 2007)
"To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin."7.73Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ( Gage, BF; O'Brien, CL, 2005)
"To determine the effect of access to ambulatory anticoagulation management services (AMS) on the rate of warfarin use in patients with atrial fibrillation."7.73Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. ( Burkiewicz, JS, 2005)
"Warfarin can be more effective than aspirin for stroke prevention in elderly patients with atrial fibrillation, but in clinical practice, the usage rate of warfarin still remains low with insufficient monitoring."7.73[Comparative study of warfarin and aspirin for stroke prevention in elderly patients with atrial fibrillation]. ( Han, W; Shen, DT; Wang, YM, 2006)
"Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available."7.73Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006)
"In part III of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors present data on clinical pharmacology of aspirin as well as discussion of results of randomized trials in which cerebroprotective efficacy and safety of the use of aspirin for primary and secondary prevention of thromboembolism was studied in comparison with placebo and warfarin."7.72[Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Aspirin]. ( Batyraliev, TA; Kiktev, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2004)
"The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF."7.72Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). ( Benjamin, EJ; D'Agostino, RB; Lambert, JW; Levy, D; Massaro, JM; Sam, C; Wolf, PA, 2004)
"170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation."7.72Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. ( Chang, Y; Fang, MC; Go, AS; Greenberg, SM; Hylek, EM; Rosand, J; Singer, DE, 2004)
"To investigate the incidence of new thromboembolic (TE) stroke in older persons with chronic atrial fibrillation treated with oral warfarin versus aspirin."7.70Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. ( Ahn, C; Aronow, WS; Gutstein, H; Kronzon, I, 1999)
"56 patients had previously diagnosed atrial fibrillation; 82% were not taking warfarin and 71% of these were not on aspirin either."7.70Additional risk factors in atrial fibrillation patients not receiving warfarin. ( Caine, S; Keir, S; Mac Mahon, M; Wensley, S, 1999)
"The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established."7.70Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000)
"The recommended treatment of ischaemic stroke patients with atrial fibrillation (AF) is anticoagulation therapy with warfarin sodium and if this is contraindicated then aspirin should be used."7.70Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. ( Craig, J; Goudie, BM; MacWalter, RS, 2000)
"To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease)."7.69Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. ( Albers, GW; Cardinalli, AB; Gage, BF; Owens, DK, 1995)
"Aspirin 330/mg/day suppressed platelet function in patients with atrial fibrillation, although it did not affect the increased coagulation activity in these patients."7.69Effects of aspirin on status of thrombin generation in atrial fibrillation. ( Fukazawa, H; Ikeda, U; Shimada, K; Yamamoto, K, 1996)
"Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation."7.68Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. ( Hayashi, Y; Nakahama, H; Nakanishi, T; Shimizu, S; Sugita, M; Takiguchi, A; Uyama, O; Yamamoto, S, 1992)
"The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events."6.87An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018)
" It is impossible to exclude that long term administration of warfarin in strategy of sinus rhythm maintenance attenuated advantages of normal rhythm in relation of lowering of stroke risk in AFFIRM study and other similar works."6.73[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin]. ( Kanorskiĭ, SG; Shevelev, VI; Zafiraki, VK; Zingilevskiĭ, KB, 2007)
"Bleedings were documented in 19 versus four patients (W/A 5."6.71Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Omblus, R; Pehrsson, K, 2003)
"Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making."6.58Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018)
"5, and aspirin was administered at a dosage of 75 to 325 mg/d."6.52Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015)
"The prevention of thromboembolism is an important component in the management of patients with atrial fibrillation."6.45[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?]. ( Bergmann, C; Krpciar, V; Rose, E; Vetter, S; Volkmann, H; Walter, M, 2009)
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)."6.27Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013)
"We sought to derive and internally validate a simple and easily applied clinical prediction rule to identify patients with nonvalvular atrial fibrillation (AF) whose stroke risk while taking aspirin is, irrespective of age, low enough that oral anticoagulation therapy is unnecessary."6.20A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. ( Gullov, AL; Hart, RG; Hellemons, BS; Koefed, BG; Koudstaal, PJ; Laupacis, A; Petersen, P; van Walraven, C; Wells, GA, 2003)
"To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups."6.19Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. ( Chen, ZM; Collins, R; Counsell, C; Liu, LS; Pan, HC; Peto, R; Sandercock, P; Warlow, C; Xie, JX, 2000)
" The risk of bleeding during anticoagulant therapy has been evaluated in 10 recent studies of warfarin treatment for the prevention of arterial thromboembolism."6.17[Bleeding complications in oral anticoagulant treatment]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1995)
"Seven randomized studies during the past 5 years have evaluated or are evaluating the efficacy of warfarin or aspirin or both in decreasing the risk of embolic events in patients with nonrheumatic atrial fibrillation."6.16How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. ( Cairns, J; Connolly, SJ; Gent, M; Joyner, C; Laupacis, A; Roberts, RS, 1991)
"A multicenter randomized controlled trial (OPtimal management of anTIthroMbotic Agents [OPTIMA]-4) is designed to test the hypothesis that, for ACS patients with concomitant nonvalvular atrial fibrillation (NVAF) and having low-to-moderate risk of bleeding, clopidogrel is comparable in efficacy but superior in safety compared to ticagrelor while being used in combination with dabigatran after new-generation drug-eluting stent (DES) implantation."5.69Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial. ( Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023)
" Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE."5.51Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022)
"To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil."5.51Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption. ( Kowacs, PA; Macuco, ALB; Nascimento, MTMS; Rizelio, V; Sato, HK; Souza, RKM, 2019)
"When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata."5.42Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. ( Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2015)
"Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin."5.41Apixaban for Anticoagulation After Robotic Mitral Valve Repair. ( Arghami, A; Crestanello, JA; Daly, RC; Dearani, JA; King, KS; Macielak, SA; Mazur, PK; Nei, SD; Schaff, HV; Viehman, JK, 2023)
"The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain."5.41A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021)
"The aim of this study was to investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) versus warfarin triple therapy in patients with atrial fibrillation and STEMI."5.41Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021)
"In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease."5.41Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021)
"It is the common clinical practice to prescribe indefinite aspirin for patients with non-valvular atrial fibrillation (NVAF) post left atrial appendage occlusion (LAAO)."5.41Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial. ( Chen, M; Chen, TZ; Li, W; Li, YG; Mo, BF; Sun, J; Tang, X; Wang, Q; Zhang, PP, 2021)
"We evaluated patients from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial who received rivaroxaban plus an antiplatelet agent; the choice of antiplatelet agent was left to the physician's discretion."5.41Aspirin versus P2Y ( Akao, M; Ako, J; Fukaya, H; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamra, M; Ogawa, H; Yasuda, S, 2021)
"Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA₂DS₂-VASc score≥2."5.40Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. ( Choi, KJ; Joung, B; Kim, YH; Lee, MH; Nam, GB; Pak, HN; Uhm, JS; Won, H, 2014)
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."5.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
" In patients considered at moderate risk, the choice is now possible between VKA and aspirin, with a reduced dosage of aspirin (75 to 325 mg)."5.35[Indications of vitamin K antagonists and aspirin in the atrial fibrillation of the elderly]. ( Estivin, S; Gentric, A; Jestin, C, 2009)
"To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes."5.34Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020)
"In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy."5.34A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. ( Baldus, S; Dangas, GD; De Backer, O; Gilard, M; Giustino, G; Guimarães, AHC; Gullestad, L; Herrmann, HC; Kini, A; Mack, M; Makkar, RR; Mehran, R; Möllmann, H; Moreno, R; Schäfer, U; Seeger, J; Søndergaard, L; Tchétché, D; Thomitzek, K; Tijssen, JGP; Valgimigli, M; van Amsterdam, RGM; Volkl, AA; von Lewinski, D; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Wöhrle, J; Zazula, A, 2020)
"The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy)."5.34Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. ( Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020)
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."5.33Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005)
"In a multicenter, open-label trial conducted in Japan, we randomly assigned 2236 patients with atrial fibrillation who had undergone percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) more than 1 year earlier or who had angiographically confirmed coronary artery disease not requiring revascularization to receive monotherapy with rivaroxaban (a non-vitamin K antagonist oral anticoagulant) or combination therapy with rivaroxaban plus a single antiplatelet agent."5.30Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2019)
"In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)."5.30Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019)
" In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2."5.30Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019)
"The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel."5.30Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019)
"Using the standard maintenance dose of prasugrel (10 mg/day) as part of triple therapy with aspirin and an oral anticoagulant (OAC) is not recommended in the current guidelines because it increases the risk of bleeding compared with clopidogrel."5.30Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention　- From the TWMU-AF PCI Registry. ( Arashi, H; Ebihara, S; Fujii, S; Hagiwara, N; Honda, A; Jujo, K; Kawamoto, T; Mori, F; Nakao, M; Ota, Y; Otsuki, H; Saito, K; Takagi, A; Tanaka, H; Tanaka, K; Yamaguchi, J; Yoshikawa, M, 2019)
"The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)."5.30Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019)
" This study investigated the effect of warfarin versus aspirin on WBV in patients presenting with non-valvular atrial fibrillation (NVAF) and acute cardioembolic stroke."5.30Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial. ( Cho, DJ; Jeong, SK; Jung, KH; Lee, CH, 2019)
"Concomitant aspirin (ASA) is often prescribed in anticoagulated patients with atrial fibrillation (AF)."5.27Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. ( Lip, GYH; Proietti, M, 2018)
"The objective was to assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent atrial arrhythmias for at least 1 year after their most recent AF ablation procedure."5.27The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. ( Birnie, DH; Champagne, J; Essebag, V; Gupta, D; Ha, ACT; Healey, JS; Heidbuchel, H; Hill, MD; Hindricks, G; Kirchhof, P; Sanders, P; Sharma, M; Verma, A; Wells, G; Wyse, DG, 2018)
"To compared the therapeutic effect of a Chinese patent medicine Naoxintong Capsule (, NXT) and aspirin with adjusted-dose warfarin in Chinese elderly patients (over 65 years) with nonvalvular atrial fibrillation (NVAF) and genetic variants of vitamin K epoxide reductase (VKORC1), who are at high-risk of thromboembolism."5.27Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. ( Chen, H; Wang, H; Wu, XY; Zheng, LF; Zhou, XK, 2018)
" We identified patients with ICH from the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received ≥1 dose of the study drug (n = 18 140)."5.24Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. ( Al-Khatib, SM; Alexander, JH; Bushnell, CD; Diener, HC; Easton, JD; Gabriel Melo de Barros E Silva, P; Granger, CB; Guimarães, PO; Hanna, M; Held, C; Kolls, BJ; Lopes, RD; Thomas, L; Wallentin, L; Wojdyla, DM, 2017)
"To elucidate the efficacy and safety between aspirin and clopidogrel, a multicenter randomized controlled trial was designed in AF patients with low stroke risk."5.24Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial. ( Bang, CS; Hong, KS; Hong, MK; Jeong, H; Jung, MH; Kim, CY; Park, SM, 2017)
"The Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6 ) trial tests whether oral anticoagulation with edoxaban is superior to prevent the primary efficacy outcome of stroke or cardiovascular death compared with aspirin or no antithrombotic therapy based on evidence-based indications."5.24Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. ( Blank, BF; Calvert, M; Camm, AJ; Chlouverakis, G; Diener, HC; Goette, A; Huening, A; Kirchhof, P; Lip, GYH; Simantirakis, E; Vardas, P, 2017)
"Trials investigating aspirin omission in patients taking oral anticoagulation (OAC) after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) were not powered to assess rates of major bleeding or ischemic events."5.22Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. ( Alvarez-Covarrubias, HA; Byrne, RA; Cassese, S; Colleran, R; Kastrati, A; Kuna, C; Mayer, K; Ndrepepa, G; Rai, H, 2022)
"compared with aspirin, apixaban was more efficacious for preventing strokes and systemic embolism in patients ≥85 years (absolute rate [AR] 1%/year on apixaban versus 7."5.22Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. ( Avezum, A; Connolly, SJ; Diaz, R; Eikelboom, JW; Hart, RG; Lanas, F; Ng, KH; Shestakovska, O; Yusuf, S, 2016)
" In the AVERROES trial, we performed serial brain magnetic resonance imaging (MRI) scans in a subgroup to explore the effect of apixaban, compared with aspirin, on clinical and covert brain infarction and on microbleeds in patients with atrial fibrillation."5.22Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. ( Avezum, A; Connolly, S; Dias, R; Diener, HC; Eikelboom, JW; Flaker, G; Gladstone, DJ; Hart, RG; Lewis, G; O'Donnell, MJ; Sharma, M; Smith, EE; Yusuf, S; Zhu, J, 2016)
"The AVERROES trial name is the following: The Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial demonstrated that apixaban reduced the risk of stroke relative to aspirin, without significantly increasing major bleeding risk in patients with atrial fibrillation (AF) considered unsuitable for warfarin therapy."5.20Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial. ( Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D, 2015)
"We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases."5.20Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015)
"This prospective, randomized, multicenter study is going to assess the hypothesis that in persistent or permanent AF patients (score of CHA₂DS₂VASc≥2) after PCI-eS, the combination therapy of oral anticoagulation (warfarin) and ticagrelor (90 mg/bid) could reduce the risk of bleeding events."5.20Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. ( Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P, 2015)
"Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction."5.20Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015)
"Apixaban was associated with fewer strokes and systemic embolism versus aspirin across all subgroups; however, it caused more major bleeding events."5.20Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. ( Dorian, P; Kongnakorn, T; Lanitis, T; Lip, GY; Mardekian, J; Phatak, H, 2015)
"The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients."5.19The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014)
"Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use."5.19Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Alexander, JH; Alings, M; Atar, D; Aylward, P; Goto, S; Granger, CB; Hanna, M; Huber, K; Husted, S; Lewis, BS; Lopes, RD; McMurray, JJ; Pais, P; Pouleur, H; Steg, PG; Thomas, L; Verheugt, FW; Wallentin, L; Wojdyla, DM, 2014)
"We randomised 238 patients with non-valvular atrial fibrillation and a moderate stroke risk to aspirin or adjusted vitamin K antagonist therapy after TEE had ruled out thrombogenic features in the atria and aorta."5.19Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study. ( Baur, LH; Cheriex, EC; Crijns, HJ; Dinh, T; Heesen, WF; Kamp, O; Lindeboom, JE; Pisters, R; Prins, MH; Smeets, JL; Tieleman, RG; Verheugt, FW, 2014)
"The AVERROES double-blinded, randomized trial demonstrated that apixaban reduces the risk of stroke or systemic embolism (SSE) by 55% compared with aspirin without an increase in major bleeding in patients with atrial fibrillation either who previously tried but failed vitamin K antagonists (VKA) therapy or who were expected to be unsuitable for VKA therapy."5.19Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. ( Connolly, SJ; Coppens, M; Eikelboom, JW; Shestakovska, O; Synhorst, D; Yusuf, S, 2014)
"A total of 973 patients aged≥75 years with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (n=488; target international normalized ratio, 2-3) or aspirin (n=485; 75 mg/d)."5.19Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). ( Fitzmaurice, D; Fletcher, K; Hobbs, FD; Lip, GY; Mant, J; Mavaddat, N; Roalfe, A, 2014)
"To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients."5.19Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014)
"Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences."5.19Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014)
"The safety and efficacy of combined low dose aspirin and warfarin therapy in patients with atrial fibrillation after mechanical heart valve replacement were evaluated."5.19Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement. ( Dong, MF; Ma, SJ; Ma, ZS; Song, GM; Wang, JT, 2014)
"We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score."5.17The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013)
"The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation."5.17Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. ( Buchbinder, M; Doshi, SK; Halperin, JL; Holmes, D; Huber, K; Neuzil, P; Reddy, VY; Sievert, H, 2013)
"The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated."5.17Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013)
"In AVERROES, 5599 patients (mean age 70 years) with atrial fibrillation who were at increased risk of stroke and unsuitable for vitamin K antagonist therapy were randomly assigned to receive apixaban (5 mg twice daily) or aspirin (81-324 mg per day)."5.16Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. ( Connolly, SJ; Diener, HC; Eikelboom, J; Hankey, GJ; Hart, RG; Hohnloser, SH; Joyner, CD; Lip, GY; O'Donnell, M; Shestakovska, O; Yusuf, S, 2012)
"Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation."5.16Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012)
"Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy."5.16Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012)
"In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior."5.15Apixaban in patients with atrial fibrillation. ( Afzal, R; Avezum, A; Budaj, A; Commerford, P; Connolly, SJ; Dans, AL; Diaz, R; Diener, HC; Eikelboom, J; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Hart, R; Hohnloser, SH; Jansky, P; Joyner, C; Kim, JH; Lanas-Zanetti, F; Lawrence, J; Lewis, BS; Lewis, G; Lip, GY; Munawar, M; O'Donnell, M; Pais, P; Parkhomenko, A; Sim, KH; Talajic, M; Tan, RS; Van Mieghem, W; Yusuf, S; Zhu, J, 2011)
"Oral anticoagulants are effective at reducing stroke compared with aspirin in atrial fibrillation patients older than 75 years."5.15Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. ( Bryan, S; Fitzmaurice, D; Fletcher, K; Hobbs, FD; Jowett, S; Lip, GY; Mant, J; Roalfe, A, 2011)
"001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)."5.15Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011)
"Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage."5.15Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011)
"Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead."5.14Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
" However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low."5.14Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). ( Kowey, PR; Myerburg, R; Naccarelli, GV; Packer, DL; Pratt, CM; Reiffel, JA; Reiter, MJ; Waldo, AL, 2010)
" In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5."5.14Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010)
"Atrial fibrillation (AF) associated to rheumatic mitral valve disease (RMVD) increases the incidence of thromboembolism (TE), with warfarin being the standard therapy, in spite of difficulties in treatment adherence and therapeutic control."5.14Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. ( Bôer, BN; Grinberg, M; Lavitola, Pde L; Oliveira, WA; Sampaio, RO; Spina, GS; Tarasoutchi, F, 2010)
"The objective was to determine the main parameters taken into account for the decision of antithrombotic treatment of atrial fibrillation (AF) by vitamin K antagonist or aspirin."5.13Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. ( Delaunay, O; Doucet, J; Gréboval-Furstenfeld, E; M'bello, L; Moirot, P; Mouton-Schleifer, D; Pesqué, T; Tavildari, A, 2008)
"In a posthoc analysis, the TTRs of patients on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE W]) were used to calculate the mean TTR for each of 526 centers and 15 countries."5.13Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. ( Commerford, P; Connolly, SJ; Eikelboom, J; Flaker, G; Franzosi, MG; Healey, JS; Pogue, J; Yusuf, S, 2008)
"We extended the follow-up of 2473 patients from the Dutch TIA Trial (recruitment March 1986 to March 1989, all treated with aspirin; CIAO) and 186 Dutch participants of the European Atrial Fibrillation Trial (recruitment June 1988 to May 1992, 26% on anticoagulants during the trial; CIAF)."5.13Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event. ( Algra, A; Gorter, JW; Kappelle, LJ; Koudstaal, PJ; van Gijn, J; van Wijk, I, 2008)
"Aspirin offers modest reduction in stroke in patients with atrial fibrillation."5.13Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. ( Berger, PB; Bhatt, DL; Fox, KA; Hacke, W; Hankey, GJ; Hart, RG; Hu, T; Topol, EJ, 2008)
"In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation."5.13Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008)
"To investigate the effects of aspirin-omitted dual antithrombotic therapy (DAT) on myocardial infarction and stent thrombosis in non-valvular atrial fibrillation (NVAF) patients presenting with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)."5.12Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. ( Li, GQ; Liu, SM; Luo, CF; Mo, P, 2021)
"In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI)."5.12Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo ( Wang, Q; Yang, K, 2021)
"For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe."5.12Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006)
"Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy."5.12Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006)
"To investigate whether warfarin is more effective and superior to aspirin for the prevention of thromboembolism in nonvalvular atrial fibrillation in Chinese."5.12[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. ( Hu, DY; Jiang, LQ; Sun, YH; Zhang, HP, 2006)
"To determine the efficacy of a computerised decision aid in patients with atrial fibrillation making decisions on whether to take warfarin or aspirin therapy."5.12A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. ( Eccles, MP; Greenaway, J; May, CR; Murtagh, MJ; Steen, IN; Stobbart, L; Thomson, RG, 2007)
"2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day)."5.12Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. ( Fitzmaurice, D; Fletcher, K; Hobbs, FD; Lip, GY; Mant, J; Murray, E; Roalfe, A, 2007)
"This is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with atrial fibrillation (AF)."5.12Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). ( Ezekowitz, MD; Lionetti, DA; Nagarakanti, R; Nehmiz, G; Parcham-Azad, K; Pedersen, KE; Reilly, PA; Simmers, TA; Stangier, J; Wallentin, L, 2007)
"The ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) was a trial comparing OAC to combined antiplatelet therapy with aspirin and clopidogrel for prevention of vascular events in 6,706 AF patients."5.12Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. ( Connolly, SJ; Healey, JS; Hohnloser, SH; Pajitnev, D; Pfeffer, MA; Pogue, J; Yusuf, S, 2007)
"Atrial fibrillation patients with TIA have a lower long-term risk of subsequent stroke than those with prior stroke, but their stroke risk during aspirin therapy is still high."5.11Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. ( Hart, RG; Koudstaal, PJ; Pearce, LA, 2004)
"We evaluated the short-term safety and efficacy of aspirin-plus-clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation (AF)."5.11Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. ( Cocci, F; De Caterina, R; Lazzerini, G; Lorenzoni, R, 2004)
"This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin."5.10A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002)
"We measured vWf and sP-sel levels by ELISA in 994 participants receiving aspirin in the Stroke Prevention in Atrial Fibrillation III trial, at study entry or after 3 months, and related these indices to the subsequent incidence of stroke and vascular events."5.10Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. ( Chin, BS; Conway, DS; Hart, RG; Lip, GY; Pearce, LA, 2003)
"Patients with atrial fibrillation and with documented aortic plaque who were assigned to adjusted-dose warfarin therapy (international normalized ratio 2."5.09Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. ( Asinger, R; Blackshear, JL; Fenster, P; Halperin, J; Pearce, LA; Pennock, G; Strauss, R; Zabalgoitia, M, 1999)
"We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2."5.09Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999)
"In inhibiting platelet function, aspirin seems to reduce the risk of cerebrovascular accidents, death, and acute coronary events in patients with nonrheumatic atrial fibrillation."5.09Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. ( Barriales, V; Posada, IS, 1999)
"In the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 2) Study, we studied the rate of bleeding events associated with the incidence of thromboembolic events in patients receiving warfarin sodium, 1."5.09Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1999)
"A total of 287 patients from the SPAF III aspirin cohort study, in which patients with atrial fibrillation and a relatively low risk of stroke received 325 mg/d of aspirin and were followed up for a mean of 2 years."5.09A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. ( Biggs, J; Drake, E; Hart, RG; Laupacis, A; Man-Son-Hing, M; O'Connor, AM; Yetisir, E, 1999)
"To investigate the effectiveness of aspirin and coumarin in preventing thromboembolism in patients with non-rheumatic atrial fibrillation in general practice."5.09Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. ( Hellemons, BS; Knottnerus, JA; Langenberg, M; Lemmens, T; Lodder, J; Schouten, HJ; van Ree, JW; Vermeer, F, 1999)
"A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years."5.09Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000)
"Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation."5.09Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
"Warfarin is effective in preventing thromboembolism in patients with atrial fibrillation, but aspirin is frequently used as an alternative treatment."5.09[Risk factors for thromboembolism in patients with atrial fibrillation during treatment with aspirin: a multicenter, cooperative retrospective study. Research Group for Antiarrhythmic Drug Therapy]. ( , 2000)
" We assessed three schemes for stroke risk stratification in these patients who were treated with aspirin and who did not have prior cerebral ischemia."5.09Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. ( Halperin, JL; Hart, RG; Pearce, LA, 2000)
"The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients."5.09Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001)
"In this cohort of stroke patients with atrial fibrillation, anticoagulation was superior to aspirin in preventing cardioembolic but not lacunar recurrence."5.09Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? ( Evans, A; Kalra, L; Perez, I; Yu, G, 2001)
"The Stroke Prevention in Atrial Fibrillation II study compared the efficacy and safety of aspirin and warfarin in patients with atrial fibrillation."5.08Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. ( Anderson, DC; Feinberg, WM; Hart, RG; Miller, VT; Pearce, LA; Rothrock, JF, 1996)
"The Stroke Prevention in Atrial Fibrillation II study compared warfarin vs aspirin for stroke prevention in atrial fibrillation."5.08Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. ( , 1996)
" Combined warfarin and aspirin therapy was associated with greater fecal hemoglobin excretion than standard warfarin therapy, suggesting the potential for increased gastrointestinal hemorrhage."5.08Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. ( Ahlquist, DA; Baker, VS; Blackshear, JL; Ellefson, R; Hart, RG; Holland, A; Koehler, J; Litin, SC, 1996)
"Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF)."5.08Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. ( , 1996)
"The prothrombin time (expressed as the international normalized ratio [INR]) is the standard method of monitoring warfarin therapy in patients with atrial fibrillation."5.08Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. ( Bovill, EG; Cornell, ES; Feinberg, WM; Hart, RG; Nightingale, SD; Pearce, LA; Tracy, RP, 1997)
"The Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled trial examining the following therapies: warfarin sodium, 1."5.08Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. ( Andersen, ED; Boysen, G; Godtfredsen, J; Gulløv, AL; Koefoed, BG; Pedersen, TS; Petersen, P, 1998)
"The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand."5.07A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. ( Chaithiraphan, S; Opartkiattikul, N; Poungvarin, N; Viriyavejakul, A, 1994)
"Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation, but the value of this agent relative to aspirin in unclear."5.07Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. ( , 1994)
"The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) demonstrated that low-intensity warfarin anticoagulation can, with safety, sharply reduce the rate of stroke in patients with nonvalvular atrial fibrillation."5.07Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. ( Barzegar, S; Bauer, KA; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Millenson, MM; Oertel, LB; Sheehan, MA; Singer, DE, 1993)
"Although warfarin and perhaps aspirin may be effective in preventing thromboembolism in patients with nonvalvular atrial fibrillation, some patients develop cerebral infarction despite these therapies."5.07Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. ( Brace, LD; Helgason, CM; Hoff, JA; Kondos, GT, 1993)
"Recent randomized trials have consistently demonstrated the marked efficacy of warfarin in reducing the risk of stroke caused by nonrheumatic atrial fibrillation."5.07The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1992)
"The Stroke Prevention in Atrial Fibrillation Study, a multicenter, randomized trial, compared 325 mg/day aspirin (double-blind) or warfarin with placebo for prevention of ischemic stroke and systemic embolism (primary events), and included 1,330 inpatients and outpatients with constant or intermittent atrial fibrillation."5.07Stroke Prevention in Atrial Fibrillation Study. Final results. ( , 1991)
"Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring."5.06The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1990)
"The Stroke Prevention in Atrial Fibrillation Study recently found and reported (SPAF Investigators, N Engl J Med, 1990;322:863-868) a beneficial effect of both warfarin and aspirin compared with placebo in the primary prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."5.06Progress report of the Stroke Prevention in Atrial Fibrillation Study. ( Anderson, DC, 1990)
"From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo."5.06Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. ( Andersen, B; Andersen, ED; Boysen, G; Godtfredsen, J; Petersen, P, 1989)
"Recently, three randomized trials reported that dual antithrombotic treatments (DATs) including non-vitamin K antagonist oral anticoagulants (NOACs) and a P2Y12 inhibitor without aspirin were associated with significantly less bleeding than vitamin K antagonist (VKA)-based triple antithrombotic therapy (TAT) in atrial fibrillation (AF) patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)."5.05Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr ( Collet, JP; Dagres, N; Heidbuchel, H; Hindricks, G; Lip, GYH; Mujovic, N; Potpara, TS; Proietti, M; Valgimigli, M, 2020)
" In addition, among HBR patients, (i) new recommendations prefer direct oral anticoagulants (DOAC) over vitamin K antagonists in DOAC-eligible patients with atrial fibrillation and coronary artery disease; (ii) measures to minimize bleedings while on DAPT should be pursued, including de-escalation of P2Y12 receptor inhibitor therapy; and (iii) new studies are testing reversal strategies for short DAPT regimens, with early discontinuation of aspirin."5.05[Short dual antiplatelet therapy: how, when and why]. ( Carrozzi, C; Ditali, V; Leonardi, S, 2020)
"The safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear."5.05Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. ( Al-Abdouh, A; Hasan, RK; Khan, MS; Khan, MU; Khan, SU; Mamas, MA; Michos, ED; Osman, M; Savji, N; Zhao, D, 2020)
"A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety."5.05Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. ( Georgiopoulos, G; Korompoki, E; Leventis, I; Lip, GYH; Makaritsis, K; Milionis, H; Ntaios, G; Sagris, D; Vemmos, K, 2020)
" The objective of this study was to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin or aspirin."5.01A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. ( Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S, 2019)
" Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation."5.01Antithrombotic dose: Some observations from published clinical trials. ( Dimmitt, SB; Ferner, RE; Floyd, CN, 2019)
"A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome."4.98Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018)
"Clopidogrel combined with aspirin is routinely prescribed after coronary artery stenting, in patients with acute coronary syndromes, and recently to prevent stroke in patients with acute minor ischemic stroke and TIA."4.91Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials. ( Bakheet, MF; Hart, RG; Pearce, LA, 2015)
"Despite its lack of efficacy, aspirin is commonly used for stroke prevention in atrial fibrillation."4.91Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. ( Gándara, E; Gonzalez, JP; Vazquez, FJ, 2015)
" Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor."4.90Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? ( Alpert, JS; Asencio, LA; Huang, JJ, 2014)
" In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis."4.90Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014)
"The role of aspirin in the early management of stroke is well established."4.89Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013)
"Until recently, pharmaceutical options for stroke prevention in atrial fibrillation were restricted to aspirin or vitamin K antagonist therapy."4.88Apixaban for the prevention of stroke in atrial fibrillation. ( Flaker, G; Littrell, R, 2012)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."4.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"The use of triple therapy (warfarin plus dual antiplatelet therapy) has increased in recent years due to an aging population with a higher risk for atrial fibrillation, as well as the increased use of coronary stents for acute coronary syndromes."4.87Triple therapy in hospitalized patients: facts and controversies. ( Smetana, GW; Srour, JF, 2011)
"Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin."4.87Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011)
"The role of aspirin for the primary prevention of stroke in patients with non valvular atrial fibrillation is critically reviewed."4.86Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. ( Owen, A, 2010)
" The CHADS2 risk-stratification scheme, based on a clinical history of heart failure, hypertension, age >75, diabetes, or prior stroke, is a useful clinical tool to identify patients likely to benefit from warfarin, distinguishing these patients from patients at lower risk for whom aspirin is sufficient."4.84Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies. ( Halperin, JL; Strong, SH, 2007)
" The ACTIVE-W study was a noninferiority comparison of the combination of clopidogrel and acetylsalicylic acid versus oral anticoagulant among patients with atrial fibrillation."4.84Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. ( Cairns, JA; Gent, M; Hirsh, J; Marler, J; Pogue, J; Pritchett, EL; Wittes, J; Wyse, DG, 2008)
"Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation."4.84Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007)
"Warfarin for stroke prevention in patients with atrial fibrillation (AF) is well documented."4.84Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. ( Andersen, LV; Deichgraeber, P; Frost, L; Lindholt, JS; Mortensen, LS; Vestergaard, P, 2008)
"Primary literature was identified through PubMed MEDLINE (1966-December 2007) and EMBASE (1980-December 2007) using the search terms anticoagulation, warfarin, aspirin, elderly, falls, older persons, atrial fibrillation, bleeding, education, stroke, and use."4.84Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. ( Corbett, TL; Garwood, CL, 2008)
"To compare the effectiveness of aspirin, warfarin, and ximelagatran as thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF)."4.83Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. ( Edwards, SJ; Lip, GY, 2006)
"A lower rate of ischemic stroke and a higher rate of major bleeding episodes were found to be associated with oral anticoagulants compared with aspirin, and both anticoagulants and aspirin were found to be associated with a reduction in the rate of stroke compared with placebo."4.83Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. ( Cooper, NJ; Khunti, K; Lu, G; Sutton, AJ, 2006)
" Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity."4.83Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006)
" Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%."4.83Optimising stroke prevention in non-valvular atrial fibrillation. ( Cohen, A; Ederhy, S, 2006)
" In moderate- to high-risk subjects, oral anticoagulation with warfarin reduces stroke by two-thirds, while aspirin reduces stroke by 22%."4.83Atrial fibrillation and stroke prevention. ( Kakar, P; Lip, GY, 2006)
"Current guidelines relating to the primary prevention of stroke in non-valvular atrial fibrillation are primarily based on randomised trials comparing warfarin with placebo."4.82[Choice of antithrombotic therapy in atrial fibrillation, a daily challenge. No convincing evidence that warfarin is better than acetylsalicylic acid]. ( Mooe, T, 2003)
"Individual patient data of patients who received aspirin or placebo after cerebral ischemia were obtained from 9 clinical trials."4.82Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. ( Algra, A; Ariesen, MJ; Koudstaal, PJ; Rothwell, PM; van Walraven, C, 2004)
"Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity."4.82Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003)
"Warfarin has been in routine clinical use for more than 50 years; however, it was not proven to be of benefit in both primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (AF) until about a decade ago."4.82Warfarin for atrial fibrillation: the end of an era? ( Chambers, BR; Dewey, HM; Donnan, GA, 2004)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."4.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"Warfarin therapy achieving an International Normalized Ratio between 2 and 3 has been shown to be effective in preventing stroke."4.82New possibilities in anticoagulant management of atrial fibrillation. ( Waldo, AL, 2004)
"Three trials tested aspirin in dosages ranging from 75 mg to 325 mg per day and 125 mg every other day to placebo (in two trials) or control (in one trial) in 1965 AF patients without prior stroke or TIA."4.82Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. ( Aguilar, M; Hart, R, 2005)
" Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%."4.82[Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005)
"We present a critical review of 3 randomized clinical trials testing aspirin, heparin/heparinoid, or both involving 5029 patients with AF and acute stroke."4.81Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. ( Hart, RG; Palacio, S; Pearce, LA, 2002)
"To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)."4.81Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002)
"To examine the benefits and risks of long term anticoagulation (warfarin) compared with antiplatelet treatment (aspirin/indobufen) [corrected] in patients with non-rheumatic atrial fibrillation."4.81Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. ( Cohen, H; Ebrahim, S; Taylor, FC, 2001)
"To review and evaluate the evidence supporting the use of warfarin and/or aspirin for stroke prevention in patients with atrial fibrillation."4.80Preventing stroke in patients with atrial fibrillation. ( Ezekowitz, MD; Levine, JA, 1999)
"A recent analysis of the literature, published in the 19 May issue of the JAMA, once again demonstrates the efficacy of warfarin, and its superiority on aspirin, in preventing stroke in patients with atrial fibrillation, at least in subjects at highest risk."4.80[Clinical study of the month. Prevention of cerebral vascular accidents in patients with atrial fibrillation]. ( Scheen, AJ, 1999)
"Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin."4.80Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. ( Benavente, O; Hart, RG; McBride, R; Pearce, LA, 1999)
" In primary prevention, the benefit of aspirin has been established only for patients with non-valvular atrial fibrillation and a low risk of cardioembolism, or as an alternative choice of warfarin, and in subjects at high risk of atherosclerosis."4.80[Prevention of cerebral ischemia: anti-platelet agents]. ( Leys, D, 1999)
" For primary prevention, aspirin showed no effect in a British study, but reduced the incidence of myocardial infarction by 44% per year in an American trial concerning men and by 32% concerning women."4.79[Blood thinning in heart patients]. ( Meier, B, 1995)
"English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders."4.79Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994)
"In these five randomized trials warfarin consistently decreased the risk of stroke in patients with atrial fibrillation (a 68% reduction in risk) with virtually no increase in the frequency of major bleeding."4.79Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. ( , 1994)
"Aspirin given as a platelet antiaggregant has been shown to be effective for secondary prevention both in cardiology (myocardial infarction, uncontrolled angina pectoris, coronary bypass, etc."4.79[From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention]. ( Chollet, F, 1994)
"Antithrombotic prophylaxis with long term warfarin or aspirin reduces thromboembolic risk in atrial fibrillation."4.79ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. ( Lip, GY; Lowe, GD, 1996)
"Warfarin prophylaxis in patients with nonvalvular atrial fibrillation may be one of the most valuable public-health interventions."4.79Stroke prevention: the emerging strategies. ( Matchar, DB; McCrory, DC, 1996)
"As the risks of adverse effects of warfarin and aspirin in certain patients with chronic atrial fibrillation are high, intervention with these agents should be targeted towards those who will derive most benefit."4.79The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. ( Gray, NJ; Hankey, GJ, 1996)
"Anticoagulation with warfarin has been shown to be effective in preventing ischemic stroke in patients with atrial fibrillation."4.79Anticoagulation: risks and benefits in atrial fibrillation. ( Fiore, LD, 1996)
" Anticoagulant therapy with warfarin is now established as effective thromboprophylaxis against stroke in atrial fibrillation, in high-risk persons."4.79Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. ( Lip, GY; Lowe, GD, 1996)
"Recent randomized trials of antithrombotic therapy in non-rheumatic atrial fibrillation have helped to clarify the benefits of warfarin and aspirin."4.79Anti-thrombotic therapy for non-rheumatic atrial fibrillation. ( Chauhan, A; More, RS, 1996)
"In the absence of randomized, controlled trials of low-dose amiodarone in atrial fibrillation or a randomized, controlled trial of ventricular rate control versus antifibrillatory therapy, a Markov decision analysis is useful in comparing different therapeutic strategies for atrial fibrillation."4.79Therapeutic strategies for atrial fibrillation. The value of decision analysis. ( Disch, DL; Greenberg, ML; Malenka, DJ, 1996)
" Although aspirin use seemed particularly effective in younger patients and in those with hypertension in the Stroke Prevention in Atrial Fibrillation 1 Study, this was not the case in the other studies."4.79The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. ( , 1997)
"There is now adequate clinical evidence that the most appropriate treatment of elderly patients with non-valvular atrial fibrillation is with low dose warfarin."4.78Anticoagulant treatment of atrial fibrillation in the elderly. ( Blackburn, T; Dunn, M, 1992)
" Patients with rheumatic heart disease complicated by atrial fibrillation should receive long-term warfarin therapy to reduce the risk of stroke unless an absolute contraindication exists."4.78Anticoagulant therapy for atrial fibrillation. Recommendations from major studies. ( Kahn, JK, 1992)
"Considering the 11 trials that reported > 10 ischemic strokes during follow-up (97,578 participants, 1195 ischemic strokes), 1 tested apixaban (57 strokes), 1 betrixaban (52 strokes), and 9 rivaroxaban (1086 strokes)."4.31Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. ( Eikelboom, JW; Hart, RG; Katsanos, AH; Perera, KS, 2023)
" Key consensus points include efforts to improve medical adherence through deprescribing and polypill use; adoption of universal risk definitions for bleeding, myocardial infarction, stroke and cause-specific death; multiple bleeding-avoidance strategies, ranging from gastroprotection with aspirin use to selection of antithrombotic-drug composition, dosing and duration tailored to multiple variables (setting, history, overall risk, age, weight, renal function, comedications, procedures) that need special consideration when managing older adults."4.31Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis ( Andreotti, F; Collet, JP; Geisler, T; Gigante, B; Gorog, DA; Halvorsen, S; Lip, GYH; Morais, J; Navarese, EP; Patrono, C; Rocca, B; Rubboli, A; Sibbing, D; Storey, RF; Verheugt, FWA; Vilahur, G, 2023)
" DOAC, vitamin K antagonist and aspirin treatment were assessed in the 6 months prior to the start of each year while strokes and bleeds were assessed during the year."4.31Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. ( Bennie, M; Carragher, R; Forslund, T; Hjemdahl, P; Hunt, NB; Karlstad, Ø; Kjerpeseth, LJ; Klungel, OH; Komen, JJ; Mueller, T; Olesen, M; Pottegård, A; Wettermark, B, 2023)
" OAC prescribing status was explored for patients at risk for stroke and classified into the following: OAC, aspirin only, or no treatment."4.12Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. ( Ajabnoor, AM; Ashcroft, DM; Carr, MJ; Doran, T; Kontopantelis, E; Mamas, MA; Parisi, R; Rutter, MK; Zghebi, SS, 2022)
"For some patients receiving warfarin, adding aspirin (acetylsalicylic acid) increases bleeding risk with unclear treatment benefit."4.12Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation. ( Alexandris-Souphis, T; Ali, MA; Barnes, GD; Errickson, J; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Schaefer, JK; Shah, V; Sood, SL, 2022)
"AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospitalizations, and similar ischemic events than regimens including a vitamin K antagonist (VKA), aspirin, or both."4.02Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. ( Dhanda, D; Di Fusco, M; Kang, A; Kongnakorn, T; Polanco, C; Rivolo, S; Savone, M; Skandamis, A; Soto, J, 2021)
" The purpose of this study was to evaluate the incidence of major bleeding and thromboembolic events (TEs) in patients with atrial fibrillation (AF) receiving warfarin alone (monotherapy group) versus warfarin plus aspirin (combination therapy group)."4.02Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation. ( Afzal, M; Davidson, E; Li, J; Nagaraj, TA; Snider, MJ; Weiss, R, 2021)
"COMBINE AF incorporates de-identified individual patient data from 77,282 patients with atrial fibrillation at risk for stroke randomized to NOAC, warfarin, or aspirin from 5 pivotal randomized controlled trials."4.02Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutio ( Alexander, JH; Carnicelli, AP; Connolly, SJ; Eikelboom, J; Giugliano, RP; Granger, CB; Hohnloser, SH; Hong, H; Hua, K; Lopes, RD; Morrow, DA; Oldgren, J; Patel, MR; Piccini, JP; Ruff, CT; Wallentin, L; Wojdyla, D, 2021)
"The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events."3.96Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020)
"Bleeding is a frequently encountered complication in patients undergoing percutaneous coronary intervention (PCI) treated with a dual antiplatelet therapy regimen with aspirin plus an oral inhibitor of the P2Y12 platelet receptor (clopidogrel, prasugrel, ticagrelor) or with the combination of antiplatelet drugs and an anticoagulant in patients who have a specific indication for chronic anticoagulation therapy such as atrial fibrillation."3.96[Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention]. ( Capodanno, D; Capranzano, P; Francaviglia, B; Tamburino, C, 2020)
"In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin."3.96Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020)
"In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone."3.96Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort. ( George, J; Hafeez, A; Halalau, A; Keeney, S; Matka, M; Said, A, 2020)
"The prospective WATCH-AF registry (Warfarin Aspirin Ten-A Inhibitors and Cerebral Infarction and Hemorrhage and Atrial Fibrillation) enrolled consecutive patients admitted within 72 hours of an acute stroke associated with atrial fibrillation in 2 stroke centers."3.96Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. ( Amarenco, P; Cabrejo, L; Charles, H; Guidoux, C; Hobeanu, C; Labreuche, J; Lavallée, PC; Martin-Bechet, A; Meseguer, E; Nighoghossian, N; Ong, E; Rigual, R, 2020)
"In patients with atrial fibrillation, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care after percutaneous coronary intervention (PCI)."3.96Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. ( Aksoy, F; Altınbaş, A; Bağcı, A; Baş, HA; Varol, E, 2020)
"The biomarkers in the ABC-bleeding risk score (growth differentiation factor 15, hemoglobin, and troponin) were measured in blood samples collected at randomization between 2006 and 2010 in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial and between 2005 and 2009 in the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial, both of which were multinational randomized clinical trials."3.96Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. ( Alexander, JH; Alings, M; De Caterina, R; Eikelboom, JW; Ezekowitz, MD; Granger, CB; Held, C; Hijazi, Z; Huber, K; Hylek, EM; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Vinereanu, D; Wallentin, L, 2020)
"Comparative gastrointestinal bleeding (GIB) risk between rivaroxaban and low-dose aspirin is unknown in patients with atrial fibrillation (AF)."3.96Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study. ( Bell, JS; Chan, EW; Darzins, P; Fanning, L; Ilomaki, J; Lau, WCY; Leung, WK; Li, X; Man, KKC; Mongkhon, P; Wei, L; Wong, ICK, 2020)
"Despite international treatment guidelines currently advocating oral anticoagulants (OACs) as the only appropriate stroke prevention therapy for patients with atrial fibrillation (AF) and evidence that OACs can greatly reduce the risk of stroke with similar risk of bleeding compared with aspirin, the underuse of OACs in patients with AF is common globally, especially in Asia."3.96Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study. ( Chiu, PKC; Jamieson, E; Kng, CPL; Lam, MPS; Ng, VWS; Siu, CW; Wong, ICK, 2020)
" Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular atrial fibrillation (NVAF)."3.91Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. ( Arachchillage, DRJ; Farag, M; Gorog, DA; Gue, Y; Lip, GYH; Spinthakis, N; Srinivasan, M; Wellsted, D, 2019)
"Background As an alternative to vitamin K antagonist and low-dose aspirin (< 325 mg), non-vitamin K oral anticoagulants are available for the prevention of stroke in patients with atrial fibrillation."3.91Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. ( Burden, A; de Boer, A; de Vries, F; Gieling, E; Kramers, C; Ten Cate, V; van Onzenoort, HAW; Williams, R, 2019)
"This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan."3.91Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019)
"Compared with warfarin monotherapy, receipt of combination warfarin and aspirin therapy was associated with increased bleeding and similar observed rates of thrombosis."3.91Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. ( Almany, SL; Barnes, GD; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Sood, SL; Souphis, NM, 2019)
"We investigated whether the use of aspirin (irreversible COX1 inhibitor) in the preoperative period may prevent non-valvular atrial fibrillation, which is the most common rhythm problem in the postoperative period."3.91The Effect of Aspirin as an Irreversible COX1 Inhibitor in Preventing Non-Valvular Atrial Fibrillation After Coronary Bypass Surgery. ( Ates, A; Erkut, B, 2019)
" Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias."3.91Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. ( Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A, 2019)
"To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and/or percutaneous coronary intervention (PCI)."3.88Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. ( Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018)
"Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk."3.88Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018)
"8 years) with non-valvular atrial fibrillation (NVAF) underwent LAAC procedure using a Watchman device followed by DAPT (75 mg/d aspirin and 75 mg/d clopidogrel)."3.88Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. ( Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018)
"This study sought to assess safety and effectiveness of low-dose aspirin in heart failure (HF) not complicated by atrial fibrillation."3.88Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study. ( Bjerre, J; D'Souza, M; Fosbøl, EL; Gislason, G; Gustafsson, F; Kober, L; Kristensen, SL; Madelaire, C; Schou, M; Torp-Pedersen, C, 2018)
"The authors investigated the risk of bleeding, ischemic stroke, MI, and all-cause mortality associated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in combination with aspirin, clopidogrel, or both in patients with AF following MI and/or PCI."3.88Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. ( Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018)
"The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events."3.85Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. ( Eckman, MH; So, CH, 2017)
"To determine the clinical and cost effectiveness of apixaban compared to aspirin in the prevention of thromboembolic events for patients with atrial fibrillation for whom vitamin K antagonist (VKA) therapy (warfarin) has been considered unsuitable."3.85Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective. ( Ademi, Z; Liew, D; Pasupathi, K, 2017)
"Based on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon."3.85Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. ( Athanasakis, K; Bilitou, A; Boubouchairopoulou, N; Karampli, E; Kyriopoulos, J; Savvari, P; Tarantilis, F, 2017)
"Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K antagonists (VKA) and aspirin."3.85Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. ( Bos, J; Burden, AM; de Boer, A; de Vries, F; Gieling, EM; Kramers, C; van den Ham, HA; van Onzenoort, H, 2017)
"We conducted a post hoc ancillary analysis of clinically relevant bleeding and major bleeding events among 2293 patients receiving warfarin therapy in the AMADEUS trial."3.83Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. ( Lane, DA; Lip, GY; Proietti, M; Senoo, K, 2016)
"Little is known about the ischaemic stroke risk and benefit of warfarin therapy for stroke prevention in chronic kidney disease (CKD) patients on peritoneal dialysis (PD) with concomitant atrial fibrillation (AF)."3.83Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. ( Chan, PH; Chan, TM; Hai, J; Huang, D; Lip, GY; Lo, WK; Siu, CW; Tse, HF; Yip, PS, 2016)
"Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])."3.83Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016)
"A cost-effectiveness model was constructed using data from three studies on stroke prevention in patients with contraindications: the ASAP study evaluating the Watchman device, the ACTIVE A trial of aspirin and clopidogrel, and the AVERROES trial evaluating apixaban."3.83Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. ( Akehurst, RL; Amorosi, SL; Armstrong, SO; Brereton, N; Hertz, DS; Holmes, DR; Reddy, VY, 2016)
" Analysis of patient demographics and stroke risk identified trends in prescribing DOAC versus warfarin."3.83Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation. ( Baker, D; Narasimhan, S; Wilsmore, B, 2016)
"Concomitant use of vitamin K antagonist (VKA) and aspirin (ASA) is becoming increasingly prevalent among atrial fibrillation (AF) patients."3.83Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. ( Atarashi, H; Chishaki, A; Inoue, H; Kiyono, K; Kodama, I; Kodani, E; Lip, GY; Okumura, K; Okuyama, Y; Origasa, H; Watanabe, E; Yamamoto, M; Yamashita, T, 2016)
"This model demonstrates that increased use of rivaroxaban in inadequately-managed NVAF patients could avoid 456 081 non-fatal ischemic strokes (IS) and 76 975 cardiovascular deaths over 10 years in Japan."3.83Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. ( Briere, JB; Evers, T; Hori, M; Ikeda, S; Koretsune, Y; Matsuda, S; Montouchet, C; Okumura, K; Rossi, B; Ruff, L; Watanabe-Fujinuma, E, 2016)
"Oral anticoagulation (OAC), rather than aspirin, is recommended in patients with atrial fibrillation (AF) at moderate to high risk of stroke."3.83Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. ( Gehi, AK; Hsu, JC; Katz, DF; Kennedy, K; Lubitz, SA; Maddox, TM; Marcus, GM; Marzec, LN; Turakhia, MP, 2016)
"2% of dabigatran-treated patients had renal insufficiency requiring a dose reduction."3.83Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. ( Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW, 2016)
"LAAC is a novel stroke preventative therapy for nonvalvular AF and is a cost-effective alternative to aspirin in patients with contraindications to OAC."3.83Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. ( Bennell, MC; Saw, J; Singh, SM; Wijeysundera, HC, 2016)
"To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control."3.83Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. ( Björck, F; Lip, GY; Renlund, H; Själander, A; Svensson, PJ; Wester, P, 2016)
"Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear."3.83Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016)
"Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD."3.83Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016)
" aspirin to achieve a reduction in three strokes in 100 patients over a 2-year period."3.81Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. ( Alonso-Coello, P; Coll-Vinent, B; Devereaux, PJ; Díaz, MG; Diez, AI; Gich, I; Guyatt, G; Mas, G; Montori, VM; Oliver, S; Roura, M; Ruiz, R; Schünemann, HJ; Solà, I; Souto, JC, 2015)
" We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy."3.81Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015)
"Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)."3.81Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)
"Aspirin use increased among Chinese patients newly diagnosed with AF, with no relationship to the patient's stroke or bleeding risk."3.81Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. ( Guo, Y; Lip, GYH; Tian, Y; Wang, H; Wang, Y, 2015)
" We studied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc risk factor; 23,572 were not treated, 5,353 were initiated on aspirin, and 10,475 were initiated on warfarin."3.81Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2015)
"Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke."3.81Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015)
"We aimed to study differences in the prescribing of warfarin, aspirin and statins to patients with atrial fibrillation (AF) in socio-economically diverse neighborhoods."3.81Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. ( Carlsson, AC; Gasevic, D; Sundquist, J; Sundquist, K; Wändell, P, 2015)
"Long-term warfarin therapy has been used to decrease thromboembolic events in patients with atrial fibrillation (AF) following bioprosthetic mitral valve replacement (BMVR) and left atrial appendage obliteration (LAAO)."3.81Is long-term warfarin therapy necessary in Chinese patients with atrial fibrillation after bioprosthetic mitral valve replacement and left atrial appendage obliteration? ( Gao, C; Jiang, S; Ren, C; Zhang, L, 2015)
" For subgroup analysis, all patients were stratified by the following factors: age (above 75), disease (presence of hypertension, diabetes, congestive heart failure, and a history of stroke or thromboembolism), rhythm control procedure, and concurrent aspirin therapy."3.81INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation. ( Choi, YR; Chung, JE; Gwak, HS; La, HO; Seong, JM, 2015)
"Secondary prevention treatment with aspirin/ clopidogrel, beta blockers, inhibitors of the rennin-angiotensin-aldosterone converting system and statins reduces the morbidity and mortality of patients after acute coronary syndrome (ACS)."3.81[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS]. ( Elis, A; Lishner, M; Pereg, D; Yahia, DH, 2015)
"The purpose of this study was to investigate whether aspirin use can be captured from the clinical notes in a nonvalvular atrial fibrillation population."3.81Medication Extraction from Electronic Clinical Notes in an Integrated Health System: A Study on Aspirin Use in Patients with Nonvalvular Atrial Fibrillation. ( An, J; Koblick, R; Rashid, N; Zheng, C, 2015)
"Atrial fibrillation (AF) increases risk of stroke, and although this stroke risk can be ameliorated by warfarin therapy, some patients decline to adhere to warfarin therapy."3.81Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis. ( Arellano, AR; Bare, LA; Devlin, JJ; Louie, JZ; Perez, MV; Shiffman, D, 2015)
"An 80-year-old female with a history of hypertension and atrial fibrillation had been receiving warfarin anticoagulant therapy and had stably maintained an international normalized ratio (INR) within the 2."3.81Hemoptysis due to aspirin treatment alternative to warfarin therapy in a patient with atrial fibrillation. ( Cao, J; Cui, X; Han, Z; Song, W; Wen, H; Xu, Y, 2015)
"In patients with both stable coronary disease and atrial fibrillation, a baseline treatment of aspirin and an oral anticoagulant is often prescribed due to the proven benefits of each therapy on cardiovascular and thromboembolic events and mortality."3.81[Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?]. ( Lister, K; Louis Simonet, M, 2015)
"To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention."3.80Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. ( He, B; Kun, L; Liu, X; Wu, B, 2014)
" However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding."3.80Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014)
" Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin."3.80Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014)
"To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective."3.80Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014)
"Apixaban was found to be a cost-effective alternative to warfarin and aspirin for stroke prevention in patients with AF in Sweden."3.80Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. ( De Geer, A; Jacobson, L; Kongnakorn, T; Lanitis, T, 2014)
"Inflammatory processes have been associated with an increased risk of atrial fibrillation (AF), potentially allowing for preventive therapy by anti-inflammatory agents such as aspirin."3.80Aspirin use and risk of atrial fibrillation in the Physicians' Health Study. ( Albert, CM; Djousse, L; Gaziano, JM; Hoffmeister, P; Ofman, P; Peralta, A; Petrone, AB; Rahilly-Tierney, CR, 2014)
"Evidence indicates that vitamin K antagonists (VKAs) and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non-valvular atrial fibrillation (AF), and patients who decline or cannot tolerate such treatment are often prescribed aspirin instead."3.80Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. ( Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014)
" The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities."3.80Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2014)
"To project the long-term cost-effectiveness of treating non-valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to warfarin in Portugal."3.80Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. ( Aguiar, C; Chatzitheofilou, I; Fonseca Santos, I; McLeod, E; Morais, J; Pereira, S, 2014)
"A 73-yr-old Korean man with permanent atrial fibrillation visited outpatient clinic with severely increased International Normalized Ratio (INR) values after taking a usual starting dosage of warfarin to prevent thromboembolism."3.80Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. ( Jeong, HJ; Jun, JE; Kim, JH; Kim, JS; Lee, JE; Lee, SY; Ryu, DH, 2014)
" The net clinical benefit of warfarin was assessed using 4 endpoints: a composite endpoint of death/hospitalization from stroke/bleeding; a composite endpoint of fatal stroke/fatal bleeding; cardiovascular death; and all-cause death."3.80Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. ( Bonde, AN; Gislason, GH; Hansen, ML; Hansen, PR; Hommel, K; Kamper, AL; Lamberts, M; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2014)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."3.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"64%) relative increase in the use of aspirin or warfarin in the population with atrial fibrillation 6 and 12 months after the program, respectively, and in a 1."3.79Improving cardiovascular disease management in Australia: NPS MedicineWise. ( Bartlett, MJ; Gadzhanova, SV; Roughead, EE, 2013)
"Earlier validation studies of risk scoring by CHA2DS2VASc for assessments of appropriateness of warfarin treatment in patients with atrial fibrillation have been performed solely with diagnoses recorded in hospital based care, even though many patients to a large extent are managed in primary care."3.79Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2013)
"Aspirin is one of the preferred therapies in the primary prevention of ischemic stroke in paroxysmal atrial fibrillation (PAF)."3.79The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation. ( Colkesen, Y; Coskun, I; Muderrisoglu, H, 2013)
"the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin."3.78Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. ( O'Shea, D; Romero-Ortuno, R, 2012)
"Evidence from pivotal clinical trials conducted more than a decade ago supports the use of antithrombotic therapy, particularly warfarin, for stroke prevention in atrial fibrillation (AF)."3.78Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now. ( Bajorek, BV; Ren, S, 2012)
"Guidelines for atrial fibrillation (AF) recommend clopidogrel plus aspirin as an alternative stroke prevention strategy in patients in whom warfarin is unsuitable."3.78Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. ( Anglade, MW; Coleman, CI; Kluger, J; Sobieraj, DM; Straznitskas, AD, 2012)
"Practice guidelines recommend anticoagulation therapy with warfarin for stroke prevention in patients with atrial fibrillation (AF)."3.78Warfarin use in nursing home residents: results from the 2004 national nursing home survey. ( Ghaswalla, PK; Harpe, SE; Slattum, PW, 2012)
"For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel."3.78Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012)
"Only 50% of patients who would benefit from warfarin therapy for atrial fibrillation (AF) receive treatment because of clinical concerns regarding chronic anti-coagulation."3.78Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation. ( Alison, JF; Lockwood, S; Mottram, P; Obeyesekere, MN, 2012)
" Aspirin has been increasingly recognised as an inferior choice for stroke prevention, and may not be any safer than warfarin in terms of major bleeding, especially in the elderly."3.78What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? ( Lip, GY, 2012)
"As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of patients with atrial fibrillation (AF)."3.78A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. ( Azoulay, L; Dell'Aniello, S; Langleben, D; Renoux, C; Simon, TA; Suissa, S, 2012)
"Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF) patients unsuitable for warfarin by 63% but does not increase major bleeding."3.78Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. ( Anglade, MW; Coleman, CI; Hagstrom, K; Kluger, J; Lee, S; Meng, J, 2012)
"Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge."3.78Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012)
"We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years."3.78[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012)
" Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel."3.78Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012)
" She was on dabigatran for atrial fibrillation and aspirin, with intermittent intake of ibuprofen."3.78Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"! ( Cirra, VR; Kamboj, J; Kamboj, R; Kottalgi, M; Shah, N, 2012)
"In this relatively small, nonrandomized study comparing endovenous thermal ablation in patients with and without warfarin, no differences were found in periprocedural risk of major bleeding or closure rate of the treated venous segments."3.77Effect of anticoagulation on endothermal ablation of the great saphenous vein. ( Bay, C; Emrani, F; Mehdipour, M; Sharifi, J; Sharifi, M, 2011)
" This study aimed to measure agreement on warfarin and aspirin use between medical records and automated pharmacy data among patients with newly detected atrial fibrillation (AF)."3.77Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data. ( Garg, RK; Glazer, NL; Heckbert, SR; Newton, KM; Psaty, BM; Siscovick, DS; Smith, NL; Thacker, EL; Wiggins, KL, 2011)
"Underuse and an inadequate range for the international normalized ratio (INR) for warfarin use are still problems in the management of the patients with atrial fibrillation (AF) in Japan."3.77Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. ( Atarashi, H; Inoue, H; Kumagai, N; Okumura, K; Origasa, H; Yamashita, T, 2011)
"Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA)."3.77Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. ( Bushnell, CD; Lopes, RD; Olson, DM; Pan, W; Peterson, ED; Shah, BR; Zhao, X, 2011)
"The tool provides education incorporating patients ' illness perceptions to explain the relationship between NVAF and stroke, and then presents individualized risk estimates, derived using separate risk calculators for stroke and bleeding over a clinically meaningful time period (5 years) associated with no treatment, aspirin, and warfarin."3.77Development of a tool to improve the quality of decision making in atrial fibrillation. ( Fraenkel, L; Fried, TR; Street, RL, 2011)
" We report an independent 88-year-old female, on aspirin only for chronic atrial fibrillation, who presented with a 12-hour history of acute lumbar back pain, urinary incontinence and progressive bilateral lower limb paresis."3.76Spontaneous spinal epidural haematoma in a geriatric patient on aspirin. ( Dimou, J; Jithoo, R; Morokoff, A, 2010)
"In AF patients with CHADS(2) score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications."3.76The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. ( Choi, DH; Hwang, ES; Kim, SK; Kim, YH; Kwak, JJ; Lee, BH; Pak, HN; Park, JH; Park, JS, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."3.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"The authors investigated the use of warfarin at hospital discharge in 557 consecutive patients, mean age 76 years, with nonvalvular atrial fibrillation (AF) at a university hospital."3.76Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin. ( Aronow, WS; Bakerywala, S; Desai, HV; Gandhi, K; Laimuanpuii, J; Peterson, SJ; Sharma, M, 2010)
"Current guidelines for ischemic stroke prevention in atrial fibrillation or flutter (AFF) recommend Vitamin K antagonists (VKAs) for patients at high-intermediate risk and aspirin for those at intermediate-low risk."3.76Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. ( Corrao, S; Iorio, A; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M, 2010)
"The objective of this study was to evaluate the rate of stroke associated with aspirin and warfarin in routine clinical practice."3.75How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. ( Gallagher, AM; Plumb, JM; Rietbrock, S; van Staa, TP, 2009)
"Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings."3.75Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009)
"The aim of this study was to determine the prescribing patterns, risks, and benefits of anticoagulation with warfarin or acetylsalicylic acid (ASA) in elderly patients with AF at risk for stroke and hemorrhage, including those with falls and/or dementia."3.75Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. ( Billett, HH; Dinglas, C; Freeman, K; Jacobs, LG; Jumaquio, L, 2009)
" This is a case of a 79-year-old female with newly diagnosed atrial fibrillation who was inappropriately started on aspirin for anticoagulation despite her high risk for stroke."3.75Prevention and treatment of cardioembolic stroke: a case study. ( Brophy, GM; Glick, JA, 2009)
" The patient had been on no anticoagulation for approximately 30 years secondary to recurrent epistaxis occurring two years after starting warfarin therapy postoperatively."3.74Freedom from complications related to dual ball-and-cage mechanical valve prostheses despite thirty years without anticoagulation. ( Hipp, R; Matsumura, ME; Miller, MM, 2008)
" Patients were stratified according to their stroke risk (highest, high, low, or lowest) and antithrombotic medication (aspirin, warfarin, ticlopidine/clopidogrel, or none)."3.74Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. ( Cheng, CL; Cheng, MH; Kao Yang, YH; Lee, CH; Lin, LJ; Wung, DC, 2008)
", warfarin, anti-platelet agents) to prevent both device thrombosis and thromboembolism."3.74Patient with hypofibrinolysis-mediated thromboembolism converted to a hypercoagulable/hyperfibrinolytic state via ventricular assist device placement. ( Ellis, TC; George, JF; Holman, WL; Kirklin, JK; Nielsen, VG; Steenwyk, BL, 2008)
"Oral anticoagulation prevents strokes in patients with atrial fibrillation but, for reasons that remain unclear, less than 40% of all patients with atrial fibrillation receive warfarin."3.74Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. ( Alonso, R; Alonso-Coello, P; Charles, C; Coll-Vinent, B; Devereaux, P; Díaz, MG; Diez, AI; Gich, I; Guyatt, G; Montori, VM; Oliver, S; Roura, M; Ruiz, R; Schünemann, HJ; Solà, I; Souto, JC, 2008)
"Patients from SPORTIF III (n=3407) and SPORTIF V (n=3922) trials were categorized by prior stroke/TIA (21%) versus no prior stroke/TIA (79%) and by treatment group (ximelagatran vs warfarin)."3.74Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. ( Akins, PT; Albers, GW; Diener, HC; Feldman, HA; Newman, D; Spitzer, SG; Zoble, RG, 2007)
" Among the 76% (437/572) of patients with AF at high risk for stroke, 59% (257/437) used warfarin, 28% (123/437) used aspirin, and 24% (104/437) used neither."3.74Newly detected atrial fibrillation and compliance with antithrombotic guidelines. ( Dublin, S; French, B; Glazer, NL; Heckbert, SR; Hrachovec, JB; Jackson, LA; Psaty, BM; Siscovick, DS; Smith, NL, 2007)
"To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage."3.74Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007)
"Using prescriptions for digoxin as a surrogate for atrial fibrillation, we identified its coprescription with antithrombotic therapy, aspirin or warfarin in a national prescribing database in 27 571 patients over 45 years old."3.74National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. ( Bennett, K; Feely, J; Mahmud, A; Okechukwu, I, 2007)
"We compared 3 alternative treatment strategies for permanent atrial fibrillation in hemodialysis patients: warfarin, ASA, or no treatment."3.74Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. ( Bayoumi, AM; Naimark, DM; Oliver, MJ; Quinn, RR, 2007)
" Hypertension, diabetes mellitus, transient ischemic attack (TIA), hyperlipemia and mural thrombus in left atrium were significantly correlated with the recurrence rate by univariate Cox proportional hazards regression analysis; but aspirin therapy, warfarin therapy and hypertension control were protective factors for the recurrence of ischemic stroke in patients with NVAF."3.74[A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation]. ( Cai, YY; Hu, Y; Luo, M; Quan, HB; Xie, RM, 2007)
"Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year."3.74[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. ( Ataullakhanova, DM; Bykova, ES; Dobrovol'skiĭ, AB; Kropacheva, ES; Panchenko, EP; Titaeva, EV; Zharkova, TV, 2007)
"To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin."3.73Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. ( Gage, BF; O'Brien, CL, 2005)
"To determine the effect of access to ambulatory anticoagulation management services (AMS) on the rate of warfarin use in patients with atrial fibrillation."3.73Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation. ( Burkiewicz, JS, 2005)
"Warfarin can be more effective than aspirin for stroke prevention in elderly patients with atrial fibrillation, but in clinical practice, the usage rate of warfarin still remains low with insufficient monitoring."3.73[Comparative study of warfarin and aspirin for stroke prevention in elderly patients with atrial fibrillation]. ( Han, W; Shen, DT; Wang, YM, 2006)
"Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available."3.73Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006)
"The aim of the present study was to assess which clinical determinants influence coumarin and aspirin prescription in patients with atrial fibrillation in primary care."3.72Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment? ( Hak, E; Hoes, AW; Rutten, FH; Stalman, WA; Verheij, TJ, 2003)
"To evaluate recent trends, we examined longitudinal national data on the outpatient use of warfarin in atrial fibrillation (AF), beta-blockers and aspirin in coronary artery disease (CAD), and angiotensin-converting enzyme inhibitors (ACEIs) in congestive heart failure (CHF)."3.72The underutilization of cardiac medications of proven benefit, 1990 to 2002. ( Radley, DC; Stafford, RS, 2003)
"Medical records of all patients with atrial fibrillation admitted to acute internal medicine wards in April 2000 and between July and October 2001 were reviewed for details of antithrombotics given, results of international normalised ratio monitoring for patients receiving warfarin, side-effects, and additional risk factors for complications of atrial fibrillation."3.72Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. ( Leung, CS; Tam, KM, 2003)
"Warfarin increases both the likelihood and the mortality of intracerebral hemorrhage (ICH), particularly in patients with a history of prior ICH."3.72Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. ( Eckman, MH; Greenberg, SM; Knudsen, KA; Rosand, J; Singer, DE, 2003)
"Aspirin provides benefit in nearly all groups of patients with clinical manifestations of coronary heart disease."3.72Aspirin for cardiovascular disease prevention. ( Hung, J, 2003)
"Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy."3.72Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. ( Chang, Y; Go, AS; Henault, LE; Hylek, EM; Jensvold, NG; Selby, JV; Singer, DE, 2003)
"Although warfarin was the most appropriate treatment in nearly all of this population at high risk for stroke, it was prescribed in fewer than two-thirds of patients."3.72Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. ( Bungard, TJ; Lau, E; Tsuyuki, RT, 2004)
"Anticoagulation with warfarin is the most effective means of reducing stroke in AF."3.72Anticoagulation in atrial fibrillation. ( Anderson, M; Kirk, M, 2004)
"Although recent randomized trials with antithrombotic therapy in nonrheumatic atrial fibrillation (AF) patients emphasized the benefits of warfarin in preventing stroke, warfarin treatment is still far from optimal."3.72Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. ( Blich, M; Gross, B, 2004)
"In part III of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors present data on clinical pharmacology of aspirin as well as discussion of results of randomized trials in which cerebroprotective efficacy and safety of the use of aspirin for primary and secondary prevention of thromboembolism was studied in comparison with placebo and warfarin."3.72[Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Aspirin]. ( Batyraliev, TA; Kiktev, VG; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA, 2004)
" Anticoagulants are effective in stroke prevention in atrial fibrillation with aspirin being a less effective alternative."3.72Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening? ( Buchalter, M; Burr, ML; Ho, SF; O'Mahony, MS; Steward, JA, 2004)
" Hospital admission data before and after the intervention revealed a significant increase in the use of warfarin in patients at high risk of stroke (33% vs 46% of eligible patients; p < 0."3.72A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. ( Jackson, SL; Peterson, GM; Vial, JH, 2004)
"The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF."3.72Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). ( Benjamin, EJ; D'Agostino, RB; Lambert, JW; Levy, D; Massaro, JM; Sam, C; Wolf, PA, 2004)
"170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation."3.72Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. ( Chang, Y; Fang, MC; Go, AS; Greenberg, SM; Hylek, EM; Rosand, J; Singer, DE, 2004)
"From a consecutive series of AF patients with first-ever ischemic stroke, we evaluated prospectively those with moderate to severe disability (grade 4-5 on the modified Rankin Scale) who were treated during a 5-year follow-up period with either warfarin or aspirin."3.72Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. ( Manios, E; Moulopoulos, SD; Spengos, K; Toumanidis, S; Tsivgoulis, G; Vemmos, KN; Zakopoulos, N, 2004)
"To determine the prevalence of atrial fibrillation in England and Wales, and examine trends in its treatment with warfarin and aspirin between 1994 and 1998."3.71Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. ( Carroll, K; Majeed, A; Moser, K, 2001)
" Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation."3.71Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. ( Anderson, DR; Brownell, BF; Cox, JL; Devereaux, PJ; Flowerdew, GJ; Gardner, MJ; Nagpal, S; Putnam, W, 2001)
"Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole."3.71Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001)
"For older patients with atrial fibrillation and no other contraindications to antithrombotic therapy, a Markov decision-analytic model was used to determine the preferred treatment strategy (no antithrombotic therapy, long-term aspirin use, or long-term warfarin sodium use) based on their risk of major upper GI tract hemorrhage."3.71Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. ( Laupacis, A; Man-Son-Hing, M, 2002)
" We aimed to compare the morbidity related to the treatment of atrial fibrillation with warfarin seen in one year at our hospital, with the morbidity in those patients in whom embolism was potentially preventable."3.71The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. ( Campbell, Do; Davis, S; Evans, A; Gerraty, R; Greenberg, P; Kilpatrick, C, 2002)
"This study examines whether social and economic factors affect physician practice and attitude with regard to warfarin anticoagulation in patients with nonvalvular atrial fibrillation."3.70Anticoagulation for nonvalvular atrial fibrillation: effects of type of practice on physicians' self-reported behavior. ( Bush, D; Tayback, M, 1998)
"Cross-sectional analysis of TEE features correlated with low, moderate and high thromboembolic risk during aspirin therapy among 786 participants undergoing TEE on entry into the Stroke Prevention in Atrial Fibrillation III trial."3.70Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. ( Asinger, RW; Blackshear, JL; Halperin, JL; Hart, RG; Pearce, LA; Zabalgoitia, M, 1998)
"To investigate the incidence of new thromboembolic (TE) stroke in older persons with chronic atrial fibrillation treated with oral warfarin versus aspirin."3.70Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. ( Ahn, C; Aronow, WS; Gutstein, H; Kronzon, I, 1999)
"To determine the prevalence of AF in patients admitted acutely to the general medical service at Auckland Hospital and to assess the adequacy of heart rate control, the number cardioverted and the use of warfarin to prevent thromboembolism."3.70Atrial fibrillation: prevalence and management in an acute general medical unit. ( Braatvedt, GD; Gamble, GD; Persson, S; Singh, Y; Stewart, FM, 1999)
"Several recent randomized clinical trials have demonstrated that warfarin sodium treatment, and to a lesser extent aspirin, reduces risk of stroke and death compared with placebo in persons with atrial fibrillation."3.70Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. ( Furberg, CD; Lima, JA; Manolio, TA; Newman, AB; Psaty, BM; Smith, NL; White, R, 1999)
"56 patients had previously diagnosed atrial fibrillation; 82% were not taking warfarin and 71% of these were not on aspirin either."3.70Additional risk factors in atrial fibrillation patients not receiving warfarin. ( Caine, S; Keir, S; Mac Mahon, M; Wensley, S, 1999)
"2 were not affected by aspirin use and were not associated with thromboembolism after adjustment for age (P=0."3.70Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. ( Bovill, EG; Cornell, ES; Cushman, M; Feinberg, WM; Hart, RG; Lip, GY; Pearce, LA, 1999)
" Time trends were analysed for the use of aspirin, management of hypertension and atrial fibrillation prior to the presenting episode."3.70Secular trends in the management of hypertension and atrial fibrillation in patients presenting with stroke. ( Kalra, L; Perez, I; Smithard, DG, 2000)
"This study assessed whether risk stratification in patients with atrial fibrillation (AF) in the community had a bearing on the likelihood of receiving aspirin or warfarin therapy."3.70Risk stratification in the management of atrial fibrillation in the community. ( Fahey, T; Godfrey, P; Rimmer, J, 1999)
"The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established."3.70Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000)
" We compared the proportion of patients classified as having a low enough stroke risk to receive aspirin using published criteria from the Atrial Fibrillation Investigators (AFI), American College of Chest Physicians (ACCP), and the Stroke Prevention in Atrial Fibrillation Investigators (SPAF)."3.70Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. ( Borowsky, LH; Chang, Y; Go, AS; Henault, LE; Hylek, EM; Phillips, KA; Selby, JV; Singer, DE, 2000)
"Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke."3.70Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000)
"(1) In the acute phase of ischaemic stroke in patients free of thrombogenic heart disease, combined treatment with aspirin + moderate-dose unfractionated heparin reduces the risk of relapse and death."3.70Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention. ( , 2000)
"(1) In patients with atrial fibrillation and a moderate embolic risk, aspirin reduces the risk of stroke and has a comparable risk-benefit ratio to oral anticoagulants."3.70Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease. ( , 2000)
"The recommended treatment of ischaemic stroke patients with atrial fibrillation (AF) is anticoagulation therapy with warfarin sodium and if this is contraindicated then aspirin should be used."3.70Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee. ( Craig, J; Goudie, BM; MacWalter, RS, 2000)
" In this article, we outline the essential elements in the development and evaluation of a decision aid to help patients with atrial fibrillation choose, in consultation with their physicians, appropriate antithrombotic therapy (warfarin, aspirin, or no therapy) to prevent stroke."3.70Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy. ( Anderson, DC; Blackshear, JL; Feldman, G; Hart, RG; Laupacis, A; Man-Son-Hing, M; O'Connor, AM, 2000)
"To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease)."3.69Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. ( Albers, GW; Cardinalli, AB; Gage, BF; Owens, DK, 1995)
"Aspirin 330/mg/day suppressed platelet function in patients with atrial fibrillation, although it did not affect the increased coagulation activity in these patients."3.69Effects of aspirin on status of thrombin generation in atrial fibrillation. ( Fukazawa, H; Ikeda, U; Shimada, K; Yamamoto, K, 1996)
" For patients with a low risk of embolism aspirin is a valuable alternative to anticoagulation."3.69[Should every patient with atrial fibrillation get anticoagulants?]. ( Turina, J, 1997)
"After reviewing these published studies, I think one can conclude that in the patient population with chronic and/or paroxysmal atrial fibrillation, warfarin is beneficial and the benefits outweigh the risks."3.68Stroke and atrial fibrillation: to anticoagulate or not. ( Conti, CR, 1993)
"Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation."3.68Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. ( Hayashi, Y; Nakahama, H; Nakanishi, T; Shimizu, S; Sugita, M; Takiguchi, A; Uyama, O; Yamamoto, S, 1992)
"To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population."3.68Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. ( Asplund, K; Britton, M; Gustafsson, C; Marké, LA; Norrving, B; Olsson, B, 1992)
"Thirty patients (18 women, 12 men) with permanent or paroxysmal atrial fibrillation were treated with a new antiplatelet drug, ticlopidine, in order to study platelet aggregation behaviour, to see whether the drug prevents thromboembolisms and to observe side-effects over a period of 6 months."3.67Platelet aggregation behaviour in patients treated with ticlopidine. ( Balbarini, A; Evangelisti, L; Gherarducci, G; Giordani, R; Mariani, M; Petronio, AS; Preti, R, 1987)
"A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation."3.01Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. ( Bahit, MC; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Easton, JD; Granger, CB; Grauer, C; Kleine, E; Lopes, RD; Lyrer, P; Meyerhoff, J; Sacco, RL; Segura, T; Wachter, R, 2021)
"Aspirin was used by 56."2.90Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. ( Green, JB; Guimarães, PO; Holman, RR; Lokhnygina, Y; Lopes, RD; McGuire, DK; Peterson, ED; Stevens, SR, 2019)
"The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events."2.87An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018)
"Hypertension is more commonly diagnosed in older patients with atrial fibrillation than in the general population."2.73A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. ( Fletcher, K; Hobbs, FD; Hurley, V; Ireson, R; Lip, GY; Mant, J, 2007)
" It is impossible to exclude that long term administration of warfarin in strategy of sinus rhythm maintenance attenuated advantages of normal rhythm in relation of lowering of stroke risk in AFFIRM study and other similar works."2.73[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin]. ( Kanorskiĭ, SG; Shevelev, VI; Zafiraki, VK; Zingilevskiĭ, KB, 2007)
"The term embolic stroke of undetermined source (ESUS) was coined to describe ischemic strokes in which the radiographic features demonstrate territorial infarcts resembling those seen in patients with confirmed sources of embolism but without a clear source of embolism detected."2.72Reexamination of the Embolic Stroke of Undetermined Source Concept. ( Albers, GW; Bernstein, R; Brachmann, J; Camm, AJ; Fromm, P; Goto, S; Granger, CB; Hohnloser, SH; Hylek, E; Kowey, P; Krieger, D; Passman, R; Pines, JM, 2021)
"Bleedings were documented in 19 versus four patients (W/A 5."2.71Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Omblus, R; Pehrsson, K, 2003)
"Stroke and systemic thromboembolism are serious problems for patients with atrial fibrillation (AF), but their incidence can be substantially reduced by appropriate anticoagulation."2.71Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005)
"The risk of thromboembolism is small in atrial paced patients in whom atrial fibrillation has never been documented."2.69Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings. ( Andersen, HR; Mortensen, PT; Nielsen, JC; Pedersen, AK; Thomsen, PE; Thuesen, L; Vesterlund, T, 1999)
"Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients."2.67Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993)
"Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making."2.58Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018)
" Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding."2.58Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. ( Huang, J; Liu, L; Tang, X; Zhang, X, 2018)
"Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality."2.58Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence. ( Argyriou, C; Georgakarakos, EI; Georgiadis, GS; Koutsoumpelis, A; Tasopoulou, KM, 2018)
"Cryptogenic stroke is one-fourth among cerebral infarction, but most of them could be ascribed to embolic stroke."2.53[ESUS (embolic stroke of undetermined sources)]. ( Kitagawa, K, 2016)
"5, and aspirin was administered at a dosage of 75 to 325 mg/d."2.52Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015)
" However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD)."2.52Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. ( Cicci, JD; Danelich, IM; Lose, JM; Reed, BN; Tefft, BJ; Wright, SS, 2015)
"Warfarin has been the traditional choice, but the recently introduced novel oral anticoagulants offer similar efficacy with less bleeding risk."2.52Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation. ( Hussein, A; Saliba, W; Wazni, OM, 2015)
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."2.48Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012)
" Nevertheless, VKAs do require frequent coagulation monitoring and dose adjustment because of their variable dose-response profile, narrow therapeutic window, increased risk for bleeding complications and numerous food and drug interactions."2.47Challenges of stroke prevention in patients with atrial fibrillation in clinical practice. ( Hobbs, FD; Leach, I, 2011)
"The prevention of thromboembolism is an important component in the management of patients with atrial fibrillation."2.45[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?]. ( Bergmann, C; Krpciar, V; Rose, E; Vetter, S; Volkmann, H; Walter, M, 2009)
"Stroke is the most serious complication."2.44Antithrombotic treatment in atrial fibrillation. ( Boos, CJ; Lip, GY, 2008)
"Aspirin is a less effective alternative, and any benefit of aspirin might be due to its favourable effects on arterial thrombosis caused by vascular disease."2.44Atrial fibrillation and stroke prevention. ( Lim, HS; Lip, GY, 2007)
"Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies."2.43Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. ( Hart, RG; Pearce, LA; Tonarelli, SB, 2005)
"About 80% of strokes have ischemic origin."2.43[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005)
"Many elderly patients with recurrent paroxysmal atrial fibrillation have high rates of stroke."2.42Lessons from the Stroke Prevention in Atrial Fibrillation trials. ( Anderson, DC; Halperin, JL; Hart, RG; Kronmal, RA; Marler, JR; McBride, R; Nasco, E; Pearce, LA; Sherman, DG; Talbert, RL, 2003)
"Aspirin also has been studied and is effective, but with a more modest benefit (relative risk reduction of 22%)."2.42Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. ( Connolly, SJ, 2003)
"Stroke is the most feared complication of atrial fibrillation, and the risk of stroke increases markedly with age."2.42Trials of newer approaches to anticoagulation in atrial fibrillation. ( Cooper, HA, 2004)
"Patients with paroxysmal atrial fibrillation have a risk of thromboembolic complications probably equivalent to those with permanent atrial fibrillation."2.42[Anticoagulation therapy in paroxysmal atrial fibrillation]. ( Gjesdal, K; Risøe, C, 2004)
"Paroxysmal AF is an important cause of brain embolism, that is often difficult to document."2.42Atrial fibrillation and cardioembolic stroke. ( Ferro, JM, 2004)
"Aspirin was inconclusively more efficacious than placebo for stroke prevention (OR 0."2.41Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. ( Bass, EB; Goodman, SN; Kim, N; McNamara, RL; Miller, MR; Powe, NR; Robinson, KA; Segal, JB, 2000)
"Aspirin has a modest effect on reducing stroke."2.41[Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. ( Kitabatake, A; Kohya, T; Tomita, F, 2000)
"Aspirin has a modest effect on reducing stroke (about 20% risk reduction)."2.40Prevention of stroke in patients with nonvalvular atrial fibrillation. ( Cairns, JA; Easton, JD; Hart, RG; Sherman, DG, 1998)
"Prevention of recurrence with antiarrhythmic drugs is somewhat problematic because of incomplete efficacy (30% recurrence at 1 year) and the potential for inducing other, life-threatening arrhythmias."2.40Management of atrial fibrillation: out-of-hospital approach. ( Folland, ED, 1999)
"The evolution of sick sinus syndrome is slow, and its clinical and electrocardiographic manifestations are intermittent."2.38Sick sinus syndrome: strategies for reducing mortality. ( Andres, F; Cosín, J; Hernandiz, A; Olagüe, J; Solaz, J, 1992)
"Aspirin therapy is a reasonable alternative for those subjects at relatively lower risk of thromboembolism, especially subjects who are not suitable candidates for anticoagulation."2.38Rationale for antithrombotic therapy in atrial fibrillation. ( Kelley, RE, 1992)
"The risk of early recurrence of embolism in the first 30 days ranges from 8 to 15%."2.38[Embolic complications of chronic atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Théolade, R, 1992)
"Paroxysmal atrial fibrillation is associated with a lower risk of thromboembolic complications than chronic atrial fibrillation."2.38Thromboembolic complications in atrial fibrillation. ( Petersen, P, 1990)
"Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2."1.91DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis. ( Allocco, DJ; Coylewright, M; Freeman, JV; Gibson, DN; Holmes, DR; Hsu, JC; Kapadia, SR; Nair, DG; Piccini, JP; Price, MJ; Yeh, RW, 2023)
"In multivariable Cox frailty regression, the adjusted risk of any adverse event through the 45-day follow-up visit were significantly lower for discharge on warfarin alone (HR: 0."1.72Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. ( Curtis, JP; Daimee, UA; Doshi, SK; Du, C; Freeman, JV; Friedman, DJ; Gibson, D; Goldsweig, AM; Higgins, AY; Masoudi, FA; Minges, KE; Pereira, L; Price, MJ; Reddy, VY; Varosy, PD; Wang, Y, 2022)
"In Warfarin group lower educational status was associated with poor self-management; in Aspirin group, comorbidities and age < 65 years (P = ."1.72A descriptive cross-sectional study of self-management in patients with nonvalvular atrial fibrillation. ( Li, C; Liu, T; Shen, Q; Zhang, C; Zhang, Z; Zhu, H, 2022)
"We report a case of acute renal infarction due to underlying arterial fibrillation, where a novel interventional therapeutic method was used."1.72A rare cause of abdominal pain managed unconventionally: acute renal infarction caused by atrial fibrillation: a case report. ( Ge, T; Song, EJ; Tang, S; Wang, J; Zhou, W; Zhu, Z, 2022)
"Fibrosis was significantly less in treated mice atria."1.62Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation. ( Dixit, G; Li, Z; Ozcan, C, 2021)
"Acute pericarditis has a wide spectrum of clinical presentations largely depending on underlying aetiologies."1.62Age- and sex-based differences in patients with acute pericarditis. ( Antonopoulos, AS; Lazaros, G; Lazarou, E; Tousoulis, D; Vassilopoulos, D; Vlachopoulos, C; Vogiatzi, G, 2021)
"In Western European countries, acute ischemic stroke (AIS) remains the third leading cause of death."1.62Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy. ( Freitas-Silva, M; Medeiros, R; Nunes, JPL, 2021)
"To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil."1.51Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption. ( Kowacs, PA; Macuco, ALB; Nascimento, MTMS; Rizelio, V; Sato, HK; Souza, RKM, 2019)
"In ICCU lateSTEMI patients compared with STEMI patients experienced more frequently heart failure (75, 51."1.46Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters. ( Cerrato, E; Chinaglia, A; Ferro, S; Forno, D, 2017)
": A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy."1.46Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation. ( Baldi, M; Ciconte, G; Conti, M; Pappone, C; Saviano, M; Vicedomini, G, 2017)
"Device-related thrombus remains a major concern because it may result in recurrent embolic events."1.46WATCHMAN device-related thrombus successfully treated with apixaban: A case report. ( Chan, PH; Kwok, OH; Lam, CC; Lam, YY; Siu, CW; Wong, CK, 2017)
"Bleeding was the primary outcome."1.46Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017)
" Further, patients were asked about use of over-the-counter analgesics, adverse effects and how the treatment affected their everyday life."1.46Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy-based Survey. ( Grove, EL; Hellfritzsch, M; Hyllested, LMR; Meegaard, L; Pottegård, A; Wiberg-Hansen, A, 2017)
" Suboptimal dosing was seen."1.43Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. ( Bell, AD; Deschaintre, Y; Gross, P; Heffernan, M; Purdham, DM; Roux, JF; Shuaib, A, 2016)
"Rivaroxaban is an oral anticoagulant that acts as a direct, competitive factor Xa inhibitor."1.43Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report. ( Adamo, A; Bilora, F; Pomerri, F; Prandoni, P, 2016)
"Aspirin (53."1.43Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016)
"When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata."1.42Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. ( Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2015)
"Oral anticoagulation is the recommended treatment for stroke prevention in patients with atrial fibrillation."1.40Atrial fibrillation patients do not benefit from acetylsalicylic acid. ( Friberg, L; Själander, A; Själander, S; Svensson, PJ, 2014)
"We described the cardioembolic (Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack [CHADS2]/Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, Vascular disease, Age 65-75, Sex category i."1.40Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. ( Crijns, HJ; Iorio, A; Lip, GY; Marcucci, M; Nieuwlaat, R; Pisters, R, 2014)
"Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA₂DS₂-VASc score≥2."1.40Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. ( Choi, KJ; Joung, B; Kim, YH; Lee, MH; Nam, GB; Pak, HN; Uhm, JS; Won, H, 2014)
" Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction."1.40Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014)
"In selected low TE risk patients undergoing ablation for AF, a short period of periprocedural therapeutic anticoagulation with LMWH together with aspirin is an effective and safe strategy to prevent TE events."1.39Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy. ( Acena, M; Berte, B; Bun, SS; De Meyer, G; Duytschaever, M; Tavernier, R; Van Heuverswyn, F; Vandekerckhove, Y, 2013)
"While a stroke or transient ischemic attack or history of systemic thromboembolism was detected in 15."1.39Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. ( Acar, G; Akıl, MA; Arıbaş, A; Aydın, M; Bilik, MZ; Bulur, S; Cağlıyan, CE; Ergene, O; Ertaş, F; Gedik, S; Gül, M; Kahya Eren, N; Kanadaşı, M; Kaya, H; Kaya, Z; Köroğlu, B; Köse, N; Oylumlu, M; Ozhan, H; Simşek, Z; Ulgen, MS; Vatan, B; Yeter, E; Yıldız, A; Yılmaz, R; Yüksel, M, 2013)
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."1.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding."1.38Stroke and bleeding in atrial fibrillation with chronic kidney disease. ( Gislason, GH; Hommel, K; Kamper, AL; Køber, L; Lane, DA; Lindhardsen, J; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2012)
"There was no clinical occurrence of paradoxical embolism."1.37Persistent iatrogenic atrial septal defect after pulmonary vein isolation by cryoballoon: an under-recognized complication. ( Chan, NY; Choy, CC; Chu, PS; Lau, CL; Lau, ST; Lo, YK; Mok, NS; Tsui, PT; Yuen, HC, 2011)
"Secondary outcomes included stroke, congestive heart failure, and myocardial infarction."1.37Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. ( Albert, CM; Buring, JE; Chae, CU; Conen, D; Everett, BM; Glynn, RJ; Tedrow, UB, 2011)
" Primary end point was the combined incidence of major adverse coronary events and major bleedings."1.36Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. ( Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010)
" New and emerging oral alternatives to warfarin promise to combine the advantages of oral dosing and effective anticoagulation with improvements in safety, leading to reduced monitoring and dose adjustment."1.36A pharmacoeconomic perspective on stroke prevention in atrial fibrillation. ( Fendrick, AM, 2010)
" In patients considered at moderate risk, the choice is now possible between VKA and aspirin, with a reduced dosage of aspirin (75 to 325 mg)."1.35[Indications of vitamin K antagonists and aspirin in the atrial fibrillation of the elderly]. ( Estivin, S; Gentric, A; Jestin, C, 2009)
"In addition, the recurrence of atrial fibrillation increased 2."1.35[Factors influencing development of atrial fibrillation after implantation of cardiac pacemaker for sinus node dysfunction]. ( Aganauskiene, J; Aidietiene, S; Aidietis, A; Bagdonas, K; Barysiene, J; Jezovas, V; Jurkuvenas, P; Kaireviciūte, D; Laucevicius, A; Marinskis, G, 2009)
"Paroxysmal atrial fibrillation is considered a frequent complication of acute myocardial infarction and the patients with paroxysmal atrial fibrillation probably should be targeted for earlier and more aggressive treatment."1.35Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction. ( Chiribiri, A; Di Bella, G; Marte, F; Patanè, S, 2008)
"The cumulative 10 year mortality and recurrence rate were 92."1.33Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. ( Manios, E; Peppes, V; Spengos, K; Tsivgoulis, G; Vemmos, K; Zakopoulos, N, 2005)
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."1.33Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005)
"Two patients complained of amaurosis fugax at 1 and 3 months after the procedure, and two patients complained of blurred vision at 3 and 4 months after the procedure."1.33Do complaints of amaurosis fugax and blurred vision after transcatheter device closure of atrial septal defect indicate microemboli to retinal vessels? ( Averbuch, L; Dotan, G; Ehrlich, R; Hirsh, R; Mutzmacher, L, 2005)
"Acute myocardial infarction is a rare complication of mitral stenosis."1.33Acute myocardial infarction in a patient with severe unrecognized mitral stenosis. ( Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S, 2006)
"The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention."1.32Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003)
"Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1."1.32[Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003)
"However, the relationship between LA thrombus and transient ischemic attack (TIA) in patients with AF is less well established."1.32Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. ( Dawn, B; Longaker, RA; Singh, P; Stoddard, MF, 2003)
"Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking."1.32Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004)
"Warfarin is used in patients with persistent atrial fibrillation who are at higher risk for thromboembolic complications because of advanced age, history of coronary artery disease or stroke, or presence of left-sided heart failure."1.31Acute management of atrial fibrillation: Part II. Prevention of thromboembolic complications. ( Dickerson, LM; King, DE; Sack, JL, 2002)
"Aspirin use was associated with reduced platelet aggregation response to epinephrine (P=0."1.31A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. ( Aleil, B; Blann, AD; Cazenave, JP; Chin, BS; Kamath, S; Lanza, F; Lip, GY, 2002)
"Once stroke has occurred, it is not recommended to initiate an anticoagulation (unfractioned or low molecular weight heparin) within the first hours."1.31[Anticoagulation in permanent atrial fibrillation after 75 years of age]. ( Tilly-Gentric, A, 2002)
"Among 801 patients not receiving treatment for thromboembolism, the annual rate was 0."1.30[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy]. ( , 1998)
"At reexamination, one thrombus was detected in the patient without anticoagulant treatment and one thrombus was detected in the 8 patients treated with aspirin (13%), compared with ten thrombi detected in the 20 patients (50%) treated with phenprocoumon (p = NS)."1.29Left atrial thrombi despite anticoagulant and antiplatelet therapy. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, RJ, 1994)
"Advanced age, previous stroke or transient ischemic attack (TIA), hypertension and diabetes were all found to be risk factors for stroke in patients with atrial fibrillation."1.29[Atrial fibrillation and apoplexy--risks and prevention]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1996)
"Prevention of recurrence of fibrillation is unnecessary for many after a first episode, especially when idiopathic."1.28[Drug treatments of atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A, 1992)
"Aspirin was used by 91 physicians (36."1.28Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. ( Kutner, M; Nixon, G; Silverstone, F, 1991)

Research

Studies (1,090)

TimeframeStudies, this research(%)All Research%
pre-199014 (1.28)18.7374
1990's227 (20.83)18.2507
2000's344 (31.56)29.6817
2010's410 (37.61)24.3611
2020's95 (8.72)2.80

Authors

AuthorsStudies
Kitagawa, K3
Bahit, MC5
Sacco, RL4
Easton, JD3
Meyerhoff, J1
Cronin, L1
Kleine, E5
Grauer, C1
Brueckmann, M3
Diener, HC11
Lopes, RD25
Brainin, M1
Lyrer, P1
Wachter, R1
Segura, T1
Granger, CB22
Falasconi, G1
Gaspardone, C1
Godino, C2
Gaspardone, A1
Radinovic, A1
Pannone, L1
Leo, G1
Posteraro, GA1
Slavich, M1
Melillo, F1
Marzi, A1
D'Angelo, G1
Limite, LR1
Frontera, A1
Brugliera, L1
Agricola, E1
Margonato, A2
Della Bella, P1
Mazzone, P1
Lv, WH1
Dong, JZ1
Du, X1
Hu, R1
He, L1
Long, DY1
Sang, CH1
Jia, CQ1
Feng, L2
Li, X2
Ning, M1
Chen, X1
Cui, YK1
Tang, RB1
Ma, CS2
Rivolo, S1
Di Fusco, M1
Polanco, C1
Kang, A1
Dhanda, D1
Savone, M1
Skandamis, A1
Kongnakorn, T6
Soto, J1
Cook, HE1
Hewitt, JH1
Patterson, EP1
Randolph, AE1
Welsh, RC4
Dehghani, P1
Lopes, R1
Wojdyla, DM9
Aronson, R8
Windecker, S12
Vora, AN7
Vinereanu, D6
Halvorsen, S7
Parkhomenko, A6
Mehran, R11
Alexander, JH17
Goodman, S1
Espinola-Klein, C1
Matsumoto, C1
Ogawa, H4
Saito, Y3
Okada, S1
Soejima, H1
Sakuma, M1
Masuda, I1
Nakayama, M1
Doi, N1
Jinnouchi, H1
Waki, M1
Morimoto, T1
Bor, WL1
de Veer, AJW1
Olie, RH1
Rikken, SAOF1
Chan Pin Yin, DRPP1
Herrman, JPR1
Vrolix, M1
Meuwissen, M1
Vandendriessche, T1
van Mieghem, C1
Magro, M1
Bennaghmouch, N3
Hermanides, R1
Adriaenssens, T3
Dewilde, WJM2
Ten Berg, JM14
Freeman, JV2
Higgins, AY1
Wang, Y3
Du, C1
Friedman, DJ1
Daimee, UA1
Minges, KE1
Pereira, L1
Goldsweig, AM1
Price, MJ2
Reddy, VY4
Gibson, D1
Doshi, SK3
Varosy, PD1
Masoudi, FA1
Curtis, JP1
Alexopoulos, D3
Li, Z3
Thomas, L9
Goodman, SG9
Jordan, JD1
Kolls, BJ2
Dombrowski, KE1
Berwanger, O4
Ajabnoor, AM1
Zghebi, SS1
Parisi, R1
Ashcroft, DM1
Rutter, MK1
Doran, T1
Carr, MJ1
Mamas, MA2
Kontopantelis, E1
Zheng, F1
Stavrinou, P1
Hu, W1
Mazur, PK1
Arghami, A1
Macielak, SA1
Nei, SD1
Viehman, JK1
King, KS1
Daly, RC1
Crestanello, JA1
Schaff, HV1
Dearani, JA1
Schaefer, JK3
Errickson, J2
Gu, X2
Alexandris-Souphis, T2
Ali, MA2
Haymart, B3
Kaatz, S4
Kline-Rogers, E4
Kozlowski, JH3
Krol, GD3
Shah, V1
Sood, SL3
Froehlich, JB3
Barnes, GD3
Hart, RG58
Katsanos, AH1
Perera, KS3
Eikelboom, JW16
Shen, Q1
Zhang, C1
Liu, T1
Zhu, H1
Zhang, Z1
Li, C3
Ge, T1
Zhu, Z1
Wang, J4
Zhou, W1
Song, EJ1
Tang, S1
Andreotti, F4
Geisler, T2
Collet, JP4
Gigante, B2
Gorog, DA3
Lip, GYH23
Morais, J5
Navarese, EP2
Patrono, C4
Rocca, B3
Rubboli, A5
Sibbing, D2
Storey, RF8
Verheugt, FWA4
Vilahur, G2
Van den Eynde, J1
Possner, M1
Alahdab, F1
Veldtman, G1
Goldstein, BH1
Rathod, RH1
Hoskoppal, AK1
Saraf, A1
Feingold, B1
Alsaied, T1
Chow, JK1
Bagai, A1
Tan, MK1
Har, BJ1
Yip, AMC1
Paniagua, M1
Elbarouni, B1
Bainey, KR1
Paradis, JM1
Maranda, R1
Cantor, WJ1
Eisenberg, MJ1
Dery, JP1
Madan, M1
Cieza, T1
Matteau, A1
Roth, S1
Lavi, S1
Glanz, A1
Gao, D1
Tahiliani, R1
Kim, HH1
Robinson, SD1
Daneault, B1
Chong, AY1
Le May, MR1
Ahooja, V1
Gregoire, JC1
Nadeau, PL1
Laksman, Z1
Heilbron, B1
Yung, D1
Minhas, K1
Bourgeois, R1
Overgaard, CB1
Bonakdar, H1
Logsetty, G1
Lavoie, AJ1
De LaRochelliere, R1
Mansour, S1
Spindler, C1
Yan, AT1
Gong, X1
Hua, R1
Bai, J1
Wu, T1
Wang, Q3
Zhang, J3
Zhang, W1
Ying, L1
Ke, Y1
Wang, X2
Zhang, X2
Liu, K1
Chen, Y2
Zhang, B1
Dong, P1
Xiao, J1
Zhu, L1
Kar, S1
Alkhouli, M1
Camm, AJ5
Coylewright, M3
Gibson, MC1
Gurol, ME1
Huber, K7
Mansour, M1
Nair, DG2
Natale, A2
Pocock, SJ1
Reddy, VR1
Saliba, W4
Christen, T1
Allocco, DJ2
Ellenbogen, KA1
Leon, MB1
Komen, JJ1
Hunt, NB1
Pottegård, A2
Hjemdahl, P5
Wettermark, B5
Olesen, M1
Bennie, M1
Mueller, T1
Carragher, R1
Karlstad, Ø1
Kjerpeseth, LJ1
Klungel, OH1
Forslund, T5
Chikumbanje, MM1
Raza, S1
Barham, L1
Kamel, H1
Elkind, MSV1
Yakushin, SS1
Pereverzeva, KG1
Holmes, DR2
Kapadia, SR2
Hsu, JC3
Gibson, DN1
Yeh, RW1
Piccini, JP9
Riva, L1
Di Pasquale, G2
Xu, ZQ1
Xu, ZH1
Zhang, N1
Elvira Ruiz, G1
Caro Martínez, C1
Flores Blanco, PJ1
Cerezo Manchado, JJ1
Albendín Iglesias, H1
Lova Navarro, A1
Arregui Montoya, F1
García Alberola, A1
Pascual Figal, DA1
Bailén Lorenzo, JL1
Manzano-Fernández, S2
Yasuda, S3
Kaikita, K3
Akao, M4
Ako, J4
Matoba, T3
Nakamura, M3
Miyauchi, K3
Hagiwara, N4
Kimura, K3
Hirayama, A3
Matsui, K3
Saw, J2
Nielsen-Kudsk, JE2
Bergmann, M1
Daniels, MJ1
Tzikas, A1
Reisman, M1
Rana, BS1
Spinthakis, N1
Gue, Y1
Farag, M1
Srinivasan, M1
Wellsted, D1
Arachchillage, DRJ1
Ng, KKH1
Nayar, S1
Catanese, L1
Dyal, L1
Sharma, M5
Connolly, SJ31
Yusuf, S21
Bosch, J1
Darius, H6
Averkov, O2
Budaj, A5
Kong, DF1
Kobalava, Z1
Mehta, RH1
Mirza, Z1
Guimaraes, PO4
Quadros, A1
Thiele, H3
Massaro, T2
Jones-Burton, C1
Heizer, G2
Jones, WS2
Aschermann, M1
Brieger, D1
Cura, F1
Engstrøm, T1
Fridrich, V1
Kang, HJ1
Leiva-Pons, JL1
Lewis, BS5
Malaga, G1
Meneveau, N1
Merkely, B2
Milicic, D2
Potpara, TS4
Raev, D1
Sabaté, M1
de Waha-Thiele, S2
Xavier, D2
Gieling, E1
de Vries, F3
Williams, R1
van Onzenoort, HAW1
de Boer, A3
Ten Cate, V1
Kramers, C2
Burden, A1
Mujovic, N2
Proietti, M3
Dagres, N1
Hindricks, G2
Valgimigli, M3
Heidbuchel, H2
Grant, PJ1
Cosentino, F1
Pouru, JP1
Jaakkola, S1
Lund, J1
Biancari, F3
Saraste, A1
Airaksinen, KEJ1
Leonardi, S2
Popkirov, S1
Healey, JS12
Gladstone, DJ3
De Backer, O2
Dangas, GD2
Jilaihawi, H1
Leipsic, JA1
Terkelsen, CJ1
Makkar, R1
Kini, AS1
Veien, KT1
Abdel-Wahab, M1
Kim, WK1
Balan, P1
Van Mieghem, N1
Mathiassen, ON1
Jeger, RV1
Arnold, M1
Guimarães, AHC2
Nørgaard, BL1
Kofoed, KF1
Blanke, P1
Søndergaard, L2
Tijssen, JGP1
Wöhrle, J1
Gilard, M2
Möllmann, H1
Makkar, RR1
Herrmann, HC1
Giustino, G1
Baldus, S1
Gullestad, L1
Kini, A1
von Lewinski, D1
Mack, M1
Moreno, R1
Schäfer, U1
Seeger, J1
Tchétché, D1
Thomitzek, K1
Vranckx, P1
Wildgoose, P1
Volkl, AA1
Zazula, A1
van Amsterdam, RGM1
de Veer, A2
Oldgren, J10
Steg, PG8
Zateyshchikov, DA1
Jansky, P2
Seung, KB1
Hohnloser, SH17
Nordaby, M7
Bhatt, DL15
Cannon, CP10
Maeng, M2
Miede, C4
Kimura, T5
Liao, YWB1
Wang, TKM1
Kobayashi, Y2
Tanabe, K1
Ikari, Y1
Mercado-Lubo, R1
Yarzebski, J1
Lessard, D1
Gore, J1
Goldberg, RJ1
Luo, CF1
Mo, P1
Li, GQ1
Liu, SM1
Ditali, V1
Carrozzi, C1
Capranzano, P1
Francaviglia, B1
Capodanno, D2
Tamburino, C1
Peterson, BE1
Benetou, DR1
Varlamos, C1
Mpahara, A1
Khan, SU1
Osman, M1
Khan, MU1
Khan, MS1
Zhao, D1
Savji, N1
Al-Abdouh, A1
Hasan, RK1
Michos, ED1
Pande, SD1
Win, MM1
Khine, AA1
Zaw, EM1
Manoharraj, N1
Lolong, L1
Tin, AS1
Wojdyla, D2
Berry, NC1
Mauri, L2
Nagaraj, TA1
Snider, MJ1
Davidson, E1
Weiss, R1
Li, J3
Afzal, M1
Pivato, CA1
Messé, SR2
Gronseth, GS1
Kent, DM1
Kizer, JR1
Homma, S4
Rosterman, L1
Carroll, JD1
Ishida, K1
Sangha, N1
Kasner, SE2
Mill, J1
Olivares, AL1
Arzamendi, D1
Agudelo, V1
Regueiro, A1
Camara, O1
Freixa, X1
Sagris, D1
Leventis, I1
Georgiopoulos, G1
Korompoki, E1
Makaritsis, K1
Vemmos, K2
Milionis, H1
Ntaios, G2
Said, A1
Keeney, S1
Matka, M1
Hafeez, A1
George, J1
Halalau, A1
Gryaznov, AA1
Saeyeldin, A1
Abdelbaky, M1
Zafar, MA1
Tanweer, M1
Papanikolaou, D1
Imran, M1
Li, Y4
Ziganshin, BA1
Elefteriades, JA1
Ong, E1
Meseguer, E1
Guidoux, C1
Lavallée, PC1
Hobeanu, C1
Charles, H1
Labreuche, J1
Cabrejo, L1
Martin-Bechet, A1
Rigual, R1
Nighoghossian, N1
Amarenco, P1
Edward, JA1
Gopal, RK1
Baş, HA1
Aksoy, F1
Bağcı, A1
Varol, E1
Altınbaş, A1
Benz, AP2
Ozcan, C1
Dixit, G1
Lazaros, G1
Antonopoulos, AS1
Lazarou, E1
Vlachopoulos, C1
Vogiatzi, G1
Vassilopoulos, D1
Tousoulis, D1
Patti, G2
Sticchi, A1
Verolino, G1
Pasceri, V2
Vizzi, V1
Brscic, E1
Casu, G1
Golino, P1
Russo, V1
Rapacciuolo, A1
Boccuzzi, G1
Mangieri, A1
Pagnotta, PA1
Colombo, A1
Hoffer, EP1
Yong, CM1
Bittl, JA1
Hijazi, Z3
Lindbäck, J1
Alings, M3
De Caterina, R12
Ezekowitz, MD12
Held, C2
Hylek, EM9
Siegbahn, A1
Wallentin, L8
Fanning, L1
Wong, ICK3
Chan, EW2
Mongkhon, P1
Man, KKC1
Wei, L1
Leung, WK1
Darzins, P1
Bell, JS1
Ilomaki, J1
Lau, WCY2
Guimarães, HP1
de Barros E Silva, PGM1
Liporace, IL1
Sampaio, RO2
Tarasoutchi, F2
Paixão, M1
Hoffmann-Filho, CR1
Patriota, R1
Leiria, TLL1
Lamprea, D1
Precoma, DB1
Atik, FA1
Silveira, FS1
Farias, FR1
Barreto, DO1
Almeida, AP1
Zilli, AC1
de Souza Neto, JD1
Cavalcante, MA1
Figueira, FAMS1
Junior, RA1
Moisés, VA1
Mesas, CE1
Ardito, RV1
Kalil, PSA1
Paiva, MSMO1
Maldonado, JGA1
de Lima, CEB1
D'Oliveira Vieira, R1
Laranjeira, L1
Kojima, F1
Damiani, L1
Nakagawa, RH1
Dos Santos, JRY1
Sampaio, BS1
Campos, VB1
Saraiva, JFK1
Fonseca, FH1
Pinto, IM1
Magalhães, CC1
Ferreira, JFM1
Pavanello, R1
Cavalcanti, AB1
Yang, Y1
Qidwai, U1
Burton, BJL1
Canepa, C1
Zeymer, U2
Leiva, O1
Nickenig, G1
Gabor Kiss, R1
Ongen, Z1
Navarro Estrada, J1
Oude Ophuis, T1
Yamato, H1
Abe, K1
Osumi, S1
Yanagisawa, D1
Kodashima, S1
Asaoka, Y1
Konno, K1
Kozuma, K2
Yamamoto, T1
Tanaka, A1
Ng, VWS1
Siu, CW6
Chiu, PKC1
Kng, CPL1
Jamieson, E1
Lam, MPS1
Taha, A1
Nielsen, SJ1
Bergfeldt, L1
Ahlsson, A1
Friberg, L3
Björck, S1
Franzén, S1
Jeppsson, A1
Carnicelli, AP1
Hong, H1
Giugliano, RP1
Eikelboom, J6
Patel, MR3
Morrow, DA1
Hua, K1
Ruff, CT2
Sinnaeve, P2
Guedeney, P1
Song, CG1
Bi, LJ1
Zhao, JJ1
Li, W2
Yang, F1
Jiang, W1
Freitas-Silva, M1
Medeiros, R1
Nunes, JPL1
Chen, M1
Sun, J1
Zhang, PP1
Mo, BF1
Chen, TZ1
Tang, X2
Li, YG1
Tanner, R1
Cronin, M1
Macken, L1
Murphy, R1
Maree, AO1
Ullah, I1
Cosgrave, J1
O'Connor, S1
Daly, C1
Yang, K1
Kong, X2
Decamillo, D1
Shankar, SR1
Colleran, R1
Byrne, RA1
Ndrepepa, G1
Alvarez-Covarrubias, HA1
Mayer, K1
Kuna, C1
Rai, H1
Kastrati, A1
Cassese, S1
Dizon, K1
Ng, PCK1
Battistella, M2
Albers, GW11
Bernstein, R1
Brachmann, J1
Fromm, P1
Goto, S3
Hylek, E3
Krieger, D1
Passman, R1
Pines, JM1
Kowey, P4
Bahrani, S1
Teimouri-Jervekani, Z1
Sadeghi, M1
Fukaya, H2
Nakamra, M1
Stolk, LM1
Ebbelaar, C1
Schalekamp, T1
Souverein, P1
Ten Cate-Hoek, A1
Burden, AM2
Bushnell, CD2
Hanna, M3
Al-Khatib, SM4
Gabriel Melo de Barros E Silva, P1
Melkonian, M1
Jarzebowski, W1
Pautas, E1
Siguret, V1
Belmin, J1
Lafuente-Lafuente, C3
Pareek, M1
Kristensen, SD1
Grove, EL2
Cerrato, E1
Forno, D1
Ferro, S1
Chinaglia, A1
Abdul-Rahim, AH1
Flaker, GC4
Lees, KR1
McMurray, JJV1
Choi, HI1
Ahn, JM1
Kang, SH1
Lee, PH1
Kang, SJ1
Lee, SW1
Kim, YH3
Lee, CW1
Park, SW1
Park, DW1
Park, SJ1
Ondrakova, M1
Motovska, Z1
Waldauf, P1
Knot, J1
Havluj, L1
Bittner, L1
Bartoska, R1
Gűrlich, R1
Krbec, M1
Dzupa, V1
Grill, R1
Widimsky, P1
Chang, KW1
Arbit, B1
Park, SM1
Jeong, H1
Jung, MH1
Hong, KS1
Hong, MK1
Bang, CS1
Kim, CY1
Vlachakis, P1
Lekakis, J1
Yuan, C1
Zhong, L1
Huang, RC1
Jolobe, OMP1
Meid, AD1
Mächler, S1
Haefeli, WE1
Mikus, G1
Kirchhof, P4
Blank, BF1
Calvert, M1
Chlouverakis, G1
Goette, A1
Huening, A1
Simantirakis, E1
Vardas, P1
Ellis, SG2
Gropper, S1
Harper, R1
Manassie, J1
Januzzi, JL1
Ciconte, G1
Conti, M1
Baldi, M1
Saviano, M1
Vicedomini, G1
Pappone, C1
Sindet-Pedersen, C2
Staerk, L2
Lamberts, M8
Gerds, TA1
Berger, JS2
Nissen Bonde, A2
Langtved Pallisgaard, J1
Hansen, ML9
Torp-Pedersen, C11
Gislason, GH9
Bjerring Olesen, J1
Qiu, J1
Grine, K1
de Veer, AJWM2
Bode, K1
Mahmoodi, BK2
Venkataraman, G1
Bliden, KP1
Tantry, US1
Gurbel, PA1
Manaktala, R1
Kluger, J3
Fluschnik, N1
Becher, PM1
Schnabel, R1
Blankenberg, S1
Westermann, D1
Gaubert, M1
Resseguier, N1
Laine, M2
Bonello, L1
Camoin-Jau, L1
Paganelli, F1
Pearce, LA23
Benavente, O3
Eichenlaub, M1
Pfeufer, A1
Behrens, L1
Klauss, V1
Roettinger, M1
Brodherr, T1
Lewalter, T1
Maksym, J1
Mazurek, T1
Kochman, J1
Grygier, M1
Kapłon-Cieślicka, A1
Marchel, M1
Lodziński, P1
Piątkowski, R1
Wilimski, R1
Czub, P1
Fojt, A1
Karolczak, N1
Hendzel, P1
Opolski, G1
Wong, CK1
Chan, PH5
Lam, CC1
Kwok, OH1
Lam, YY1
Weise, FK2
Bordignon, S2
Perrotta, L2
Konstantinou, A2
Bologna, F1
Nagase, T1
Chen, S3
Chun, KRJ2
Schmidt, B3
Madelaire, C2
Gislason, G2
Kristensen, SL3
Fosbøl, EL1
Bjerre, J1
D'Souza, M1
Gustafsson, F1
Kober, L1
Schou, M2
Cleland, JGF1
Kumar, S2
de Lusignan, S1
McGovern, A1
Correa, A1
Hriskova, M1
Gatenby, P1
Jones, S1
Goldsmith, D1
Verma, A2
Ha, ACT1
Hill, MD1
Wyse, DG3
Champagne, J1
Essebag, V1
Wells, G1
Gupta, D1
Sanders, P1
Birnie, DH1
Kopin, D1
Sherwood, MW1
Dugani, S1
Ames, JM1
Manson, JE1
Mora, S1
Lee, S2
Je, NK1
Feldberg, J1
Patel, P2
Farrell, A1
Sivarajahkumar, S1
Cameron, K1
Ma, J1
James, S1
Chi, G1
Jamil, A1
Radulovic, M1
Jamil, U1
Balouch, MA1
Marszalek, J1
Karimi, Z1
Pahlavani, S1
Jafarizade, M1
Shaukat, H1
Kalayci, A1
Bertrand, PB1
Habran, M1
Kenis, K1
Lecomte, J1
Moonen, L1
Stroobants, D1
Benit, E1
Liu, CY1
Chen, HC1
Aimo, A1
Ripoli, A1
Emdin, M1
Liaw, D1
Liu, L1
Huang, J1
Schwill, S1
Krug, K1
Peters-Klimm, F1
van Lieshout, J1
Laux, G1
Szecsenyi, J1
Wensing, M1
Lee, TC1
Qian, M2
Di Tullio, MR3
Graham, S2
Mann, DL2
Nakanishi, K1
Teerlink, JR2
Freudenberger, RS2
Mohr, JP2
Labovitz, AJ2
Ponikowski, P2
Lok, DJ2
Estol, C1
Anker, SD2
Pullicino, PM2
Buchsbaum, R1
Levin, B2
Thompson, JLP1
Ye, S1
Chan, NC2
Weitz, JI3
Kılıç, S1
Çelik, A1
Çekirdekçi, E1
Altay, S1
Elçik, D1
Akboğa, MK1
Durukan, M1
Yayla, Ç1
Zoghi, M1
Leggio, M1
Fusco, A1
Severi, P1
Lombardi, M1
Caldarone, E1
D'Emidio, S1
Armeni, M1
Mereu, D1
Bendini, MG1
Mazza, A1
Gulati, S1
Solheim, O1
Carlsen, SM1
Øie, LR1
Jensberg, H1
Gulati, AM1
Madsbu, MA1
Giannadakis, C1
Jakola, AS1
Salvesen, Ø1
Clarke, A1
Ibrahim, A1
Kiernan, TJ1
Tubaro, M1
Falaschi, G1
Colivicchi, F1
Pallisgaard, JL1
Lock Hansen, M1
Olesen, JB7
Galli, M1
Savarese, G1
D'Amario, D1
Vergallo, R1
Della Bona, R1
Calò, L1
Porto, I1
Crea, F1
Tong, S1
Zhang, L2
Joseph, J1
Mo, FR1
Yan, YL1
Lai, SY1
Law, SWY1
Dannenberg, L1
Mourikis, P1
Naguib, D1
Zako, S1
Helten, C1
M'Pembele, R1
Trojovsky, K1
Konsek, D1
Wolff, G1
Brockmeyer, M1
Schulze, V1
Levkau, B1
Hohlfeld, T1
Zeus, T1
Kelm, M1
Polzin, A1
Koutsoumpelis, A1
Argyriou, C1
Tasopoulou, KM1
Georgakarakos, EI1
Georgiadis, GS1
Lemesle, G2
Wang, Z2
Sang, W1
Wei, M1
Xu, F1
Coppens, M3
Eikelboom, JWA1
Loewen, PS1
Bansback, N1
Hicklin, J1
Andrade, JG1
Kapanen, AI1
Kwan, L1
Lynd, LD1
McClean, A1
MacGillivray, J1
Salmasi, S1
Pokorney, SD1
Gersh, BJ4
Ahmad, A1
Blank, M1
DiBattiste, P1
Hedrich, O1
Peterson, ED9
Mendys, P1
Mirro, MJ1
Naccarelli, G1
Rutman, H1
Stockbridge, N1
Temple, R1
Wutzler, A1
Krogias, C1
Grau, A1
Veltkamp, R1
Heuschmann, PU1
Haeusler, KG2
Medlinskiene, K1
Fay, M1
Petty, D1
Lucassen, WAM1
van Peet, PG1
Himmelreich, JCL1
Uittenbogaart, SB1
Souphis, NM1
Almany, SL1
Otsuki, H1
Yamaguchi, J1
Kawamoto, T1
Yoshikawa, M1
Ebihara, S1
Tanaka, K1
Nakao, M1
Jujo, K1
Arashi, H1
Ota, Y1
Saito, K1
Takagi, A1
Tanaka, H1
Fujii, S1
Honda, A1
Mori, F1
Swaminathan, B1
Eckstein, J1
Mundl, H1
Epstein, AE1
Mikulik, R1
Toni, D2
Arauz, A1
Hankey, GJ8
Perera, K1
Pagola, J1
Shuaib, A3
Lutsep, H1
Yang, X1
Uchiyama, S4
Endres, M2
Coutts, SB1
Karlinski, M1
Czlonkowska, A1
Molina, CA1
Santo, G1
Berkowitz, SD2
George, S1
Onwordi, ENC1
Gamal, A1
Zaman, A1
Erkut, B1
Ates, A1
Lee, CH2
Jung, KH1
Cho, DJ1
Jeong, SK1
Dimmitt, SB1
Floyd, CN1
Ferner, RE1
Stevens, SR2
Lokhnygina, Y2
Green, JB1
McGuire, DK1
Holman, RR1
Sur, NB1
Wang, K1
Gutierrez, CM1
Dong, C1
Koch, S1
Gardener, H1
García-Rivera, EJ1
Zevallos, JC1
Burgin, WS1
Rose, DZ1
Goldberger, JJ1
Romano, JG1
Rundek, T1
Neuzil, P2
de Potter, T1
van der Heyden, J1
Tromp, SC1
Rensing, B1
Jiresova, E1
Dujka, L1
Lekesova, V1
Horie, K1
Matsumoto, T1
Mizutani, Y1
Tada, N1
Osai, N1
Isawa, T1
Taguri, M1
Kato, S1
Honda, T1
Ootomo, T1
Inoue, N1
Jacobs, MS1
van Hulst, M1
Adeoye, AM1
Tieleman, RG3
Postma, MJ1
Owolabi, MO1
Gao, X1
Ge, Z1
Zuo, G1
Wang, F1
Harskamp, RE1
Fradley, MG1
Gliksman, M1
Emole, J1
Viganego, F1
Rhea, I1
Welter-Frost, A1
Armanious, M1
Lee, DH1
Walko, C1
Shah, B2
Chavez, JC1
McLeod, H1
Pinilla-Ibarz, J1
Schabath, MB1
Gremmel, T1
Sulzgruber, P1
Niessner, A1
Cuisset, T1
Mukherjee, D1
Rizelio, V1
Macuco, ALB1
Sato, HK1
Nascimento, MTMS1
Souza, RKM1
Kowacs, PA1
McIntyre, WF1
Masiero, S1
Conen, D4
Wong, JA1
Beresh, H1
Chun, YH1
Wada, H1
Esato, M1
Hashimoto, T1
Abe, M1
Hasegawa, K1
Tsuji, H1
Furuke, K1
Sabir, IN1
Matthews, GD1
Huang, CL1
Nietlispach, F1
Gloekler, S1
Krause, R1
Shakir, S1
Schmid, M1
Khattab, AA1
Wenaweser, P1
Meier, B3
Duytschaever, M1
Berte, B1
Acena, M1
De Meyer, G1
Bun, SS1
Van Heuverswyn, F1
Vandekerckhove, Y1
Tavernier, R1
Ertas, F3
Oylumlu, M2
Akil, MA2
Acet, H2
Bilik, MZ2
Celepkolu, T1
Yildiz, A2
Kaya, H2
Alan, S1
Ozhan, H2
Kaya, Z1
Bulur, S1
Köse, N1
Gül, M1
Kahya Eren, N1
Cağlıyan, CE1
Köroğlu, B1
Vatan, B1
Acar, G1
Yüksel, M1
Gedik, S1
Simşek, Z1
Yılmaz, R1
Arıbaş, A1
Aydın, M1
Yeter, E1
Kanadaşı, M1
Ergene, O1
Ulgen, MS1
Keating, GM1
Tanrıkulu, A1
Ağırbaşlı, M1
Schjerning Olsen, AM1
Mikkelsen, A1
Christensen, CB1
Lip, GY89
Køber, L5
Apostolakis, S2
Shantsila, E2
Stöllberger, C3
Finsterer, J3
Steinberg, BA1
Kim, S1
Fonarow, GC3
Ansell, J2
Singer, DE22
Gersh, B1
Mahaffey, KW5
Go, AS8
Chang, P2
McCormack, T1
Assiri, A1
Al-Majzoub, O1
Kanaan, AO1
Donovan, JL1
Silva, M1
Lane, DA13
Raichand, S1
Moore, D1
Connock, M1
Fry-Smith, A1
Fitzmaurice, DA1
Gadzhanova, SV1
Roughead, EE1
Bartlett, MJ1
Kansal, AR1
Zheng, Y1
Pokora, T1
Sorensen, SV2
Stiefelhagen, P3
Suh, SY1
Kang, WC1
Oh, PC1
Choi, H1
Moon, CI1
Lee, K1
Han, SH1
Ahn, T1
Choi, IS1
Shin, EK1
Fiaccadori, E1
Maggiore, U1
Regolisti, G1
Gulba, DC1
Moser, M1
Bode, C1
Wu, B1
Kun, L1
Liu, X2
He, B1
Reilly, PA2
Lehr, T1
Haertter, S1
Nehmiz, G2
Wang, S1
Amin, A1
Deitelzweig, S1
Jing, Y2
Makenbaeva, D2
Wiederkehr, D1
Lin, J1
Graham, J1
White, HD3
Nessel, CC2
Becker, RC2
Halperin, JL23
Hacke, W5
Califf, RM2
Fox, KA4
Breithardt, G2
Atar, D1
Aylward, P1
Husted, S3
McMurray, JJ1
Pais, P3
Pouleur, H1
Verheugt, FW9
Själander, S1
Själander, A3
Svensson, PJ4
Wändell, P4
von Euler, M3
Hasselström, J2
Lau, YC2
Lackland, DT1
Roccella, EJ1
Deutsch, AF1
Fornage, M1
George, MG1
Howard, G2
Kissela, BM1
Kittner, SJ1
Lichtman, JH1
Lisabeth, LD1
Schwamm, LH1
Smith, EE2
Towfighi, A1
van den Donk, M1
Opstelten, W1
Enomoto, Y1
Iijima, R1
Tokue, M1
Ito, N1
Nagashima, Y1
Araki, T1
Yamazaki, K1
Utsunomiya, M1
Hori, M6
Itaya, H1
Shiba, M1
Hara, H1
Sugi, K1
Lassen, JF1
Mikkelsen, AP1
Sørensen, R2
Schlitt, A4
Kiviniemi, T2
Karjalainen, PP1
Valencia, J1
Niemelä, M2
Vikman, S2
Airaksinen, KE3
Dinh, T3
Baur, LH1
Pisters, R4
Kamp, O1
Smeets, JL1
Cheriex, EC1
Lindeboom, JE1
Heesen, WF1
Prins, MH1
Crijns, HJ5
Dorian, P4
Phatak, H2
Rublee, DA1
Kuznik, A1
Lanitis, T5
Liu, LZ1
Iloeje, U1
Hernandez, L1
Ice, DS1
Shapiro, TA1
Gnall, EM1
Kowey, PR3
Culebras, A1
Chaturvedi, S2
Kase, CS1
Gronseth, G1
Synhorst, D2
Shestakovska, O8
Asencio, LA1
Huang, JJ1
Alpert, JS1
Lin, AH1
Oakley, LS1
Phan, HL1
Shutt, BJ1
Birgersdotter-Green, U1
Francisco, GM1
Vardi, M1
Debidda, M1
Laranjo, S1
Tavares, C1
Oliveira, M1
Rocha, I1
Mavaddat, N2
Roalfe, A4
Fletcher, K6
Hobbs, FD8
Fitzmaurice, D6
Mant, J6
Huang, H1
Yu, J1
Cao, G1
Xu, Q1
Zhang, S3
Zhou, M1
Alonso-Coello, P2
Montori, VM2
Díaz, MG2
Devereaux, PJ2
Mas, G1
Diez, AI2
Solà, I2
Roura, M2
Souto, JC2
Oliver, S2
Ruiz, R2
Coll-Vinent, B2
Gich, I2
Schünemann, HJ2
Guyatt, G2
Cotté, FE1
Gaudin, AF1
Kachaner, I1
Durand-Zaleski, I1
Marcucci, M2
Nieuwlaat, R2
Iorio, A2
Connolly, S6
Jacobson, L1
De Geer, A1
Ofman, P1
Petrone, AB2
Peralta, A1
Hoffmeister, P1
Albert, CM4
Djousse, L3
Gaziano, JM3
Rahilly-Tierney, CR1
Taylor, J1
Velagapudi, P2
Turagam, MK2
Agrawal, H1
Mittal, M1
Kocheril, AG2
Aggarwal, K1
Uhm, JS1
Won, H1
Joung, B1
Nam, GB1
Choi, KJ1
Lee, MH1
Pak, HN2
Zito, S1
Lattanzio, F1
Di Nisio, M1
Winkle, RA2
Mead, RH2
Engel, G2
Kong, MH3
Patrawala, RA2
Guo, X1
Zhang, Y1
Xu, G1
Zhou, X1
Li, L2
Tang, B1
Lieven, A1
Annemans, L1
Thijs, V1
Marbaix, S1
Gabrilovich, MI1
Buxton, DE1
Lykins, DM1
McMillen, SM1
Onadeko, OOA1
Vanassche, T1
Lauw, MN1
Avezum, A4
Díaz, R4
Llull, L1
Martín, V1
Vidal, B1
Cervera, A1
Thompson, PL2
Dewilde, WJ2
Janssen, PW2
Aguiar, C1
McLeod, E1
Chatzitheofilou, I1
Fonseca Santos, I1
Pereira, S1
Lee, JE1
Ryu, DH1
Jeong, HJ1
Kim, JH2
Jun, JE1
Kim, JS2
Lee, SY1
Cairns, JA4
Mitchell, LB1
Macle, L1
Stiell, IG1
Gladstone, D1
McMurtry, MS1
Cox, JL2
Ivers, N1
Leblanc, K1
Nattel, S2
Arkin, JM1
Gitt, AK1
Zahn, R1
Thompson, AG1
Judkins, C1
Ho, CW1
Ho, MH1
Hai, JJ3
Cheung, E1
Yeung, CY1
Lau, KK1
Chan, KH1
Lau, CP1
Leung, GK1
Tse, HF6
Deitelzweig, SB1
Swindle, JP1
Braun, OÖ1
Bico, B1
Chaudhry, U1
Wagner, H1
Koul, S1
Tydén, P1
Scherstén, F1
Jovinge, S1
Gustav Smith, J1
van der Pals, J1
Bakheet, MF1
Wang, JT1
Dong, MF1
Song, GM1
Ma, ZS1
Ma, SJ1
Bonde, AN1
Kamper, AL2
Hansen, PR2
Hommel, K2
Guo, Y1
Wang, H2
Tian, Y1
Lu, W1
Chen, L1
Yao, Y1
Fu, C1
Zuo, P1
Ma, G1
Ben Freedman, S1
Sun, Y2
Hu, D2
Nikoo, MH1
Taghavian, SR1
Golmoghaddam, H1
Arandi, N1
Abdi Ardakani, A1
Doroudchi, M1
Johnsson, H1
Holmström, M1
Sandhu, RK1
Pfeffer, MA3
Yuan, F1
McAlister, FA1
Zhang, JT1
Chen, KP2
Feng, X1
Huan, Y1
Lv, Y1
Kang, DO1
Yu, CW1
Kim, HD1
Cho, JY1
Joo, HJ1
Choi, RK1
Park, JS3
Lee, HJ1
Park, JH2
Hong, SJ1
Lim, DS1
Skjøth, F4
Rasmussen, LH3
Larsen, TB5
Huisman, MV2
Horie, N1
Kaminogo, M1
Izumo, T1
Hayashi, K1
Tsujino, A1
Nagata, I1
Aguilar, C1
Angoulvant, D1
Villejoubert, O1
Bejan-Angoulvant, T1
Ivanes, F1
Saint Etienne, C1
Fauchier, L2
Argulian, E1
Messerli, FH1
Carlsson, AC2
Gasevic, D1
Sundquist, J2
Sundquist, K2
Jolobe, OM3
Jiang, S1
Ren, C1
Gao, C1
Danelich, IM1
Wright, SS1
Lose, JM1
Tefft, BJ1
Cicci, JD1
Reed, BN1
Sambola, A2
García-Dorado, D2
Gao, F2
Shen, H2
Wang, ZJ2
Yang, SW2
Liu, XL2
Zhou, YJ2
Blann, AD9
Chung, JE1
Choi, YR1
Seong, JM1
La, HO1
Gwak, HS1
Khawaja, O2
Kanjwal, Y1
Agewall, S1
Li, WH1
Yahia, DH1
Pereg, D1
Lishner, M1
Elis, A1
An, J2
Niu, F1
Lang, DT1
Jazdzewski, KP1
Le, PT1
Rashid, N2
Meissner, B1
Mendes, R1
Dills, DG1
Aranda, G1
Bruno, A1
Oo, W1
Kozikowski, A1
Stein, J1
Lolis, J1
Pekmezaris, R1
Makaryus, AN1
Wolf-Klein, G1
Nielsen, PB2
Kopjar, T1
Petricevic, M1
Gasparovic, H1
Svetina, L1
Biocina, B1
Zheng, C1
Koblick, R1
Sennesael, AL1
Dogné, JM1
Spinewine, A1
Rothman, KJ1
Paquette, M1
Teutsch, C1
Dubner, SJ1
Ma, C1
Zint, K1
Elsaesser, A1
Bartels, DB1
Hess, CN2
Peng, SA1
de Lemos, JA1
Fosbol, EL2
Saucedo, JF1
Wang, TY3
Tziomalos, K1
Giampatzis, V1
Bouziana, SD1
Spanou, M1
Kostaki, S1
Papadopoulou, M1
Dourliou, V1
Sofogianni, A1
Savopoulos, C1
Hatzitolios, AI1
Mardekian, J1
Rosenqvist, M2
Fabiaña, N1
Ramaswami, AP1
Ang, ES1
De Silva, DA1
Shiffman, D1
Perez, MV1
Bare, LA1
Louie, JZ1
Arellano, AR1
Devlin, JJ1
Song, W1
Cao, J1
Xu, Y1
Han, Z1
Wen, H1
Cui, X1
Turan, B1
Demir, H1
Mutlu, A1
Daşlı, T1
Erkol, A1
Erden, İ1
Senoo, K1
Huang, D1
Yip, PS1
Hai, J1
Chan, TM1
Lo, WK1
Vazquez, FJ1
Gonzalez, JP1
Gándara, E1
Ng, KH1
Lanas, F2
Lister, K1
Louis Simonet, M1
Hussein, A1
Wazni, OM1
Schöffel, N1
Gamayunov, A1
Mutze, S1
Groneberg, DA1
Ekkernkamp, A1
Thielemann, H1
Rao, M1
Simon, DN1
Kato, TS1
Wu, M1
Thompson, JL1
Estol, CJ1
Mutuberría, M1
García Del Blanco, B1
Alonso, A1
Barrabés, JA1
Bueno, H1
Alfonso, F1
Cequier, A1
Zueco, J1
Rodríguez-Leor, O1
Tornos, P1
Akehurst, RL1
Armstrong, SO1
Amorosi, SL1
Brereton, N1
Hertz, DS1
Dan, GA1
Trendafilova, E1
Goda, A1
Kusljugic, Z1
Manola, S1
Music, L1
Musetescu, R1
Badila, E1
Mitic, G1
Paparisto, V1
Dimitrova, ES1
Polovina, MM1
Petranov, SL1
Djergo, H1
Loncar, D1
Bijedic, A1
Brusich, S1
Bell, AD1
Gross, P1
Heffernan, M1
Deschaintre, Y1
Roux, JF1
Purdham, DM1
Merli, GJ1
Weitz, HH1
Zhou, XK1
Zheng, LF1
Wu, XY1
Chen, H1
Mochalina, N1
Jöud, A1
Carlsson, M1
Sandberg, MEC1
Juhlin, T1
Xiong, Q1
Ranjit, P1
Allende, M1
Molina, E1
Guruceaga, E1
Tamayo, I1
González-Porras, JR1
Gonzalez-López, TJ1
Toledo, E1
Rabal, O1
Ugarte, A1
Roldán, V2
Rivera, J1
Oyarzabal, J1
Montes, R1
Hermida, J1
Lee, TH4
Lee, RT2
Baker, D1
Wilsmore, B1
Narasimhan, S1
Watanabe, E1
Yamamoto, M1
Kodama, I1
Inoue, H3
Atarashi, H2
Okumura, K3
Yamashita, T2
Kodani, E1
Okuyama, Y1
Chishaki, A1
Kiyono, K1
Origasa, H4
Qamar, A1
Ikeda, S1
Matsuda, S1
Koretsune, Y3
Montouchet, C1
Watanabe-Fujinuma, E1
Evers, T1
Rossi, B1
Ruff, L1
Briere, JB1
Freedman, SB2
Van Gelder, I1
Gianni, C1
Potpara, T1
Rienstra, M1
Faza, NN1
Mentias, A1
Parashar, A1
Chaudhury, P1
Barakat, AF1
Agarwal, S2
Wayangankar, S1
Murat Tuzcu, E1
Bilora, F1
Adamo, A1
Pomerri, F1
Prandoni, P1
Maddox, TM1
Kennedy, K1
Katz, DF1
Marzec, LN1
Lubitz, SA1
Gehi, AK1
Turakhia, MP1
Marcus, GM1
Deshpande, S1
Wann, LS1
Barra, ME1
Fanikos, J1
Connors, JM1
Sylvester, KW1
Piazza, G1
Goldhaber, SZ3
Schurtz, G1
Bauters, C1
Ducrocq, G1
Lamblin, N1
Bennell, MC1
Singh, SM1
Wijeysundera, HC1
Björck, F1
Renlund, H1
Wester, P1
Hoshi, T1
Sato, A1
Nogami, A1
Gosho, M1
Aonuma, K1
Nelson, S1
Cloonan, L1
Kanakis, AS1
Fitzpatrick, KM1
Shideler, KI1
Perilla, AS1
Furie, KL1
Rost, NS1
Jackson, LR1
Cyr, DD1
Roe, MT2
Neely, ML1
Martinez, F1
Lüscher, TF1
Winters, KJ1
Armstrong, PW1
Prabhakaran, D1
Magnus Ohman, E1
Corbalán, R1
Hernández Martín, J1
Vial Escolano, R1
Correa Ballester, M1
Dugo, D1
Fürnkranz, A1
Chun, JK1
O'Donnell, MJ1
Dias, R1
Flaker, G9
Zhu, J2
Lewis, G2
Fahed, E1
Ghauche, J1
Rahme, R1
Okais, N1
Samaha, E1
Nohra, G1
Rizk, T1
Maarrawi, J1
Menassa-Moussa, L1
Moussa, R1
Shah, R1
Hellkamp, A1
So, CH1
Eckman, MH5
Ademi, Z1
Pasupathi, K1
Liew, D1
Dawood, FZ1
Judd, S1
Howard, VJ1
Limdi, NA1
Meschia, JF1
Cushman, M2
Herrington, DM1
Soliman, EZ1
Holzmann, M1
Ärnlöv, J1
Johansson, SE1
Athanasakis, K1
Boubouchairopoulou, N1
Karampli, E1
Tarantilis, F1
Savvari, P1
Bilitou, A1
Kyriopoulos, J1
Zhao, SJ1
Zhao, HW1
Wang, XP1
Gao, CY1
Qin, YH1
Cai, HX1
Chen, BY1
Cao, JJ1
Wong, CW1
Korsholm, K1
Nielsen, KM1
Jensen, JM1
Jensen, HK1
Andersen, G1
Jolly, SS1
Natarajan, MK1
Renou, P2
Thambo, JB2
Iriart, X2
Nicot, S1
Kabore, N1
Jalal, Z2
Olindo, S1
Debruxelles, S1
Poli, M1
Rouanet, F1
Sibon, I2
Dinet, ML1
Combes, N1
Pillois, X1
Hellfritzsch, M1
Hyllested, LMR1
Meegaard, L1
Wiberg-Hansen, A1
Gieling, EM1
van den Ham, HA1
van Onzenoort, H1
Bos, J1
Boos, CJ1
Gallagher, AM2
Rietbrock, S2
Plumb, J1
van Staa, TP2
Dalen, JE3
Fang, MC5
Manning, WJ3
Neundörfer, B1
Buerke, M2
Eeckhout, E1
Gershlick, AH2
Pastor, FJ1
Marín, F2
Cambronero, F1
Caro, C1
Pascual-Figal, DA1
Garrido, IP1
Pinar, E1
Valdés, M1
Miller, MM1
Hipp, R1
Matsumura, ME1
Khoo, CW1
Marmagkiolis, K1
Nikolaidis, IG1
Politis, T1
Goldstein, L1
Turtzo, LC1
McCullough, LD1
Maegdefessel, L1
Faerber, J1
Bond, SP1
Messow, CM1
Raaz, U1
Werdan, K1
Muenzel, T1
Weiss, C1
Schwarz, M1
Bode, Ch1
Lin, LJ1
Cheng, MH1
Wung, DC1
Cheng, CL1
Kao Yang, YH1
Doucet, J1
Gréboval-Furstenfeld, E1
Tavildari, A1
M'bello, L1
Delaunay, O1
Pesqué, T1
Moirot, P1
Mouton-Schleifer, D1
Nielsen, VG1
Kirklin, JK1
Holman, WL1
George, JF1
Ellis, TC1
Steenwyk, BL1
Lammey, ML1
Doane, CJ1
Gigliotti, A1
Lee, DR1
Sleeper, MM1
Devereaux, P1
Charles, C1
Alonso, R1
Pogue, J9
Commerford, P2
Franzosi, MG1
Abuladze, G1
Jinjolia, N1
Narsia, E1
Abashidze, R1
Kajaia, T1
Bockeria, LA1
Skopin, II1
Kuts, EV1
Palareti, G1
Gentric, A1
Estivin, S1
Jestin, C1
Csiba, L1
Kovács, KR1
Eckermann, S1
Coory, M1
Willan, AR1
Rao, S1
Julka, M1
Paruchuri, R1
Puccio, D1
Novo, G1
Baiamonte, V1
Nuccio, A1
Fazio, G1
Corrado, E1
Coppola, G1
Muratori, I1
Vernuccio, L1
Novo, S1
Tay, KH2
Plumb, JM2
Pfeffer, M3
Chrolavicius, S3
Aidietis, A1
Barysiene, J1
Marinskis, G1
Aidietiene, S1
Kaireviciūte, D1
Jurkuvenas, P1
Aganauskiene, J1
Bagdonas, K1
Jezovas, V1
Laucevicius, A1
Tedrow, UB2
Koplan, BA1
Glynn, RJ2
Buring, JE2
Griffith, KE1
Pye, M1
Christensen, TD1
Jensen, C1
Christiansen, K1
Sørensen, B1
Bischoff, A1
Boysen, G5
Preobrazhenskiĭ, DV4
Dewilde, S1
Monz, BU1
Volkmann, H1
Walter, M1
Bergmann, C1
Rose, E1
Krpciar, V1
Vetter, S1
Duygu, H1
Eren, NK1
Nazli, C1
Ergene, AO1
Chandra, S1
Lenihan, DJ1
Wei, W1
Yusuf, SW1
Tong, AT1
Jacobs, LG1
Billett, HH1
Freeman, K1
Dinglas, C1
Jumaquio, L1
Einecke, D1
Bover, R1
Pérez-Gómez, F1
Maluenda, MP1
Asenjo, S1
Pérez-Saldaña, R1
Igea, A1
Suárez, M1
Coleto, D1
Fernández, C1
Chua, D1
Legal, M1
Shalansky, SJ1
Lee, YE1
DeZee, KJ1
Goldstein, LB2
Richard, T1
Butaffuoco, F1
Vanhaeverbeek, M1
Shalimar, S1
Pangtey, GS1
Singh, KK1
Iuliano, L1
Di Matteo, A1
Straface, G1
Depta, JP1
Zhao, X2
Peacock, WF1
Seet, RC1
Chen, CP1
Dimou, J1
Jithoo, R1
Morokoff, A1
Lee, BH1
Kwak, JJ1
Hwang, ES1
Kim, SK1
Choi, DH1
Mahé, I2
Extramiana, F1
Tomoda, H1
Moia, M1
Mannucci, PM2
Wandeler-Meyer, K1
Bremerich, J1
Christ, M1
Owen, A2
Hopps, S1
Marcy, TR1
Pullicino, P1
Barrios, V1
Escobar, C1
Echarri, R1
Pristipino, C1
Pelliccia, F1
Irini, D1
Varveri, A1
Roncella, A1
Di Sciascio, G1
Speciale, G1
Glick, JA1
Brophy, GM1
Nozawa, T1
Hirai, T1
Shimada, K2
Hirabayashi, T1
Ono, S1
Hasegawa, T1
Sasagawa, Y1
Kaneko, Y1
Ikeda, Y1
Laufs, U1
Hoppe, UC2
Rosenkranz, S1
Böhm, M1
Grond, M1
Meinertz, T3
Ringelstein, EB1
Röther, J1
Dichgans, M1
Nie, B1
Yan, ZX1
Jia, de A1
Yu, M1
O'Donnell, M4
Hart, R5
Hohnloser, S4
Joyner, C3
Lawrence, J2
Corvol, A1
Legendre, C1
Jean, C1
Lahjibi-Paulet, H1
Saint-Jean, O1
Somme, D1
Reiffel, JA1
Myerburg, R1
Naccarelli, GV1
Packer, DL1
Pratt, CM1
Reiter, MJ1
Waldo, AL3
Paikin, JS1
Mehta, SR1
Chaudhari, D1
Bhuriya, R1
Arora, R1
Shaw, LK2
O'Connor, C1
Blazing, MA1
Renda, G3
Clausen, MT1
Fog-Petersen, ML1
Raunsø, J2
Gadsbøll, N1
Folke, F1
Andersen, SS1
Schramm, TK1
Abildstrøm, SZ1
Poulsen, HE1
Desai, HV1
Aronow, WS4
Gandhi, K1
Bakerywala, S1
Laimuanpuii, J1
Peterson, SJ1
Sharifi, M1
Mehdipour, M1
Bay, C1
Emrani, F1
Sharifi, J1
Doğan, M1
Akdemir, R1
Biçer Yeşilay, A1
Kılıç, H1
Karakurt, O1
Balcı, MM1
Orçan, S1
Lavitola, Pde L1
Oliveira, WA1
Bôer, BN1
Spina, GS1
Grinberg, M1
Nobili, A1
Tettamanti, M1
Pasina, L1
Marengoni, A1
Salerno, F1
Corrao, S1
Emery, C1
Laurendeau, C1
Fagnani, F1
Bergmann, JF2
Yanagisawa, S1
Suzuki, N1
Tanaka, T1
Golitsyn, S1
Talajic, M1
Tan, RS1
Sim, KH1
Van Mieghem, W1
Lanas-Zanetti, F1
Gonzalez-Hermosillo, A1
Dans, AL1
Munawar, M1
Afzal, R1
Garg, RK1
Glazer, NL2
Wiggins, KL1
Newton, KM1
Thacker, EL1
Smith, NL3
Siscovick, DS2
Psaty, BM3
Heckbert, SR2
Srour, JF1
Smetana, GW1
Khan, M1
Kamal, AK1
Kumagai, N1
Jowett, S1
Bryan, S2
Stecker, EC1
Fendrick, AM1
Ziegelstein, RC1
Green, A1
Sauder, M1
Poisson, S1
Johnston, SC1
Chan, NY1
Choy, CC1
Lau, CL1
Lo, YK1
Chu, PS1
Yuen, HC1
Mok, NS1
Tsui, PT1
Lau, ST1
Chae, CU1
Everett, BM1
Garg, N1
Rajpurohit, N1
Lynch, DR1
Leach, I1
Lindhardsen, J2
Ahlehoff, O1
Tolstrup, JS1
Clem, JR1
Bhattacharya, P1
Abbate, R1
Shah, BR1
Olson, DM1
Pan, W1
Asinger, RW6
Herzog, CA1
Cardona, L1
Ana, G1
Luísa, B1
Leal, A1
António, F1
Lídia, S1
Cruz, FR1
Fraenkel, L1
Street, RL1
Fried, TR1
Rodríguez-Yáñez, M1
Arias-Rivas, S1
Fernández-Ferro, J1
Leira, R1
Castillo, J1
Blanco, M1
Ng, J1
Hirsh, J4
Almadi, MA1
Barkun, A1
Brophy, J1
Romero-Ortuno, R1
O'Shea, D1
Bajorek, BV2
Ren, S1
Coleman, CI2
Straznitskas, AD1
Sobieraj, DM1
Anglade, MW2
Ghaswalla, PK1
Harpe, SE1
Slattum, PW1
Rothwell, PM2
Littrell, R1
Belousov, IuB1
Mareev, VIu1
Iavelov, IS1
Belousov, DIu1
Afanas'eva, EV1
Joyner, CD1
Douketis, JD1
Spyropoulos, AC1
Spencer, FA2
Mayr, M1
Jaffer, AK1
Dunn, AS1
Kunz, R1
You, JJ1
Howard, PA1
Schulman, S1
Hughes, M1
Kate, MP1
Oliveira, LH1
Mallmann, FB1
Botelho, FN1
Paul, LC1
Gianotto, M1
Abt, Rde B1
Silva, NJ1
Luize, CM1
Nogueira, FL1
Carvalho, RS1
Paola, AA1
Cirenza, C1
Obeyesekere, MN1
Lockwood, S1
Mottram, P1
Alison, JF1
Krittalak, K1
Sawanyawisuth, K1
Tiamkao, S1
Hachamovitch, R1
Menon, V1
Leal, MA1
Karjalainen, P1
Pietilä, M1
Ylitalo, A1
Puurunen, M1
Li, S1
Mills, RM1
Klaskala, W1
Alexander, KP3
Varughese, CJ1
Colkesen, Y1
Coskun, I1
Muderrisoglu, H1
Petrie, C1
Azoulay, L1
Dell'Aniello, S1
Simon, TA1
Langleben, D1
Renoux, C1
Suissa, S1
Meng, J1
Hagstrom, K1
Foody, JM1
Funk, M1
Gao, P1
Paolasso, E1
Shevelev, VI2
Kanorskiĭ, SG2
Ruwald, MH1
Hansen, CM1
Karasoy, D1
Tanguay, JF1
Vavalle, JP1
Rao, SV1
Ten Cate, H1
Broderick, S1
Newby, LK1
Habich, S1
Kamboj, J1
Kottalgi, M1
Cirra, VR1
Shah, N1
Kamboj, R1
Kozan, Ö1
Schlieper, G1
Krüger, T1
Floege, J1
Baumann, M1
Seifert, CL1
Poppert, H1
Sood, MM1
Tangri, N1
Sarwar, A1
Huang, CX1
Huang, DJ1
Cao, KJ1
Wang, FZ1
Sievert, H1
Buchbinder, M1
Holmes, D1
Kamath, S4
Chin, BS5
King, DE1
Dickerson, LM1
Sack, JL1
Schuchert, A1
Hidden-Lucet, F1
Lew, SJ1
Lim, JK1
Elliott, RA1
Woodward, MC1
Oborne, CA1
Reis, S1
Hermoni, D1
Livingstone, P1
Borkan, J1
Palacio, S1
Doskina, EV1
Lanza, F1
Aleil, B1
Cazenave, JP1
Tilly-Gentric, A1
van Walraven, C4
Laupacis, A10
Petersen, P14
Koudstaal, PJ8
Chang, Y4
Hellemons, B1
Ono, A1
Fujita, T1
Mas, JL3
Rutten, FH1
Hak, E1
Stalman, WA1
Verheij, TJ1
Hoes, AW1
Diner, BM1
Stafford, RS1
Radley, DC1
Abe, Y1
Asakura, T1
Sakamoto, N1
Ishikawa, S1
Muroi, S1
Saitoh, F1
Satoh, M2
Suzuki, S1
Ono, M1
Sakabe, A1
Iwai, M1
Sando, M1
Gotou, J1
Watanabe, Y1
Nagata, K1
Maehara, K1
Maruyama, Y2
Bath, PM2
Sprague, D1
Loewen, P1
Meyer, BJ1
Stoddard, MF1
Singh, P1
Dawn, B1
Longaker, RA1
Wells, GA1
Gullov, AL1
Hellemons, BS3
Koefed, BG1
Anderson, DC5
Kronmal, RA1
McBride, R4
Nasco, E1
Sherman, DG4
Talbert, RL2
Marler, JR1
Fisher, A1
Davis, M1
Kumana, CR1
Leung, CS1
Tam, KM1
Scardi, S1
Mazzone, C1
Conway, DS2
Rosand, J2
Knudsen, KA1
Greenberg, SM2
Edvardsson, N1
Juul-Möller, S1
Omblus, R1
Pehrsson, K1
Martin, DO1
Hung, J1
Mant, JW1
Richards, SH1
Murray, E3
Banting, M1
Rahman, J1
Allan, T1
Raftery, J1
Jensvold, NG1
Henault, LE2
Selby, JV2
Mooe, T1
Grenard, AS1
Caulin, C1
Gere, J1
Minier, D1
Osseby, GV1
Couvreur, G1
Moreau, T1
Giroud, M1
Leschke, M1
Klimek, W1
Mattle, HP1
Schwerzmann, M1
Seiler, Ch1
Heimig, T1
Altiner, A1
Tebbenjohanns, J1
Nagpal, S2
Anderson, D1
Putnam, W2
Flowerdew, G1
Gardner, M1
Cox, J1
Weston, C1
Rao, U1
Cooper, HA1
Chnupa, P1
Abzieher, C1
Länger, T1
Klem, I1
Hartl, E1
Wehinger, C1
Schneider, B1
Ariesen, MJ1
Algra, A2
Lau, E1
Bungard, TJ1
Tsuyuki, RT2
Leys, D2
MacAllister, R1
Hingorani, AD1
Casas, JP1
White, S1
Feely, J2
O'Neill, D1
Risøe, C1
Gjesdal, K1
Tan, KT1
Lechat, PP1
Donnan, GA2
Dewey, HM1
Chambers, BR1
Sato, H2
Fukunami, M2
Kodama, K1
Yamada, Y1
Fujii, K1
Negri, M1
Martignoni, A1
Baccheschi, J1
Santilli, G1
Marchesi, E1
Anderson, M1
Kirk, M1
Ferro, JM1
Economides Muñoz, C1
Singh, BN1
Blich, M1
Gross, B1
Sidorenko, BA3
Kiktev, VG3
Batyraliev, TA3
Pershukov, IV3
Lorenzoni, R1
Lazzerini, G1
Cocci, F1
Ruel, M1
Masters, RG1
Rubens, FD1
Bédard, PJ1
Pipe, AL1
Goldstein, WG1
Hendry, PJ1
Mesana, TG1
Robertson, SL1
Mayer, JB1
Guthmann, R1
Ho, SF1
O'Mahony, MS1
Steward, JA1
Burr, ML1
Buchalter, M1
Maeda, K1
Sakai, T1
Hira, K1
Sato, TS1
Bito, S1
Asai, A1
Hayano, K1
Matsumura, S1
Yamashiro, S1
Fukui, T1
Kovacs, MJ1
Kearon, C1
Rodger, M1
Anderson, DR2
Turpie, AG3
Bates, SM1
Desjardins, L1
Douketis, J1
Kahn, SR1
Solymoss, S1
Wells, PS1
Jackson, SL3
Peterson, GM3
Vial, JH2
Sam, C1
Massaro, JM1
D'Agostino, RB1
Levy, D1
Lambert, JW1
Wolf, PA1
Benjamin, EJ1
Gage, BF4
Pearce, L1
Boode, BS1
Falk, RH3
Fuller, R1
Freestone, B1
Rothwell, P2
Sudlow, C2
Lane, D1
Tsivgoulis, G2
Spengos, K2
Zakopoulos, N2
Manios, E2
Peppes, V1
Bereznicki, LR1
Shinohara, Y1
Kiechl, S1
O'Brien, CL1
Gandjour, J1
Zeindler, J1
Georgiadis, D1
Baumgartner, RW1
Chung, MK1
Burkhardt, JD1
Klein, AL1
Vemmos, KN1
Toumanidis, S1
Moulopoulos, SD1
Katira, R1
Chauhan, A2
More, RS2
Tonarelli, SB1
DiMarco, JP1
Corley, SD1
Greene, HL1
Safford, RE2
Rosenfeld, LE1
Mitrani, G1
Nemeth, M1
Ebell, MH1
Garnier, LF1
Rouesnel, P1
Espitalier, F1
Indredavik, B1
Rohweder, G1
Lydersen, S1
Ehrlich, R1
Mutzmacher, L1
Averbuch, L1
Dotan, G1
Hirsh, R1
Edwards, SJ1
Burkiewicz, JS1
Miyasaka, Y1
Barnes, ME1
Cha, SS1
Seward, JB1
Bailey, KR1
Iwasaka, T1
Tsang, TS1
Aguilar, M1
Ederhy, S2
Meuleman, C1
Hammoudi, N1
Janower, S1
Boccara, F1
Cohen, A2
Krass, I1
Ogle, SJ1
Duguid, MJ1
Shenfield, GM1
Szapáry, L1
García-Honrubia, A1
Climent, V1
Sogorb, F1
Ishikawa, K1
Kitabatake, A2
Ogawa, S1
Yokota, Y1
Fukuyama, T1
Doi, Y1
Mochizuki, S1
Izumi, T1
Takekoshi, N1
Yoshida, K1
Hiramori, K1
Matsumoto, M1
Yamaguchi, T1
Watson, T2
Bajraktari, G1
Kastrati, S1
Manaj, R1
Berisha, I1
Thaqi, S1
Beqiri, A1
Elezi, S1
Gurevich, MA1
Testa, L1
Trotta, G1
Abbate, A1
Agostoni, P1
Biondi-Zoccai, GG1
Steinbeck, G1
Schmidt, M1
Brömsen, J1
Blumenstein, M1
Vardas, PE1
Kallergis, EM1
Hu, DY1
Zhang, HP1
Sun, YH1
Jiang, LQ1
Han, W1
Shen, DT1
Wang, YM1
Cooper, NJ1
Sutton, AJ1
Lu, G1
Khunti, K1
Hurley, V1
Ireson, R1
Kurukulasuriya, LR1
Govindarajan, G1
Sowers, J1
Thompson, CA1
Khalifeh, MR1
Redett, RJ1
Gruber, M1
Goldman, S1
Chaparro, S1
Vahanian, A1
Halinen, MO3
Horrow, J1
Kakar, P1
Helft, G1
Le Feuvre, C1
Zaman, AG1
Karpha, M1
Rash, A1
Downes, T1
Portner, R1
Yeo, WW1
Morgan, N1
Channer, KS1
Cheng, Hy1
King, A1
Bhala, N1
Choudhury, A3
Chung, I3
Blann, A1
Morrison, CM1
Gainsborough, N1
Rajkumar, C1
Akins, PT1
Feldman, HA1
Zoble, RG1
Newman, D1
Spitzer, SG1
Dublin, S1
French, B1
Jackson, LA1
Hrachovec, JB1
Strong, SH1
Walsh, CA1
Manias, T1
Patient, C1
Gorelick, PB1
Zafiraki, VK1
Zingilevskiĭ, KB1
Han, ZX1
Ma, GY1
Ma, CM1
DeEugenio, D1
Kolman, L1
DeCaro, M2
Andrel, J1
Chervoneva, I1
Duong, P1
Lam, L1
McGowan, C1
Lee, G1
Ruggiero, N1
Singhal, S1
Greenspon, A1
Thomson, RG1
Eccles, MP1
Steen, IN1
Greenaway, J1
Stobbart, L1
Murtagh, MJ1
May, CR1
Mahmud, A1
Bennett, K1
Okechukwu, I1
Marshall, G1
Rankin, AC1
Patanè, S1
Marte, F1
Di Bella, G1
Chiribiri, A1
Garcia, D1
Quinn, RR1
Naimark, DM1
Oliver, MJ1
Bayoumi, AM1
Nogueras, C1
Miralles, R1
Roig, A1
Llorach, I1
Cervera, AM1
Zimarino, M1
Aguilar, MI1
Lim, HS1
Simmers, TA1
Nagarakanti, R1
Parcham-Azad, K1
Pedersen, KE1
Lionetti, DA1
Stangier, J1
Luo, M1
Xie, RM1
Quan, HB1
Hu, Y1
Cai, YY1
Schumann, SA1
Ewigman, B1
Göring, C1
Zuo, HJ1
Su, JL1
Zeng, H1
Yuan, BH1
Yao, CH1
Pajitnev, D1
Magnani, JW1
Telman, G1
Kouperberg, E1
Sprecher, E1
Yarnitsky, D1
de Berrazueta Fernández, JR1
Wittes, J1
Gent, M2
Marler, J1
Pritchett, EL1
van Wijk, I1
Kappelle, LJ1
van Gijn, J1
Gorter, JW1
Andersen, LV1
Vestergaard, P1
Deichgraeber, P1
Lindholt, JS1
Mortensen, LS1
Frost, L1
Tangelder, MJ1
Frison, L1
Weaver, D1
Wilcox, RG1
Bylock, A1
Emanuelsson, H1
Held, P1
Zharkova, TV1
Ataullakhanova, DM1
Bykova, ES1
Kropacheva, ES1
Dobrovol'skiĭ, AB1
Titaeva, EV1
Panchenko, EP1
Liakishev, AA1
Francescone, S1
Micheli, S1
Agnelli, G1
Caso, V1
Paciaroni, M1
Berger, PB1
Hu, T1
Topol, EJ1
Smoot, EC1
Olsson, SB2
Capucci, A1
Garwood, CL1
Corbett, TL1
Allen Lapointe, NM1
Sun, JL1
Kaplan, S1
d'Almada, P1
Cardinalli, AB2
Owens, DK2
Theiss, W1
Stratton, JR1
Harper, G1
Gulløv, AL5
Koefoed, BG6
Koskinen, P1
Kupari, M1
Rohack, JJ1
Solomon, DH2
Feinberg, WM6
Tozer, R1
Hastie, IR1
Poungvarin, N1
Opartkiattikul, N1
Chaithiraphan, S1
Viriyavejakul, A1
Kienast, J1
Matchar, DB2
McCrory, DC2
Barnett, HJ1
Feussner, JR1
Morocutti, C1
Coccheri, S1
Bussey, HI1
James, KE1
Zimmermann, M1
Menke, J1
Blair, KL1
Hatton, AC1
White, WD1
Smith, LR1
Lowe, JE1
Wolfe, WG1
Young, WG1
Oldham, HN1
Douglas, JM1
Glower, DD1
Stähelin, HB1
Evison, J1
Seiler, WO1
Miller, VT3
Chollet, F1
Nelson, KM1
Zotz, RJ1
Pinnau, U1
Genth, S1
Erbel, R1
Meyer, J1
Ramsay, LE1
Cheng, TO3
Golden, WE1
Cleves, M1
Prasad, A1
Brown, MM1
MacGregor, GA1
Rothlauf, EB1
Koffler, A1
Walker, JE1
Amano, T1
O'Connell, JE3
Gray, CS3
Lancaster, T1
Tean, KN1
Dunn, FG1
Conti, CR1
Kistler, JP3
Millenson, MM1
Bauer, KA1
Gress, DR3
Barzegar, S1
Hughes, RA4
Sheehan, MA3
Maraventano, SW3
Oertel, LB3
Helgason, CM1
Hoff, JA1
Kondos, GT1
Brace, LD1
Rothrock, JF2
Bower, S1
Sandercock, P3
Lowe, GD3
Blackshear, JL6
Kopecky, SL1
Litin, SC2
Hammill, SC1
Kan, BD1
Katz, DA1
Martinez-Riera, A1
Santolaria-Fernandez, F1
Gonzalez-Reimers, E1
Yanagihara, T1
Whisnant, JP1
Morley, J1
Marinchak, R1
Rials, SJ1
Yamamoto, K1
Ikeda, U1
Fukazawa, H1
Baker, VS1
Holland, A1
Ahlquist, DA1
Ellefson, R1
Koehler, J2
Gray, NJ1
Fiore, LD1
Gold, JA1
Codinach Huix, P1
Connelly, SJ1
Kappenberger, L1
Fromer, M1
Ricou, FJ1
Arroyo, JF1
Hutter, AM1
Cleland, JG2
Cowburn, PJ1
Lip, PL1
Zarifis, J1
Watson, RD1
Bareford, D1
Beevers, DG3
Ammash, N1
Warnes, CA1
Carlsson, J1
Tebbe, U1
Mitusch, R1
Siemens, HJ1
Garbe, M1
Wagner, T1
Sheikhzadeh, A1
Diederich, KW1
Dewarrat, A1
Bogousslavsky, J2
Martín, R1
Yim, JM1
Belew, KM1
Bittar, N2
Hattemer, CR2
Phillips, BG1
Kemp, S1
Hall, EA2
Morton, DJ2
Vlasses, PH2
Cohen, IS1
Greenberg, ML2
Malenka, DJ2
Disch, DL1
Bleyer, FL1
Quattromani, A1
Caracciolo, EA1
Bjerregaard, P1
Chalon, S1
Lechat, P2
Turina, J1
Wilber, DJ1
Gunnar, RM1
Cornell, ES2
Nightingale, SD1
Tracy, RP1
Bovill, EG2
Feddersen, C1
Young, L1
Gandhi, AJ1
Kemp, SM1
Yim, J1
Stiegler, H1
Llop, R1
Ferrer, A1
Agustí, A2
Vidal, X1
Arnau, JM1
Laporte, JR1
Wheeldon, NM1
Brotons, C1
Moral, I1
Antón, JJ1
Cobos, M1
Cucurull, E1
Gállego, C1
Ibáñez, M1
Pérez, A1
Llussà, J1
Orozco, P1
Ventureira, S1
Samarra, M1
Sanz, J1
Permanyer, G1
López, A1
Masuhr, F1
Busch, M1
Einhäupl, KM1
Ohsuzu, F1
Katsushika, S1
Akanuma, M1
Nakamura, H1
Harada, H1
Hiroi, S1
Kimura, A1
Bush, D1
Tayback, M1
Gibbs, CR1
Li-Saw-Hee, FL3
Tijssen, JG1
Ferguson, JJ1
Gonzalez, ER1
Kannel, WB1
Olin, JW1
Raps, EC1
Godtfredsen, J4
Schipper, JP1
Zabalgoitia, M4
Sparks, PB1
Mond, HG1
Kalman, JM1
Jayaprakash, S1
Lewis, MA1
Grigg, LE1
Rodríguez Cumplido, D1
Casajuana Brunet, J1
Botinas Martí, M1
Stiffman, MN1
Pedersen, TS1
Andersen, ED2
Cullinane, M1
Wainwright, R1
Brown, A1
Monaghan, M1
Markus, HS1
Cheung, R1
García, OD1
Tellería-Díaz, A1
Köhler, U1
Nademanee, K1
Kosar, EM1
Albers, G2
Dalen, J1
Dunn, MI1
Jacobson, AK1
Sharif, MN1
McGowan, DJ1
Boechler, M1
Fortune, G1
Gage, B1
Marcus, RR1
Atwood, JE2
Dyken, ML2
Pennock, G1
Fenster, P1
Strauss, R2
Halperin, J1
Asinger, R1
Ahn, C2
Kronzon, I2
Gutstein, H2
Andersen, HR1
Nielsen, JC1
Thomsen, PE1
Thuesen, L1
Pedersen, AK1
Mortensen, PT1
Vesterlund, T1
Stewart, FM1
Singh, Y1
Persson, S1
Gamble, GD1
Braatvedt, GD1
Catherwood, E1
Fitzpatrick, WD1
Holzberger, PT1
Gerling, BR1
Birkmeyer, JD1
Pauker, SG1
Rodríguez, D1
Bloom, JM1
Koudstaal, A1
Levine, JA1
Pascual, J1
Rothbart, RM3
Folland, ED1
Howes, CJ1
Posada, IS1
Barriales, V1
Furberg, CD1
White, R1
Lima, JA1
Newman, AB1
Manolio, TA1
Wellman, M1
Martin, AC1
Langenberg, M2
Lodder, J2
Vermeer, F2
Schouten, HJ2
Lemmens, TG1
van Ree, JW2
Knottnerus, JA2
Bellelli, G1
Barbisoni, P1
Gusmeri, A1
Sabatini, T1
Rozzini, R1
Trabucchi, M1
Scheen, AJ1
Wensley, S1
Keir, S1
Caine, S1
Mac Mahon, M1
Man-Son-Hing, M3
O'Connor, AM2
Biggs, J1
Drake, E1
Yetisir, E1
Gupta, I1
Bennett, G1
Gompertz, P1
Tong, DC1
Lemmens, T1
Vandenbossche, JL1
Perez, I3
Melbourn, A1
Kalra, L3
Goldman, ME1
Safford, R1
Fenster, PE1
Hess, D1
Pennock, GD1
Smithard, DG1
Segal, JB2
McNamara, RL2
Miller, MR2
Kim, N1
Goodman, SN2
Powe, NR2
Robinson, KA2
Bass, EB2
McAnulty, JH1
Jagasia, DH1
Williams, B1
Douglas, M1
Strelnick, A1
Edds, W1
Newton, W1
Walters, B1
Yim, R1
Teo, KK1
Hemphill, JC1
Krumholz, HM1
Baker, DW1
Ashton, CM1
Dunbar, SB1
Friesinger, GC1
Havranek, EP1
Hlatky, MA1
Konstam, M1
Ordin, DL1
Pina, IL1
Pitt, B1
Spertus, JA1
Fahey, T1
Rimmer, J1
Godfrey, P1
Adhiyaman, V1
Kamalakannan, D1
Oke, A1
Shah, IU1
White, AD1
Berge, E1
Abdelnoor, M1
Nakstad, PH1
Sandset, PM2
Taylor, FC2
Ebrahim, S2
Frantz, E1
Cohen, N1
Almoznino-Sarafian, D1
Alon, I1
Gorelik, O1
Koopfer, M1
Chachashvily, S1
Shteinshnaider, M1
Litvinjuk, V1
Modai, D1
Chen, ZM1
Pan, HC1
Counsell, C1
Collins, R1
Liu, LS1
Xie, JX1
Warlow, C2
Peto, R2
Stern, S1
Altkorn, D1
Levinson, W1
Tonkin, A1
Tomita, F1
Kohya, T1
Phillips, KA1
Borowsky, LH1
Kausar, SA1
Bhagat, K1
Tisocki, K1
Holroyd-Leduc, JM1
Kapral, MK1
Austin, PC1
Tu, JV1
Argentino, C1
Fieschi, C1
Cates, C1
Craig, J1
MacWalter, RS1
Goudie, BM1
McNulty, SJ1
Hutchinson, D1
Hardy, KJ1
Feldman, G1
Cohen, H1
Farquhar, D1
Matteoli, S1
Trappolini, M1
Chillotti, FM1
Maxim, R2
Edmunds, E1
Wada, Y1
Mizushige, K1
Ohmori, K1
Iwado, Y1
Kohno, M1
Matsuo, H1
Ornato, JP1
Ali, SN1
Hardman, SM1
Tanahashi, N1
Kim, NL1
Kaye, GC1
Majeed, A1
Moser, K1
Carroll, K1
Daud, R1
Ang, SY1
Dudley, N1
Frykman, V1
Beerman, B1
Rydén, L1
Lardoux, H1
Mallet, A1
Sanchez, P1
Derumeaux, G1
Lecompte, T1
Maillard, L1
Mentre, F1
Pousset, F1
Lacomblez, L1
Pisica, G1
Solbes-Latourette, S1
Raynaud, P1
Chaumet-Riffaud, P1
Pengo, V2
Gardner, MJ1
Flowerdew, GJ1
Brownell, BF1
Evans, A2
Yu, G1
Lalouschek, W1
Lang, W1
Müllner, M1
Prisco, D1
Adams, HP1
Caine, GJ1
Gurney, D1
Yamazaki, M2
Iwata, M1
Davis, S1
Kilpatrick, C1
Gerraty, R1
Campbell, Do1
Greenberg, P1
Hetzer, R1
Hill, JD1
Kerth, WJ1
Ansbro, J1
Adappa, MG1
Rodvien, R1
Kamm, B1
Gerbode, F1
Cosín, J1
Hernandiz, A1
Solaz, J1
Andres, F1
Olagüe, J1
Sawaya, JI1
Chauvin, M2
Koenig, A2
Brechenmacher, C2
Fouchard, J1
Le, F1
Py, A1
Guérin, F1
Uyama, O1
Shimizu, S1
Nakanishi, T1
Nakahama, H1
Takiguchi, A1
Hayashi, Y1
Yamamoto, S1
Sugita, M1
Dunn, M2
Feinberg, W1
Blackburn, T1
Cassidy, TP1
Asakura, H1
Hifumi, S1
Jokaji, H1
Saito, M1
Kumabashiri, I1
Uotani, C1
Morishita, E1
Shibata, K1
Mizuhashi, K1
Blewett, DR2
Rosner, B2
Nolan, J1
Bloomfield, P1
Gustafsson, C1
Asplund, K1
Britton, M1
Norrving, B1
Olsson, B1
Marké, LA1
Kahn, JK1
Kelley, RE1
Théolade, R1
Fossum, K1
Healy, B1
Roberts, RS1
Cairns, J1
Kutner, M1
Nixon, G1
Silverstone, F1
van Zuilen, EV1
Besson, G1
Kastrup, J1
Helweg-Larsen, S1
Chesebro, JH1
Fuster, V1
Andersen, B1
Adams, D1
Bousser, MG1
Abildgaard, U1
Dahl, T1
Bamford, J1
Starkey, I1
Scheinberg, P1
Fisher, M1
Harrison, MJ1
Levine, MN1
Petronio, AS1
Evangelisti, L1
Preti, R1
Gherarducci, G1
Balbarini, A1
Giordani, R1
Mariani, M1
Nuñez, L1
Pinto, AG1
Larrea, JL1
Gil Aguado, M1
Connor, FO1
Dale, J1
Nitter-Hauge, S1
Newmark, SR1
Himathongkam, T1
Shane, JM1
Lüllmann, H1
Schaefer, J1

Clinical Trials (86)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120]Phase 35,390 participants (Actual)Interventional2014-11-27Completed
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400]Phase 44,614 participants (Actual)Interventional2015-06-04Completed
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448]Phase 42,539 participants (Actual)Interventional2002-12-31Completed
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)[NCT02642419]Phase 42,200 participants (Anticipated)Interventional2015-01-31Recruiting
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]Phase 327,395 participants (Actual)Interventional2013-02-28Completed
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography ([NCT02833948]Phase 3231 participants (Actual)Interventional2016-05-31Completed
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203]Phase 31,653 participants (Actual)Interventional2015-12-16Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator)
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864]Phase 32,725 participants (Actual)Interventional2014-07-22Completed
A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER[NCT02303795]Phase 21,005 participants (Actual)Interventional2015-08-31Completed
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG[NCT04045665]Phase 33,200 participants (Anticipated)Interventional2019-12-13Recruiting
Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883]1,120 participants (Anticipated)Interventional2020-06-01Recruiting
A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation[NCT00412984]Phase 320,976 participants (Actual)Interventional2006-12-31Completed
Perioperative Ischemia Versus Perioperative Bleeding During Non-cardiac Surgery in Cardiac Patients : PRAGUE 14 Study[NCT01897220]1,200 participants (Actual)Observational [Patient Registry]2011-12-31Completed
Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk[NCT02960126]Phase 31,500 participants (Anticipated)Interventional2016-11-30Not yet recruiting
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET[NCT02618577]Phase 32,608 participants (Actual)Interventional2016-02-29Terminated (stopped due to following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.)
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
Impact of Catheter Ablation of Atrial Tachyarrhythmias on ABC Stroke and ABC Bleeding Risk Scores[NCT05635864]150 participants (Anticipated)Observational2021-06-03Recruiting
Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Study[NCT02481011]22,111 participants (Actual)Observational2015-05-31Completed
TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control[NCT00790205]Phase 314,671 participants (Actual)Interventional2008-12-10Completed
Disparities in Stroke Outcomes and Care Delivery in Patients With Atrial Fibrillation: FLorida Puerto Rico Atrial Fibrillation Stroke Study (FLiPER-AF)[NCT03627806]104,308 participants (Actual)Observational [Patient Registry]2010-01-01Completed
Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients[NCT03571789]25 participants (Actual)Interventional2017-09-12Active, not recruiting
Comparison of Clinical Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation: A Retrospective Propensity Matched Study[NCT02787525]1,000 participants (Actual)Observational2016-07-31Completed
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710]10,179 participants (Actual)Observational2010-06-30Completed
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035]1,496 participants (Actual)Observational2015-03-22Completed
Transient Electrocardiogram Assessment in Stroke Evaluation[NCT03301662]100 participants (Anticipated)Observational2017-10-09Not yet recruiting
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072]Phase 475 participants (Anticipated)Interventional2017-03-23Recruiting
Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: A Multicenter, Prospective Registry[NCT00596570]996 participants (Actual)Observational2007-01-31Completed
Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288]1,200 participants (Anticipated)Interventional2020-12-16Active, not recruiting
Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709]Phase 47 participants (Actual)Interventional2016-04-30Completed
The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236]150 participants (Actual)Interventional2016-07-31Completed
Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794]300 participants (Actual)Observational [Patient Registry]2018-03-14Completed
Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial[NCT02206815]Phase 4296 participants (Actual)Interventional2014-09-19Completed
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254]Phase 4420 participants (Anticipated)Interventional2013-08-31Recruiting
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639]Phase 4200 participants (Actual)Interventional2010-06-30Completed
Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial[NCT00496769]Phase 36,421 participants (Actual)Interventional2007-08-31Completed
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890]Phase 4510 participants (Anticipated)Interventional2018-09-01Recruiting
Rivaroxaban Evaluation in Real Life Settings[NCT02444221]5,278 participants (Actual)Observational [Patient Registry]2015-07-01Completed
Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319]1,000 participants (Anticipated)Observational2009-03-31Active, not recruiting
Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633]Phase 4614 participants (Actual)Interventional2008-09-30Active, not recruiting
Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)[NCT02666157]Phase 43,672 participants (Anticipated)Interventional2016-01-31Recruiting
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873]Phase 37,554 participants (Actual)Interventional2003-06-30Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479]Phase 339,876 participants (Actual)Interventional1992-09-30Completed
Place Des D-dimères Dans la Prise en Charge Des Patients en Fibrillation Auriculaire : Evaluation de la Valeur prédictive Des D-dimères Sur la Survenue d'événements Thromboemboliques[NCT01224574]425 participants (Actual)Observational2001-01-31Completed
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120]Phase 2200 participants (Anticipated)Interventional2021-03-02Not yet recruiting
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574]84 participants (Actual)Observational2019-02-26Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445]Phase 4160 participants (Actual)Interventional2019-05-01Completed
Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944]Phase 4400 participants (Anticipated)Interventional2015-10-13Completed
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407]Phase 4154 participants (Actual)Interventional2016-12-31Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]Phase 3105 participants (Anticipated)Interventional2014-04-30Recruiting
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475]Phase 448 participants (Actual)Interventional2014-12-10Completed
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]1,800 participants (Anticipated)Observational [Patient Registry]2018-11-21Not yet recruiting
Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.[NCT02350543]Phase 450 participants (Actual)Interventional2015-02-28Terminated (stopped due to Insufficient recruitment.)
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777]4,162 participants (Actual)Observational2014-04-30Completed
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838]1,200 participants (Anticipated)Observational2023-08-09Recruiting
China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）[NCT05975398]450 participants (Anticipated)Observational [Patient Registry]2022-07-01Recruiting
Effect and Safety of Surgical Intervention for Severe Spontaneous Intracerebral Hemorrhage Patients on Long-term Oral Antiplatelet Treatment[NCT05766865]450 participants (Actual)Observational2019-07-10Completed
[NCT02937025]Phase 1/Phase 2154 participants (Anticipated)Interventional2017-01-31Not yet recruiting
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)[NCT00129545]Phase 2/Phase 3800 participants (Actual)Interventional2005-02-28Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Feasibility and Prognostic Role of Percutaneous Left Atrial Appendage Closure in Patients With Heart Failure and Atrial Fibrillation at High Risk for Cerebrovascular Events[NCT04472871]300 participants (Anticipated)Observational2020-07-20Not yet recruiting
English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.[NCT02273609]1,524 participants (Actual)Observational2014-02-28Completed
A Prospective Randomized Controlled Study of Additonal Left Atrial Appendage Electrical Isolation in Catheter Ablation Combined With Left Atrial Appendage Occlusion of Persistent Atrial Fibrillation[NCT04897204]120 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Rehabilitation of Patients With Atrial Fibrillation[NCT03035539]58 participants (Actual)Interventional2012-05-31Completed
Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233]400 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]Phase 31,473 participants (Actual)Interventional2006-12-31Active, not recruiting
[NCT00000556]Phase 30 participants Interventional1995-03-31Completed
Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)[NCT02893215]1,622 participants (Anticipated)Observational [Patient Registry]2016-11-30Recruiting
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178]Phase 36,706 participants (Actual)Interventional2003-07-31Terminated
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948]1,080 participants (Anticipated)Observational [Patient Registry]2018-02-09Active, not recruiting
Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414]12 participants Observational2000-10-31Completed
A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073]Phase 1/Phase 295 participants (Actual)Interventional2005-03-31Completed
Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement[NCT01293188]434 participants (Actual)Observational2011-01-31Completed
Atrial Fibrillation Registry at the Emergency Department of the Medical University of Vienna: A Tool for Structured Diagnosis and Treatment[NCT03272620]3,000 participants (Anticipated)Observational [Patient Registry]2014-10-22Recruiting
Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Atrial Fibrillation Patients Defined as Population With a Low Risk of Stroke Based on a CHA2DS2-VASc Score[NCT03147911]1,181 participants (Actual)Observational2017-04-06Completed
[NCT00000517]Phase 30 participants Interventional1985-07-31Completed
National Institute of Health Research (NIHR) Global Health Research Group on Warfarin Anticoagulation in Patients With Cardiovascular Disease in Sub-Saharan Africa[NCT03512080]1,500 participants (Anticipated)Observational2018-06-11Active, not recruiting
Canadian WATCHMAN Registry[NCT02533752]100 participants (Anticipated)Observational [Patient Registry]2014-09-30Recruiting
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment[NCT04037397]Phase 3120 participants (Anticipated)Interventional2019-09-24Active, not recruiting
Vascular Access Options in Coronary Angiogram Procedures: A Patient Decision Aid Randomized Controlled Trial[NCT01032551]100 participants (Anticipated)Interventional2010-06-30Completed
Echocardiographic Risk Factors of Stroke in Patients With Atrial[NCT03824509]140 participants (Actual)Observational2019-01-01Completed
Stroke Prediction Study Using a Model Based on Internet Search Queries[NCT04755959]450 participants (Anticipated)Observational2021-02-28Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death

Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)4.80
Acetylsalicylic Acid, Aspirin (ASA) 100 mg5.40

Adjudicated Fatal Bleed

Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.00
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.05

Adjudicated Intracranial Hemorrhage

"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.67
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.63

Adjudicated Ischaemic Stroke

Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)3.97
Acetylsalicylic Acid, Aspirin (ASA) 100 mg4.71

Adjudicated Life-threatening Bleed

"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.76
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.91

Adjudicated Recurrent Stroke

Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)4.09
Acetylsalicylic Acid, Aspirin (ASA) 100 mg4.80

All-cause Death

All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)1.24
Acetylsalicylic Acid, Aspirin (ASA) 100 mg1.28

Any Bleed (Investigator-reported)

"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)15.21
Acetylsalicylic Acid, Aspirin (ASA) 100 mg11.64

Disabling Stroke

Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)0.55
Acetylsalicylic Acid, Aspirin (ASA) 100 mg0.93

First Major Bleed (Adjudicated)

"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.

InterventionAnnualised event rate (%/ year) (Number)
Dabigatran Etexilate 110 or 150 Milligram (mg)1.84
Acetylsalicylic Acid, Aspirin (ASA) 100 mg1.33

Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA

"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban24.66
Vitamin K Antagonist35.79

The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin

"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet15.28
Placebo Matching Acetylsalicylic Acid Film Coated Tablet17.73

The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA

"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban57.24
Vitamin K Antagonist69.19

The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin

"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet65.72
Placebo Matching Acetylsalicylic Acid Film Coated Tablet60.56

The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period

"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban24.66
Vitamin K Antagonist35.79

The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period

"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Acetylsalicylic Acid Film Coated Tablet40.51
Placebo Matching Acetylsalicylic Acid Film Coated Tablet21.03

The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA

"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months

InterventionPercentage per year (Number)
Apixaban15.85
Vitamin K Antagonist17.17

All-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg313
Rivaroxaban 5mg + Aspirin Placebo366
Rivaroxaban Placebo + Aspirin 100mg378

All-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg282

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg389
Rivaroxaban 5mg + Aspirin Placebo453
Rivaroxaban Placebo + Aspirin 100mg516

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg329
Rivaroxaban 5mg + Aspirin Placebo397
Rivaroxaban Placebo + Aspirin 100mg450

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg379
Rivaroxaban 5mg + Aspirin Placebo448
Rivaroxaban Placebo + Aspirin 100mg496

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg353

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg288
Rivaroxaban 5mg + Aspirin Placebo255
Rivaroxaban Placebo + Aspirin 100mg170

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg138

Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.

"Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization.~scale [0-100]" (NCT02833948)
Timeframe: 3 months

Interventionmm Hg (Mean)
ASA + Clopidogrel10
Rivaroxaban + ASA10

Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.

Death, Dichotomization by HALT (NCT02833948)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
HALT (-)0
HALT (+)0

Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.

Death, Dichotomization by RLM (NCT02833948)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
RLM>2 (-)0
RLM(+)0

Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.

"Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.~scale [0.1-4.0]" (NCT02833948)
Timeframe: 3 months

Interventioncm2 (Mean)
ASA + Clopidogrel1.8
Rivaroxaban + ASA1.8

Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan

Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (<50%), (III) moderate to severely reduced (>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is > 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets. (NCT02833948)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
ASA + Clopidogrel11
Rivaroxaban + ASA2

The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan

The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT. (NCT02833948)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
ASA + Clopidogrel33
Rivaroxaban + ASA12

The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan

The rate of prosthetic leaflets with RLM> grade 3 as assessed by cardiac 4DCT (NCT02833948)
Timeframe: 3 months

Interventionleaflets (Number)
ASA + Clopidogrel14
Rivaroxaban + ASA3

The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan

The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan (NCT02833948)
Timeframe: 3 months

InterventionLeaflets (Number)
ASA + Clopidogrel53
Rivaroxaban + ASA16

Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.

Thromboembolic event, Dichotomization by HALT (NCT02833948)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
HALT (-)2
HALT (+)0

Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.

Thromboembolic event, Dichotomization by RLM (NCT02833948)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
RLM>2 (-)2
RLM(+)0

Number of Participants With Cardiovascular Death or Thromboembolic Event

Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)83
Antiplatelet68

Number of Participants With Composite Bleeding Endpoint of BARC (Bleeding Academic Research Consortium) 2, 3, or 5 Bleeds

Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)148
Antiplatelet85

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)68
Antiplatelet63

Number of Participants With Death or First Thromboembolic Event (DTE)

Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)105
Antiplatelet78

Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeds

ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)49
Antiplatelet30

Number of Participants With Net-clinical Benefit

The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)137
Antiplatelet100

Number of Participants With Primary Bleeding Event (PBE)

PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)46
Antiplatelet31

Number of Participants With TIMI (Thrombolysis In Myocardial Infarction) Major / Minor Bleeds

Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months

InterventionParticipants (Count of Participants)
Rivaroxaban (Xarelto, BAY59-7939)42
Antiplatelet24

Time to Adjudicated All Cause Death

Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg55
Dabigatran Etexilate 150mg30
Warfarin48
Warfarin (Excluding Elder Patients Outside USA)35

Time to Adjudicated CV

"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg37
Dabigatran Etexilate 150mg21
Warfarin31
Warfarin (Excluding Elder Patients Outside USA)24

Time to Adjudicated Non-CV

"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg14
Dabigatran Etexilate 150mg4
Warfarin13
Warfarin (Excluding Elder Patients Outside USA)8

Time to Adjudicated Undetermined Cause of Death

"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg4
Dabigatran Etexilate 150mg5
Warfarin4
Warfarin (Excluding Elder Patients Outside USA)3

Time to Composite Endpoint of Death + MI + Stroke

Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg107
Dabigatran Etexilate 150mg60
Warfarin80
Warfarin (Excluding Elder Patients Outside USA)57

Time to Composite Endpoint of Death or First Thrombotic Event

Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg108
Dabigatran Etexilate 150mg60
Warfarin83
Warfarin (Excluding Elder Patients Outside USA60
All Dabigatran Etexilate168

Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg149
Dabigatran Etexilate 150mg90
Warfarin131
Warfarin (Excluding Elder Patients Outside USA)98
All Dabigatran Etexilate239

Time to First Adjudicated ISTH MBE or CRNMBE

"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg151
Dabigatran Etexilate 150mg154
Warfarin264
Warfarin (Excluding Elder Patients Outside USA)196

Time to First Adjudicated MI

Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg44
Dabigatran Etexilate 150mg26
Warfarin29
Warfarin (Excluding Elder Patients Outside USA)22

Time to First Adjudicated SE

"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg3
Dabigatran Etexilate 150mg1
Warfarin3
Warfarin (Excluding Elder Patients Outside USA)3

Time to First Adjudicated ST

Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg15
Dabigatran Etexilate 150mg7
Warfarin8
Warfarin (Excluding Elder Patients Outside USA)7

Time to First Adjudicated Stroke

"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg17
Dabigatran Etexilate 150mg9
Warfarin13
Warfarin (Excluding Elder Patients Outside USA)8

Time to First Adjudicated Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months

InterventionParticipants (Count of Participants)
Dabigatran Etexilate 110mg76
Dabigatran Etexilate 150mg51
Warfarin69
Warfarin (Excluding Elder Patients Outside USA)52

Number of Participants With All Bleeding Events During Treatment Period

All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

Interventionparticipants (Number)
Apixaban2356
Warfarin3060

Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period

ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

Interventionparticipants (Number)
Apixaban327
Warfarin462

Number of Participants With Events of All-Cause Death During the Intended Treatment Period

Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

Interventionparticipants (Number)
Apixaban603
Warfarin669

Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period

Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

Interventionparticipants (Number)
Apixaban613
Warfarin877

Number of Participants With Net-Clinical Benefit During Treatment Period

Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

Interventionparticipants (Number)
Apixaban459
Warfarin608

Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period

For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

Interventionparticipants (Number)
Apixaban229
Warfarin285

Rate of Adjudicated All-Cause Death During the Intended Treatment Period

All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

InterventionNumber of events per 100 patient years (Number)
Apixaban3.52
Warfarin3.94

Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period

Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

InterventionNumber of events per 100 patient years (Number)
Apixaban2.13
Warfarin3.09

Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period

Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

InterventionNumber of events per 100 patient years (Number)
Apixaban1.27
Warfarin1.60

Rate of All Bleeding Events During Treatment Period

"Rate=number of all bleeding events per 100 patient years. All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death." (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

Interventionnumber of events per 100 patient years (Number)
Apixaban18.08
Warfarin25.82

Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period

(NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

InterventionNumber of events per 100 patient years (Number)
Apixaban3.21
Warfarin4.06

Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period

Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

Interventionnumber of events / 100 patient years (Number)
Apixaban4.07
Warfarin6.01

Rate of Net-Clinical Benefit During Treatment Period

Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

InterventionNumber of events per 100 patient years (Number)
Apixaban3.01
Warfarin4.09

Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period

AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

,
Interventionparticipants (Number)
AESAEBleeding AEDiscontinuations due to AEDeaths
Apixaban740631822288688429
Warfarin752133022961758468

Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period

All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Time to first event in Intended Treatment Period: started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding)."

,
Interventionparticipants (Number)
Ischemic or Unspecified StrokeHemorrhagic StrokeSystemic Embolism
Apixaban1593815
Warfarin1737616

Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period

Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

,
InterventionNumber of events per 100 patient years (Number)
Severe (n=80, 172))Severe or Moderate (n=199, 328)
Apixaban0.521.29
Warfarin1.132.18

Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period

Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."

,
InterventionNumber of events per 100 patient years (Number)
Major (n=148, 256)Major or Minor (n=239, 370)
Apixaban0.961.55
Warfarin1.692.46

Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period

Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

,
InterventionNumber of events per 100 patient years (Number)
Ischemic or Unspecified Stroke (n=162, 175)Hemorrhagic Stroke (n=40, 78)Systemic Embolism (n=15, 17)Myocardial Infarction (n=90, 102)
Apixaban0.970.240.090.53
Warfarin1.050.470.100.61

Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period

Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."

,
InterventionNumber of events per 100 patient years (Number)
Stroke / SE / Major Bleeding (n=521, 666)Stroke / SE / All-Cause Death (ACD) (n=752, 837)Stroke / SE / Major Bleeding / ACD (n=1009, 1168)Stroke / SE / MI / ACD (n=810, 906)Ischemic or Unspecified Stroke / ACD (n=725, 796)Hemorrhagic Stroke / ACD (n=622, 703)SE / ACD (n=613, 679)MI / ACD (n=663, 740)
Apixaban3.174.496.134.854.323.683.633.93
Warfarin4.115.047.205.494.784.204.054.43

Percent Incidence of All-cause Mortality (Intent to Treat Population)

Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin7.5
Placebo7.3

Percent Incidence of All-cause Mortality (Per Protocol Population)

Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin4.7
Placebo4.3

Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)

Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin3.1
Placebo3.1

Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)

Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin2.8
Placebo2.8

Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)

Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin9.7
Placebo13.2

Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)

Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin8.6
Placebo11.9

Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)

Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin9.6
Placebo9.6

Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)

CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin10.2
Placebo10.2

Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)

CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin8.4
Placebo8.3

Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)

Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin11.4
Placebo11.6

Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)

In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin21.7
Placebo27.9

Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)

In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.) (NCT00790205)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Sitagliptin18.9
Placebo24.5

Change From Baseline in HbA1c Over Time (Intent to Treat Population)

HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years

,
InterventionPercentage of HbA1c (Mean)
Month 4: Sitagliptin, n= 6772; Placebo, n= 6738Month 8: Sitagliptin, n= 6478; Placebo, n= 6414Month 12: Sitagliptin, n= 6448; Placebo, n= 6384Month 24: Sitagliptin, n= 6105; Placebo, n= 5975Month 36: Sitagliptin, n= 3521; Placebo, n= 3439Month 48: Sitagliptin, n= 1432; Placebo, n= 1383Month 60: Sitagliptin, n= 123; Placebo, n= 128
Placebo0.10.10.10.10.10.10.0
Sitagliptin-0.3-0.2-0.2-0.1-0.10.00.0

Change From Baseline in HbA1c Over Time (Per Protocol Population)

HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region. (NCT00790205)
Timeframe: Baseline and up to 4 years

,
InterventionPercentage of HbA1c (Mean)
Month 4; Sitagliptin, n=6632, Placebo, n=6588Month 8; Sitagliptin, n=6294, Placebo, n=6197Month 12; Sitagliptin, n=6217, Placebo, n=6092Month 24; Sitagliptin, n=5668, Placebo, n=5475Month 36; Sitagliptin, n=3227, Placebo, n=3083Month 48; Sitagliptin, n=1271, Placebo, n=1224Month 60; Sitagliptin, n=106, Placebo, n=108
Placebo0.10.10.10.20.10.10.0
Sitagliptin-0.3-0.3-0.2-0.1-0.10.0-0.1

Change From Baseline in Renal Function Over Time (Intent to Treat Population)

Change in renal function based on eGFR using the MDRD method. (NCT00790205)
Timeframe: Baseline and up to 5 years

,
InterventionmL/min/1.73 m^2 (Mean)
Month 4; Sitagliptin, n=3949; Placebo, n=3977Month 8; Sitagliptin, n=3687; Placebo, n=3648Month 12; Sitagliptin, n=5082; Placebo, n=5015Month 24; Sitagliptin, n=5157; Placebo, n=5071Month 36; Sitagliptin, n=3037; Placebo, n=2942Month 48; Sitagliptin, n=1237; Placebo, n=1210Month 60; Sitagliptin, n=93; Placebo, n=106
Placebo-0.8-0.9-0.5-1.7-1.6-2.8-5.7
Sitagliptin-1.8-2.4-1.8-3.2-3.8-4.0-4.2

Change From Baseline in Renal Function Over Time (Per Protocol Population)

Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method. (NCT00790205)
Timeframe: Baseline and up to 5 years

,
InterventionmL/min/1.73 m^2 (Mean)
Month 4; Sitagliptin, n= 3859; Placebo, n= 3864Month 8; Sitagliptin, n= 3562; Placebo, n= 3501Month 12; Sitagliptin, n=4912, Placebo, n=4778Month 24; Sitagliptin, n=4782, Placebo, n=4637Month 36; Sitagliptin, n=2776, Placebo, n=2614Month 48; Sitagliptin, n=1096, Placebo, n=1056Month 60; Sitagliptin, n=79, Placebo, n=88
Placebo-0.8-0.9-0.5-1.7-1.6-2.8-6.4
Sitagliptin-1.9-2.5-1.8-3.1-3.7-3.7-3.5

Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)

Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years

,
Interventiong/mol Creatinine (Mean)
Month 4; n=677, n=713Month 8; n=658, n=624Month 12; n=1167, n=1115Month 24; n=1011, n=964Month 36; n=537, n=553Month 48; n=265, n=256Month 60; n=14, n=18
Placebo-1.40.51.23.13.91.66.4
Sitagliptin-2.12.11.30.52.61.9-2.5

Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)

Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value. (NCT00790205)
Timeframe: Baseline and up to 5 years

,
Interventiong/mol Creatinine (Mean)
Month 4; Sitagliptin, n=664; Placebo, n=688Month 8; Sitagliptin, n=635; Placebo, n=597Month 12; Sitagliptin, n=1126; Placebo, n=1059Month 24; Sitagliptin, n=930; Placebo, n=892Month 36; Sitagliptin, n=488; Placebo, n=513Month 48; Sitagliptin, n=238; Placebo, n=233Month 60; Sitagliptin, n=13; Placebo, n=17
Placebo-1.40.21.23.24.01.54.8
Sitagliptin-2.21.70.80.72.51.3-2.7

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Event Rate for the Composite of Stroke of Any Type, Systemic Embolism, Myocardial Infarction, or Vascular Death During the Double-blind Treatment Period

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

InterventionPercentage of events per year (Number)
Apixaban, 2.5 or 5 mg Twice Daily4.21
Acetylsalicylic Acid, 81-324 mg Once Daily6.35

Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period

Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.) (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

InterventionPercentage of events (Number)
Apixaban, 2.5 or 5 mg Twice Daily1.62
Acetylsalicylic Acid, 81-324 mg Once Daily3.63

Rate of Unrefuted Bleeding From First Dose of Double-blind Study Drug to First Occurence of Unrefuted Bleeding During the Double-blind Treatment Period

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

InterventionPercentage of events per year (Number)
Apixaban, 2.5 or 5 mg Twice Daily10.85
Acetylsalicylic Acid, 81-324 mg Once Daily8.32

Event Rate of All-cause Death; Net Clinical Benefit-Composite of Stroke, Systemic Embolism, Myocardial Infarction, Vascular Death, and Major Bleeding; and Vascular Death

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

,
InterventionPercentage of events per year (Number)
All-cause death (n=111, 140)Net clinical benefit (n=163, 220)Vascular death (n=84, 96)
Acetylsalicylic Acid, 81-324 mg Once Daily4.427.133.03
Apixaban, 2.5 or 5 mg Twice Daily3.515.232.65

Event Rates for Major Bleeding, Major or Clinically Relevant Nonmajor (CNRM) Bleeding, and All Bleeding in the Double-blind Period

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010

,
InterventionPercentage of events per year (Number)
Major bleedingMajor or CRNM bleedingAll bleeding
Acetylsalicylic Acid, 81-324 mg Once Daily0.923.248.32
Apixaban, 2.5 or 5 mg Twice Daily1.414.4610.85

Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality

BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL>2 or value ≤8; hematocrit(%), low: <0.75*BL; erythrocytes (*10^6 cells/μL), low: <0.75*BL; platelet count (*10^9 cells/L),low: <100*10^9 cells/L; leukocytes (*10^3 cells/μL), low if <0.8*BL and BLULN or <0.75*LLN when BL is missing or LLN ≤BL≤ ULN, high if >1.2*BL and BL>ULN or >ULN when BL and BL1.25*ULN when BL is missing or LLN≤BL≤ULN; neutrophils (absolute), low: <1.0*10^3 cells/μL; eosinophils (absolute), high: >0.750*10^3 cells/μL; basophils (absolute), high: >0.4*10^3 cells/μL; monocytes (absolute), high: 2*10^3 cells/μL; lymphocytes (absolute), low if <0.75*10^3 cells/μL, high if >7.50*10^3 cells/μL; ALP (U/L), high: 2*ULN; AST (U/L), high: 3*ULN; AST (U/L), high: 3*ULN; bilirubin, total (mg/dL), high: >2*ULN; bilirubin, direct (mg/dL), high: 1.5*ULN; BUN (mg/dL), high:>2*ULN; creatinine (mg/dL), high: >1.5*ULN. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
Hemoglobin, low (n=1956, 1893)Hemoglobin, high (n=1956, 1893)Hematocrit, low (n=1728, 1687)Hematocrit, high (n=1728, 1687)Erythrocytes, low (n=1728, 1687)Erythrocytes, high (n=1728, 1687)Platelet count, low (n=2148, 2098)Platelet count, high (n=2148, 2098)Leukocytes, low (n=1738, 1698)Leukocytes, high (n=1738, 1698)Neutrophils (absolute), low (n=2170, 2138)Neutrophils (absolute), high (n=2170, 2138)Eosinophils (absolute), low (n=2170, 2138)Eosinophils (absolute), high (n=2170, 2138)Basophils (absolute), low (n=2170, 2138)Basophils (absolute), high (n=2170, 2138)Monocytes (absolute), low (n=2170, 2138)Monocytes (absolute), high (n=2170, 2138)Lymphocytes (absolute), low (n=2170, 2138)Lymphocytes (absolute), high (n=2170, 2138)Alkaline phosphatase (ALP), low (n=2781, 2758)ALP, high (n=2781, 2758)Aspartate phosphatase (AST), low (n=2779, 2753)AST, high (n=2779, 2753)Alanine aminotransferase (ALT), low (n=2779, 2753)ALT, high (n=2779, 2753)Bilirubin (total), low (n=2781, 2758)Bilirubin (total), high (n=2781, 2758)Bilirubin (direct), low (n=2773, 2750)Bilirubin (direct), high (n=2773, 2750)Blood urea nitrogen (BUN), low (n=2201, 2172)BUN, high (n=2201, 2172)Creatinine, low (n=2209, 2178)Creatinine, high (n=2209, 2178)
Acetylsalicylic Acid, 81-324 mg Once Daily12009012010014181006800026250270330310430248050071
Apixaban, 2.5 or 5 mg Twice Daily13101301207012142004800005240340280230300241042067

Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)

LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if <0.95*BL and BLULN or <0.95*LLN when BL missing or LLN ≤BL≤ULN, high if >1.05*BL and BL>ULN or >ULN and BL1.05*ULN when BL missing or LLN≤BL≤ULN; potassium(mEq/L):low if <0.90*BL and BLULN or <0.90*LLN if BL missing or LLN≤BL≤ULN, high if >1.10*BL and BL>ULN or>ULN and BL1.10*ULN when BL missing or LLN≤BL≤ULN; chloride(mEq/L):low if <0.90*BL and BLULN or <0.90*LLN if BL missing or LLN≤BL ≤ULN, high if >1.10*BL and BL>ULN or >ULN and BL1.10* ULN if BL missing or LLN≤BL≤ULN; calcium(mg/dL):low if <0.75*BL and BLULN or <0.80*LLN if BL missing or LLN≤BL≤ULN, high if >1.25*BL and BL>ULN or >ULN if BL1.20*ULN if BL missing or LLN≤BL≤ULN ; bicarbonate(mEq/L):low if <0.75*BL when BLULN or <0.75*LLN if BL missing or LLN≤BL≤ULN, high if >1.25*BL when BL>ULN or >ULN (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
Sodium (serum), low (n=1768, 1740)Sodium (serum), high (n=1768, 1740)Potassium (serum), low (n=1763, 1737)Potassium (serum), high (n=1763, 1737)Chloride (serum), low (n=1768, 1740)Chloride (serum), high (n=1768, 1740)Calcium (total), low (n=106, 109)Calcium (total), high (n=106, 109)Bicarbonate, low (n=1664, 1619)Bicarbonate, high (n=1664, 1619)
Acetylsalicylic Acid, 81-324 mg Once Daily62828310000
Apixaban, 2.5 or 5 mg Twice Daily21620000000

Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)

ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:>5*ULN; protein, total(g/L):low if <0.90*BL when BLULN or <0.90*LLN when BL is missing or LLN≤BL≤ULN, high if >1.10*BL if BL>ULN or >ULN when BL1.10*ULN if BL missing or LLN≤BL≤ULN.Protein,total(g/L): low if <0.90*BL if BLULN or <0.90*LLN if BL missing or LLN≤BL≤ULN, high if >1.10*BL if BL>ULN or >ULN if BL1.10*ULN if BL or LLN≤BL≤ULN; glucose, serum fasting (mg/dL): low if <0.8*BL if BLULN or <0.8*LLN when BL missing or LLN≤BL≤ULN, high if >2*BL when BL>ULN or >ULN when BL1.5*ULN if BL missing or LLN≤BL≤ULN; uric acid (mg/dL), high: >2*BL and BL>ULN or>1.5*ULN when BL missing or BL≤ULN; glucose, urine, high; protein, urine, high; blood, urine, high; leukocyte esterase, urine, high; RBC count, urine (Hpf), high; WBC count, urine (Hpf), high: ≥2 if BL=missing,=0 or =0.5 or if ≥3 if BL=1, or if ≥4 and BL≥2. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
Creatine kinase, low (n=2780, 2758)Creatine kinase, high (n=2780, 2758)Protein (total), low (n=103, 109)Protein (total), high (n=103, 109)Uric acid, low (n=386, 390)Uric acid, high (n=386, 390)Glucose (urine), low (n=2, 3)Glucose (urine), high (n=2, 3)Protein (urine), low (n=3, 5)Protein (urine), high (n=3, 5)Blood (urine), low (n=3, 5)Blood (urine), high (n=3, 5)Leukocyte esterase (urine), low (n=3,5)Leukocyte esterase (urine), high (n=3,5)Red blood cells (RBC) (urine), low (n=2,2)RBC (urine), high (n=2,2)White blood cells (urine), low (n=2,2)WBC (urine), high (n=2,2)
Acetylsalicylic Acid, 81-324 mg Once Daily0250000010100000000
Apixaban, 2.5 or 5 mg Twice Daily0130001000101000100

Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs), Bleeding AEs, Discontinuations Due to AEs, and Death as Outcome

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
AEsSAEsBleeding AEsDiscontinuations due to AEDeaths
Acetylsalicylic Acid, 81-324 mg Once Daily1925804259362115
Apixaban, 2.5 or 5 mg Twice Daily183365728126691

Adjudicated Major Bleedings

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA251
Placebo + ASA162

Death From Any Cause (Cardiovascular and Noncardiovascular)

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA825
Placebo + ASA841

Occurrence of Stroke

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Interventionparticipants (Number)
Clopidogrel + ASA296
Placebo + ASA408

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

,
Interventionparticipants (Number)
All components- Myocardial Infarction (fatal or not)- Stroke (fatal or not)- Non-CNS systemic embolism- Vascular death
Clopidogrel + ASA8328428550413
Placebo + ASA92410539148380

Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer

(NCT00000479)
Timeframe: Average follow-up 10.1 years

,,,
Interventionparticipants (Number)
Total invasive cancerCancer death
Aspirin + Vitamin E716152
Aspirin Only722132
Both Placebos706143
Vitamin E Only721156

Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death)

(NCT00000479)
Timeframe: Average follow-up 10.1 years

,,,
InterventionParticipants (Number)
Major cardiovascular eventStrokeMyocardial infarctionCardiovascular death
Aspirin + Vitamin E23210810254
Aspirin Only2451139666
Both Placebos2721339974
Vitamin E Only2501339452

Apixaban Plasma Concentration, Cmax

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng/mL (Geometric Mean)
Apixaban 2.5 mg59.7
Apixaban 5 mg97.9

Apixaban Plasma Concentration, Cmin

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng/mL (Geometric Mean)
Apixaban 2.5 mg28.2
Apixaban 5mg49.7

Area Under the Plasma Apixaban Concentration Curve From 0 to 12 Hours After Dose (AUCO-12)

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng*h/mL (Geometric Mean)
Apixaban 2.5 mg507
Apixaban 5mg868

Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding

"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban21
Warfarin16

Number of Participants Experiencing Mortality

Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban21
Warfarin13

Number of Participants Experiencing Stroke

"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban2
Warfarin2

Number of Participants Experiencing Stroke or Systemic Embolism

Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban2
Warfarin2

Number of Participants Experiencing Stroke, Systemic Embolism, Major Bleeding or All-cause Mortality

"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban27
Warfarin29

Number of Participants Experiencing Systemic Embolism

"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban0
Warfarin0

Persistence of Therapy

Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionDays (Mean)
Apixaban304.4
Warfarin279.6

Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death

A Bayesian model allowed for sequential evaluation of the primary endpoints, event rates reported per 100 patient-years (calculated as 100*N events/Total patient-years) (NCT00129545)
Timeframe: 5 years

Interventionevents per 100 pt yrs (Number)
Implantable Device2.2
Warfarin Control3.7

Procedure Success

Implant procedure success is defined as the delivery and release of a WATCHMAN Device into the LAA. (NCT00129545)
Timeframe: Initial implant procedure

Interventionpercentage of implant attempts (Number)
WATCHMAN90.9

The Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events

Serious bleeding events evaluated by the Clinical Events Committee included pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion, and any bleeding related to the device or procedure that necessitates an operation. (NCT00129545)
Timeframe: 5 years

InterventionEvents per 100 pt-yrs (Number)
Implantable Device3.5
Warfarin Control3.2

Reviews

273 reviews available for aspirin and Auricular Fibrillation

ArticleYear
Apixaban for Anticoagulation After Robotic Mitral Valve Repair.
    The Annals of thoracic surgery, 2023, Volume: 115, Issue:4

    Topics: Aftercare; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; Male; Middle Ag

2023
Thromboprophylaxis in Patients With Fontan Circulation.
    Journal of the American College of Cardiology, 2023, 01-31, Volume: 81, Issue:4

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fontan Procedure; Hemorrhage; Hu

2023
Comprehensive systematic review and meta-analysis on anticoagulants and aspirin for stroke prevention in non-valvular atrial fibrillation patients.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:22

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Warfarin

2023
Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2020, 01-01, Volume: 22, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrino

2020
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
    Coronary artery disease, 2020, Volume: 31, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug

2020
Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective.
    Cardiovascular intervention and therapeutics, 2020, Volume: 35, Issue:1

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fi

2020
Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis.
    European heart journal. Cardiovascular pharmacotherapy, 2021, 05-23, Volume: 7, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans;

2021
[Short dual antiplatelet therapy: how, when and why].
    Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:2 Suppl 1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dual Anti-Platelet Therapy; H

2020
Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention.
    Journal of thrombosis and thrombolysis, 2020, Volume: 49, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiology; Coronary Thrombosis; Drug Therapy, Combina

2020
Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Percut

2021
Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
    Annals of internal medicine, 2020, 04-07, Volume: 172, Issue:7

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agent

2020
Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression.
    European journal of internal medicine, 2020, Volume: 79

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Venous Thromboem

2020
Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management.
    Thrombosis and haemostasis, 2021, Volume: 121, Issue:7

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Blood C

2021
Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation.
    The American journal of cardiology, 2021, 04-01, Volume: 144 Suppl 1

    Topics: Aspirin; Atrial Fibrillation; Drug Administration Schedule; Dual Anti-Platelet Therapy; Graft Occlus

2021
Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo
    Medicine, 2021, Apr-16, Volume: 100, Issue:15

    Topics: 4-Hydroxycoumarins; Aged; Aspirin; Atrial Fibrillation; Diabetes Mellitus; Diabetic Cardiomyopathies

2021
Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials.
    Cardiovascular revascularization medicine : including molecular interventions, 2022, Volume: 36

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans;

2022
Reexamination of the Embolic Stroke of Undetermined Source Concept.
    Stroke, 2021, Volume: 52, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Clinical Trials as Topic; Dual An

2021
Thrombotic Events and Anticoagulants in Beta-thalassemia Patients with Focus on Anticoagulants for Atrial Fibrillation: A Brief Review.
    Current problems in cardiology, 2022, Volume: 47, Issue:9

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thalassemia; Hemorrhage; Hu

2022
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2017
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2017
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
    Cardiovascular drugs and therapy, 2017, Volume: 31, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Female; Fibrinolytic Agents; Hum

2017
Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review.
    International journal of cardiology, 2017, Sep-15, Volume: 243

    Topics: Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agent

2017
Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role.
    Cardiovascular drugs and therapy, 2017, Volume: 31, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Meta-Analysis

2017
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
    Zhonghua xin xue guan bing za zhi, 2017, Jun-24, Volume: 45, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He

2017
Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Circulation, 2018, 03-13, Volume: 137, Issue:11

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Interact

2018
Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation.
    The Journal of the American Osteopathic Association, 2017, Dec-01, Volume: 117, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Female; Humans; Male;

2017
Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.
    Current atherosclerosis reports, 2018, 02-21, Volume: 20, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibito

2018
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 02-01, Volume: 34, Issue:2

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular

2019
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse

2018
Antithrombotic strategies after interventional left atrial appendage closure: an update.
    Expert review of cardiovascular therapy, 2018, Volume: 16, Issue:9

    Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Atrial Appendage; Atrial Fibrillation; Embolism; H

2018
Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble.
    Drugs, 2018, Volume: 78, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Drug Therapy, Combination; Drug-E

2018
Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice.
    Expert review of cardiovascular therapy, 2018, Volume: 16, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Percutaneous C

2018
[Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome].
    Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:10

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co

2018
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
    European heart journal. Cardiovascular pharmacotherapy, 2019, 01-01, Volume: 5, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Decision-Making; Clopidogrel; Evidence-Based

2019
Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Journal of cardiology, 2019, Volume: 73, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Coron

2019
Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence.
    Current pharmaceutical design, 2018, Volume: 24, Issue:38

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans;

2018
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
    Coronary artery disease, 2019, Volume: 30, Issue:2

    Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru

2019
Antithrombotic Agents.
    Circulation research, 2019, Volume: 124, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a

2019
Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome.
    Clinical drug investigation, 2019, Volume: 39, Issue:6

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrino

2019
Antithrombotic dose: Some observations from published clinical trials.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Dose-Response Relations

2019
Atrial Fibrillation in Africa-An Under-Reported and Unrecognized Risk Factor for Stroke: A Systematic Review.
    Global heart, 2019, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Africa; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Epidemiologic Methods

2019
Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.
    International heart journal, 2019, May-30, Volume: 60, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Observational St

2019
Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).
    Journal of the American College of Cardiology, 2019, 08-06, Volume: 74, Issue:5

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Th

2019
Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice.
    Postgraduate medical journal, 2013, Volume: 89, Issue:1052

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Drug Interactions; Femal

2013
Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
    Drugs, 2013, Volume: 73, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Embolism; Fibrinolytic Agents; Humans; Pyrazoles; Pyridones; Stroke; W

2013
Triple therapy (aspirin, clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2013, Volume: 13, Issue:5

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2013
Pharmacokinetic considerations for antithrombotic therapies in stroke.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor

2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr

2013
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
    Health technology assessment (Winchester, England), 2013, Volume: 17, Issue:30

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Ischemi

2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benef

2013
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.
    Stroke, 2014, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Air Pollution; American Heart Association;

2014
[Important changes in the Dutch College of General Practitioners (NHG) practice guideline 'Atrial fibrillation': revised practice guideline issued].
    Nederlands tijdschrift voor geneeskunde, 2013, Volume: 157, Issue:38

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; General Practice; Huma

2013
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
    The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru

2014
Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?
    The American journal of medicine, 2014, Volume: 127, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibri

2014
Antithrombotics in atrial fibrillation and coronary disease.
    Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:8

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Coronary Artery D

2014
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Clinical therapeutics, 2014, Sep-01, Volume: 36, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2014
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review.
    Journal of the American College of Cardiology, 2014, Sep-23, Volume: 64, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Percutaneous Coronary Interventio

2014
Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination;

2015
Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation.
    European heart journal, 2015, Mar-14, Volume: 36, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Attitude to Health; Humans; Platelet Aggregation Inhib

2015
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
    Lakartidningen, 2015, Jan-06, Volume: 112

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillat

2015
Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.
    Medicine, 2015, Volume: 94, Issue:4

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Hemorr

2015
Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:3

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Disease Management; Dronedar

2015
Misconceptions and Facts About Atrial Fibrillation.
    The American journal of medicine, 2015, Volume: 128, Issue:9

    Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Aspirin; Asymptomatic Diseases; Atrial Fibri

2015
Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.
    Pharmacotherapy, 2015, Volume: 35, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur

2015
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:5

    Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Como

2015
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug

2015
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
    International journal of cardiology, 2015, Oct-01, Volume: 196

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinati

2015
Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Hum

2015
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
    Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:12 Suppl 2

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies;

2015
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C

2016
Atrial fibrillation.
    Nature reviews. Disease primers, 2016, 03-31, Volume: 2

    Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun

2016
[ESUS (embolic stroke of undetermined sources)].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Disorders; Clinical Trials as Topic;

2016
Effect of aspirin in addition to oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation.
    Panminerva medica, 2016, Volume: 58, Issue:4

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Humans;

2016
Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?
    Hong Kong medical journal = Xianggang yi xue za zhi, 2016, Volume: 22, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Hemorrhage; Humans; Risk Assessment

2016
Antithrombotic treatment in atrial fibrillation.
    Postgraduate medical journal, 2008, Volume: 84, Issue:991

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Combinations; Fibrinolytic Agents; Humans; Platel

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi

2008
Initiation and persistence of warfarin or aspirin as thromboprophylaxis in chronic atrial fibrillation in general practice.
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Family Practice; Humans; Premedication; Thrombosis; Warfarin

2008
Approach to and management of the acute stroke patient with atrial fibrillation: a literature review.
    Journal of hospital medicine, 2008, Volume: 3, Issue:4

    Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Atrial Fibrillation; Factor VIIa; Heparin; Humans;

2008
I've heard the terms "atrial flutter" and "atrial fibrillation" used interchangeably when describing certain heart-rhythm disorders, but I thought atrial flutter was a less-serious condition. Can you elaborate?
    Heart advisor, 2008, Volume: 11, Issue:7

    Topics: Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Diagnosis,

2008
Sex differences in stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:5

    Topics: Acute Disease; Age Factors; Animals; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular

2008
[Antithrombotic therapy in primary and secondary stroke prevention of cardiac patients and in acute stroke].
    Orvosi hetilap, 2009, Feb-01, Volume: 150, Issue:5

    Topics: Acute Disease; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Fibrinoly

2009
[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?].
    Herzschrittmachertherapie & Elektrophysiologie, 2009, Volume: 20, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Hepari

2009
Management of nonvalvular atrial fibrillation: a comprehensive approach.
    Indian journal of medical sciences, 2009, Volume: 63, Issue:9

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; P

2009
Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
    Stroke, 2009, Volume: 40, Issue:12

    Topics: Antihypertensive Agents; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cardiovascular Diseases;

2009
Management of atrial fibrillation.
    BMJ (Clinical research ed.), 2009, Dec-23, Volume: 339

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Electrocardiography; Fibrinoly

2009
Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis.
    International journal of cardiology, 2010, Jul-23, Volume: 142, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Bayes Theorem; Fibrinolytic Agents; Humans; Risk Factors; Stroke; Warf

2010
Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.
    American journal of therapeutics, 2011, Volume: 18, Issue:1

    Topics: Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Factor Xa

2011
[New aspects on "triple therapy" after coronary stent implantation].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:41

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation;

2010
Triple therapy in hospitalized patients: facts and controversies.
    Journal of hospital medicine, 2011, Volume: 6, Issue:9

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2011
Incidental atrial fibrillation and its management.
    Postgraduate medicine, 2011, Volume: 123, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heart Rate; Humans; Risk Assessme

2011
Prevention of stroke following transient ischemic attack.
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin

2011
Clopidogrel hydrogen sulphate for atrial fibrillation.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel

2011
Stroke prevention in atrial fibrillation: current status and near-future directions.
    The American journal of medicine, 2011, Volume: 124, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Contrain

2011
Challenges of stroke prevention in patients with atrial fibrillation in clinical practice.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:9

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Humans; Stroke; Vitamin K

2011
The role of aspirin for stroke prevention in atrial fibrillation.
    Nature reviews. Cardiology, 2011, 07-26, Volume: 8, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Evidence-Based Medicine; Fi

2011
New insights in antiplatelet therapy for patients with ischemic stroke.
    The neurologist, 2011, Volume: 17, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I

2011
[Clopidogrel and stroke].
    Revista de neurologia, 2011, Nov-01, Volume: 53, Issue:9

    Topics: Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Inflamm

2011
Atrial fibrillation.
    Lancet (London, England), 2012, Feb-18, Volume: 379, Issue:9816

    Topics: Administration, Oral; Algorithms; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillati

2012
Apixaban for the prevention of stroke in atrial fibrillation.
    Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clinical Trials, P

2012
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel;

2012
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
    Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Guidelines as Topic; Humans; Stroke; Vascular Diseases

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr

2012
Impact of antiplatelet therapy in heart disease.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2012
Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Coronary Arte

2012
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr

2012
Challenges in atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C

2012
Aspirin and Other COX-1 inhibitors.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Animals; Aspirin; Atherosclerosis; Atrial Fibrillation; Cyclooxygenase 1; Cyclooxygenase Inhibitors;

2012
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
    European heart journal, 2013, Volume: 34, Issue:14

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biomarkers; Echocardiography; Female; Fibrinolyt

2013
[Antithrombotic drugs in atrial fibrillation].
    La Revue du praticien, 2002, Jun-15, Volume: 52, Issue:12

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibri

2002
Case report of paroxysmal atrial fibrillation and anticoagulation.
    BMJ (Clinical research ed.), 2002, Nov-02, Volume: 325, Issue:7371

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Attitude to Health; Comm

2002
Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials.
    Stroke, 2002, Volume: 33, Issue:11

    Topics: Acute Disease; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Heparin

2002
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
    JAMA, 2002, Nov-20, Volume: 288, Issue:19

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemor

2002
[Antithrombotic therapy for ischemic cerebrovascular accident].
    Archives des maladies du coeur et des vaisseaux, 2002, Volume: 95 Spec No 7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Fibrinolytic Agents; Humans; Recurrenc

2002
Evidence-based emergency medicine. Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
    Annals of emergency medicine, 2003, Volume: 41, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Fl

2003
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
    American heart journal, 2003, Volume: 145, Issue:3

    Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Dipyridamole;

2003
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.
    Archives of internal medicine, 2003, Apr-28, Volume: 163, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Decision Support Techniques; Fibrinolytic Ag

2003
Lessons from the Stroke Prevention in Atrial Fibrillation trials.
    Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Randomized Controlled Tri

2003
[Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2003, Volume: 4, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fibrinolytic Agents; Heart Failur

2003
Managing chronic atrial fibrillation: strategies to control symptoms and prevent embolism.
    Cleveland Clinic journal of medicine, 2003, Volume: 70 Suppl 3

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Echocardiogra

2003
Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice.
    Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:9 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Controlled Cl

2003
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
    Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:9 Suppl

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate

2003
[Choice of antithrombotic therapy in atrial fibrillation, a daily challenge. No convincing evidence that warfarin is better than acetylsalicylic acid].
    Lakartidningen, 2003, Aug-21, Volume: 100, Issue:34

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Fibrinolytic Agents; Humans;

2003
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
    Presse medicale (Paris, France : 1983), 2003, Jul-26, Volume: 32, Issue:25

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibril

2003
[Indications for anticoagulant use in secondary prevention of strokes].
    Presse medicale (Paris, France : 1983), 2003, Jul-26, Volume: 32, Issue:25

    Topics: Anticoagulants; Antiphospholipid Syndrome; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiovas

2003
[Atrial fibrillation and stroke].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:9

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla

2003
Antiplatelet drugs in cardiovascular diseases.
    International journal of clinical practice, 2003, Volume: 57, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio

2003
Trials of newer approaches to anticoagulation in atrial fibrillation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2004, Volume: 10 Suppl 1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Interna

2004
Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials.
    Stroke, 2004, Volume: 35, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation;

2004
[Anti-platelet agents in neurological practice].
    Revue neurologique, 2004, Volume: 160, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Neurology; Platelet Aggregation Inhibitors

2004
Anticoagulation for atrial fibrillation.
    Cardiology clinics, 2004, Volume: 22, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Tr

2004
[Anticoagulation therapy in paroxysmal atrial fibrillation].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2004, Apr-01, Volume: 124, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Platelet Aggregation Inhi

2004
Atrial fibrillation: should we target platelets or the coagulation pathway?
    Cardiac electrophysiology review, 2003, Volume: 7, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment;

2003
Aspirin--anticoagulant combination in patients with non valvular atrial fibrillation commentary on the FFAACS study results.
    Cardiac electrophysiology review, 2003, Volume: 7, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; Phenindione; Thromb

2003
Warfarin for atrial fibrillation: the end of an era?
    The Lancet. Neurology, 2004, Volume: 3, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Humans

2004
Atrial fibrillation and cardioembolic stroke.
    Minerva cardioangiologica, 2004, Volume: 52, Issue:2

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comorbidity;

2004
Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Minerva cardioangiologica, 2004, Volume: 52, Issue:2

    Topics: Aged; Ambulatory Care Facilities; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylam

2004
Clinical inquiries. Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?
    The Journal of family practice, 2004, Volume: 53, Issue:7

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, C

2004
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
    Circulation, 2004, Oct-19, Volume: 110, Issue:16

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie

2004
Stroke prevention.
    Clinical evidence, 2003, Issue:10

    Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Humans;

2003
New possibilities in anticoagulant management of atrial fibrillation.
    Reviews in cardiovascular medicine, 2004, Volume: 5 Suppl 5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Clopidogrel; Humans; Oligosa

2004
[Stroke and other thromboembolic complications of atrial fibrillation. Part VI. Choice of optimal approach and drugs for prevention of stroke].
    Kardiologiia, 2005, Volume: 45, Issue:1

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Electri

2005
[Antithrombotic therapy in patients with first-ever stroke and known non-rheumatic atrial fibrillation].
    Praxis, 2005, Jan-26, Volume: 94, Issue:4

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla

2005
Stroke prevention.
    Clinical evidence, 2004, Issue:12

    Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Drug Th

2004
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.
    Postgraduate medical journal, 2005, Volume: 81, Issue:956

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Chemic

2005
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur

2005
Atrial fibrillation and anticoagulation.
    Archives des maladies du coeur et des vaisseaux, 2004, Volume: 97, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Platelet Agg

2004
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
    Thrombosis research, 2006, Volume: 118, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; B

2006
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
    The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; R

2005
[Preventing cerebrovascular accidents during atrial fibrillation].
    Presse medicale (Paris, France : 1983), 2005, Oct-22, Volume: 34, Issue:18

    Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver

2005
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
    Orvosi hetilap, 2005, Oct-09, Volume: 146, Issue:41

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel;

2005
[Patient with antithrombotic medication. Which do bleedings or preoperative?].
    Laryngo- rhino- otologie, 2006, Volume: 85, Issue:1

    Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosc

2006
[Atrial fibrillation (the questions of etiology, classification, and treatment)].
    Klinicheskaia meditsina, 2006, Volume: 84, Issue:2

    Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Catheter Ablation; Clinical

2006
[Prevention of thromboembolism in patients with atrial fibrillation].
    MMW Fortschritte der Medizin, 2006, Apr-13, Volume: 148, Issue:15

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disea

2006
Drug therapy for atrial fibrillation.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9

    Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillat

2006
Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
    Archives of internal medicine, 2006, Jun-26, Volume: 166, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combination; H

2006
Stroke prevention in diabetes and obesity.
    Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular

2006
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
    Plastic and reconstructive surgery, 2006, Volume: 118, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Damage,

2006
Optimising stroke prevention in non-valvular atrial fibrillation.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock;

2006
Atrial fibrillation and stroke prevention.
    Expert review of neurotherapeutics, 2006, Volume: 6, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Risk Factors; Stroke; Warfarin

2006
[Primary and secondary prevention of cardiogenic cerebral embolism].
    No to shinkei = Brain and nerve, 2006, Volume: 58, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Heart Valve Diseases; Humans; Intracrani

2006
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi

2006
Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies.
    Geriatrics, 2007, Volume: 62, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Evaluation; Drug Therapy, Combination; Fema

2007
Assessing stroke risk in patients with AF.
    The Practitioner, 2007, Volume: 251, Issue:1695

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Human

2007
Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
    Neurology, 2007, Aug-07, Volume: 69, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Cohort Stu

2007
Atrial fibrillation and stroke prevention.
    The Lancet. Neurology, 2007, Volume: 6, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Stroke; Warfa

2007
[The clinical challenge of the atrial fibrillation].
    Anales de la Real Academia Nacional de Medicina, 2007, Volume: 124, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial

2007
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
    American heart journal, 2008, Volume: 155, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Tri

2008
Antiplatelet therapy for stroke prevention.
    Current atherosclerosis reports, 2007, Volume: 9, Issue:4

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel

2007
Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis.
    Heart (British Cardiac Society), 2008, Volume: 94, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Female; Huma

2008
[Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation. Results of the BAFTA trial].
    Kardiologiia, 2008, Volume: 48, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Humans;

2008
Clinical benefit of early anticoagulation in cardioembolic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 25, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Heparin; Humans; Risk Factors; Secondary Pre

2008
Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:4

    Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Int

2008
Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation.
    BMJ (Clinical research ed.), 2008, Mar-15, Volume: 336, Issue:7644

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Vascular Dise

2008
[Blood thinning in heart patients].
    Therapeutische Umschau. Revue therapeutique, 1995, Volume: 52, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Aspirin; Atrial Fibrillation; Clini

1995
Anticoagulants: when and how?
    Pacing and clinical electrophysiology : PACE, 1994, Volume: 17, Issue:5 Pt 2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Randomized Controll

1994
Warfarin or aspirin for non-rheumatic atrial fibrillation?
    Drug and therapeutics bulletin, 1994, Aug-18, Volume: 32, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Randomized Controlled Trials as Top

1994
Treatment of stroke in older patients. A state of the art review.
    Drugs & aging, 1995, Volume: 6, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Community Health Services; Deglutitio

1995
[Bleeding complications in oral anticoagulant treatment].
    Nordisk medicin, 1995, Volume: 110, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial

1995
[Antithrombotic treatment in chronic nonrheumatic atrial fibrillation].
    Duodecim; laaketieteellinen aikakauskirja, 1993, Volume: 109, Issue:19

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebral Infarction; Chronic Disease; Clinica

1993
[Thromboembolic complications in the course of non-valvular atrial fibrillation].
    La Revue du praticien, 1995, Apr-15, Volume: 45, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Tr

1995
What's new in stroke?
    Texas medicine, 1995, Volume: 91, Issue:5

    Topics: Acute Disease; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrova

1995
[Prevention of embolisms in atrial fibrillation: anticoagulation and antiplatelet therapy].
    Zeitschrift fur Kardiologie, 1994, Volume: 83 Suppl 5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Intracranial Embolism and Thrombosis; Platelet

1994
Medical treatment for stroke prevention.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Prevention of stroke in atrial fibrillation: an update.
    Health reports, 1994, Volume: 6, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Intracra

1994
[Prevention of cerebrovascular insults].
    Schweizerische medizinische Wochenschrift, 1994, Nov-12, Volume: 124, Issue:45

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebral Infarction; Diet; Fem

1994
Atrial fibrillation and stroke. Three new studies, three remaining questions.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; H

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
    Archives of internal medicine, 1994, Jul-11, Volume: 154, Issue:13

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders;

1994
[From heart to brain and from brain to heart: impact of an anticoagulant treatment with aspirin in secondary prevention].
    Presse medicale (Paris, France : 1983), 1994, Apr-02, Volume: 23, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dementia, Vascular; Humans; Ischemic Attack, Transient

1994
Preventing stroke in patients with nonrheumatic atrial fibrillation.
    American journal of hospital pharmacy, 1994, May-01, Volume: 51, Issue:9

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male; Randomized Cont

1994
Role of antithrombotic therapy in atrial fibrillation.
    Giornale italiano di cardiologia, 1994, Volume: 24, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Humans; Thrombolytic Therapy

1994
Arkansas Foundation for Medical Care report: preventing stroke in atrial fibrillation.
    The Journal of the Arkansas Medical Society, 1994, Volume: 90, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as

1994
Antithrombotic therapies for stroke prevention.
    Current opinion in neurology, 1994, Volume: 7, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti

1994
Current management of atrial fibrillation.
    Current opinion in cardiology, 1994, Volume: 9, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Electric C

1994
Stroke prevention in atrial fibrillation.
    The Mount Sinai journal of medicine, New York, 1993, Volume: 60, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Humans; Ran

1993
[The prevention of stroke in atrial fibrillation].
    Kokyu to junkan. Respiration & circulation, 1993, Volume: 41, Issue:11

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Pro

1993
Antiplatelet and anticoagulant therapy.
    Current opinion in neurology and neurosurgery, 1993, Volume: 6, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient;

1993
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.
    BMJ (Clinical research ed.), 1996, Jan-06, Volume: 312, Issue:7022

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fibrinolytic Agents; Humans

1996
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
    Mayo Clinic proceedings, 1996, Volume: 71, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibri

1996
Stroke prevention: the emerging strategies.
    Hospital practice (1995), 1996, Mar-15, Volume: 31, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Trees; Humans; Isc

1996
Atrial fibrillation, anticoagulation, and stroke.
    The American journal of cardiology, 1996, Jan-25, Volume: 77, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fe

1996
The risks and benefits of antithrombotic therapy in chronic atrial fibrillation.
    The Medical journal of Australia, 1996, May-20, Volume: 164, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Utilization; Humans; Platelet Aggregation Inhibit

1996
Anticoagulation: risks and benefits in atrial fibrillation.
    Geriatrics, 1996, Volume: 51, Issue:6

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Heart; Humans; Middle Age

1996
[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy].
    Medicina clinica, 1996, Apr-20, Volume: 106, Issue:15

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To

1996
[Antithrombotic treatment of atrial fibrillation].
    The Canadian journal of cardiology, 1996, Volume: 12 Suppl A

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Fibrinolyti

1996
[The treatment of atrial fibrillation].
    Duodecim; laaketieteellinen aikakauskirja, 1995, Volume: 111, Issue:8

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Humans; Middle

1995
[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin].
    Praxis, 1996, Feb-06, Volume: 85, Issue:6

    Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiomyopath

1996
The role of coumadin and aspirin in atrial fibrillation.
    Transactions of the American Clinical and Climatological Association, 1996, Volume: 107

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Echocardiography; Electric C

1996
Warfarin and aspirin as thromboprophylaxis in atrial fibrillation.
    British journal of clinical pharmacology, 1996, Volume: 41, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Randomized Co

1996
Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials.
    European heart journal, 1996, Volume: 17, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Risk Factors; Warfarin

1996
Antithrombotic therapy in atrial fibrillation.
    Canadian family physician Medecin de famille canadien, 1996, Volume: 42

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

1996
Anti-thrombotic therapy for non-rheumatic atrial fibrillation.
    QJM : monthly journal of the Association of Physicians, 1996, Volume: 89, Issue:6

    Topics: Aged; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Randomized Controlled Trials as Top

1996
[Anticoagulation in cardiology].
    Annales de cardiologie et d'angeiologie, 1995, Volume: 44, Issue:10

    Topics: 4-Hydroxycoumarins; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial

1995
[Antithrombotic agents and prevention of cerebrovascular accidents].
    Revue medicale de la Suisse romande, 1996, Volume: 116, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clopidogrel; Echocardiography; Humans; Intr

1996
Prevention of thromboembolism in patients with atrial fibrillation.
    Cardiology clinics, 1996, Volume: 14, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Echocardiography, Transesoph

1996
Therapeutic strategies for atrial fibrillation. The value of decision analysis.
    Cardiology clinics, 1996, Volume: 14, Issue:4

    Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; D

1996
[Antithrombotic therapy of atrial fibrillation].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascular Diso

1996
Treating the non-electrical risks of atrial fibrillation.
    European heart journal, 1997, Volume: 18 Suppl C

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Heart Valve Diseases;

1997
The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators.
    Archives of internal medicine, 1997, Jun-09, Volume: 157, Issue:11

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; Fem

1997
Atrial fibrillation.
    Harvard men's health watch, 1998, Volume: 2, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Electrocardiography; Humans

1998
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
    Nederlands tijdschrift voor geneeskunde, 1998, Jan-10, Volume: 142, Issue:2

    Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary

1998
Choice of antithrombotic therapy for stroke prevention in atrial fibrillation: warfarin, aspirin, or both?
    Archives of internal medicine, 1998, Jul-27, Volume: 158, Issue:14

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; D

1998
Prevention of stroke in patients with nonvalvular atrial fibrillation.
    Neurology, 1998, Volume: 51, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as

1998
Long-term antithrombotic treatment for atrial fibrillation.
    The American journal of cardiology, 1998, Oct-16, Volume: 82, Issue:8A

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Europe; Fibrinolytic Agents; Humans;

1998
Antithrombotic therapy in atrial fibrillation.
    Chest, 1998, Volume: 114, Issue:5 Suppl

    Topics: Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascular Disorders; Electric Countershock;

1998
Atrial fibrillation: overview of therapeutic trials.
    The Canadian journal of cardiology, 1998, Volume: 14, Issue:10

    Topics: Age Factors; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Cardiac Pacing, Artificial; Clini

1998
Atrial fibrillation and anticoagulation.
    Advances in internal medicine, 1999, Volume: 44

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chemoprevention; Drug Combi

1999
Antiplatelet agents and stroke prevention.
    Seminars in neurology, 1998, Volume: 18, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipy

1998
Stroke: part I. A clinical update on prevention.
    American family physician, 1999, May-01, Volume: 59, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic;

1999
Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascul

1999
Very low-intensity antithrombotic therapy in atrial fibrillation.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Fibrinolytic Agen

1999
Preventing stroke in patients with atrial fibrillation.
    JAMA, 1999, May-19, Volume: 281, Issue:19

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Echocardiograp

1999
[Frontiers in prevention of thromboembolism in nonvalvular atrial fibrillation].
    Journal of cardiology, 1999, Volume: 33 Suppl 1

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Humans; Male; Thromboembolism; Warfar

1999
Heart disease in older patients.
    The Practitioner, 1998, Volume: 242, Issue:1589

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin;

1998
Atrial fibrillation, thromboembolism and antithrombotic therapy.
    International journal of clinical practice, 1999, Volume: 53, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hu

1999
Management of atrial fibrillation: out-of-hospital approach.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Heart

1999
[Clinical study of the month. Prevention of cerebral vascular accidents in patients with atrial fibrillation].
    Revue medicale de Liege, 1999, Volume: 54, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Evidence-Based Medicine; Hu

1999
Antithrombotic management of atrial fibrillation for stroke prevention in older people.
    Clinics in geriatric medicine, 1999, Volume: 15, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Contraindications; Fibrinol

1999
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
    Annals of internal medicine, 1999, Oct-05, Volume: 131, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hemorrhage; Humans; Placebo

1999
[Prevention of cerebral ischemia: anti-platelet agents].
    Revue neurologique, 1999, Volume: 155, Issue:9

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Intracranial Embolism; Plate

1999
Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.
    Annals of internal medicine, 1999, Nov-02, Volume: 131, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Risk Factors; Stroke; Thromboemb

1999
Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.
    Journal of general internal medicine, 2000, Volume: 15, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Odds Ratio; Platelet Aggregation Inhibitors; R

2000
Clinical implication of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation.
    Current opinion in cardiology, 2000, Volume: 15, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Echocardi

2000
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
    Geriatrics, 2000, Volume: 55, Issue:3

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Brai

2000
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha

2000
Anticoagulation therapy for atrial fibrillation and coronary disease.
    Journal of thrombosis and thrombolysis, 2000, Volume: 9 Suppl 1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coronary Disease; Drug Thera

2000
[Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:6

    Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Diabetes Compli

2000
[Acetylsalicylic acid versus coumarin derivatives in atrial fibrillation].
    Nederlands tijdschrift voor geneeskunde, 2000, Dec-02, Volume: 144, Issue:49

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coumarins; Dose-Respo

2000
Antithrombotic therapy in atrial fibrillation.
    Chest, 2001, Volume: 119, Issue:1 Suppl

    Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Electric Countershock; Fibrinolytic Agents

2001
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.
    BMJ (Clinical research ed.), 2001, Feb-10, Volume: 322, Issue:7282

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Isoindoles; Phenylbutyrates; Plate

2001
Atrial fibrillation and stroke : concepts and controversies.
    Stroke, 2001, Volume: 32, Issue:3

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Humans; Intracranial Embolism; Prevalence; Ran

2001
[Atrial fibrillation and thromboembolic events prevention. State of the art].
    Minerva cardioangiologica, 2001, Volume: 49, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Controlled Clini

2001
Should patients with hypertension receive antithrombotic therapy?
    Journal of internal medicine, 2001, Volume: 249, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hypertension; Myocardial Infarction; Risk Factors

2001
[Antithrombotic therapy in cerebral infarction].
    Rinsho shinkeigaku = Clinical neurology, 2000, Volume: 40, Issue:12

    Topics: Acute-Phase Reaction; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Heparin; Hu

2000
Management of new onset atrial fibrillation.
    Evidence report/technology assessment (Summary), 2000, Issue:12

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Anti-Arrhythmia Agents; Anticoagu

2000
[Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:9

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Coun

2001
Platelets and atrial fibrillation.
    European heart journal, 2001, Volume: 22, Issue:24

    Topics: Aspirin; Atrial Fibrillation; Blood Platelets; Humans; Meta-Analysis as Topic; Platelet Aggregation

2001
[Thromboembolism in non-rheumatic atrial fibrillation].
    Haematologica, 2001, Volume: 86, Issue:9 Suppl

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical

2001
[Prevention of recurrence in cerebral infarction].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2002, Mar-20, Volume: 91 Suppl

    Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebral Infarction; Drug Therapy, C

2002
Sick sinus syndrome: strategies for reducing mortality.
    Cor et vasa, 1992, Volume: 34, Issue:2

    Topics: Aspirin; Atrial Fibrillation; Combined Modality Therapy; Humans; Pacemaker, Artificial; Risk Factors

1992
[Isolated atrial fibrillation. The risk of embolism and its prevention].
    Presse medicale (Paris, France : 1983), 1992, Jun-27, Volume: 21, Issue:24

    Topics: 4-Hydroxycoumarins; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Aspirin; Atrial Fibr

1992
Antithrombotic therapy in atrial fibrillation.
    Chest, 1992, Volume: 102, Issue:4 Suppl

    Topics: Aspirin; Atrial Fibrillation; Embolism; Heart Diseases; Humans; Thrombolytic Therapy; Warfarin

1992
Anticoagulant treatment of atrial fibrillation in the elderly.
    Postgraduate medical journal, 1992, Volume: 68 Suppl 1

    Topics: Aged; Aspirin; Atrial Fibrillation; Contraindications; Humans; Risk Factors; Thromboembolism; Warfar

1992
Review: atrial fibrillation and stroke prevention.
    Age and ageing, 1992, Volume: 21, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Heart At

1992
Non-rheumatic atrial fibrillation: warfarin or aspirin for all?
    British heart journal, 1992, Volume: 68, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hemorrhage; Humans; Randomized Controlled T

1992
Anticoagulant therapy for atrial fibrillation. Recommendations from major studies.
    Postgraduate medicine, 1992, Sep-01, Volume: 92, Issue:3

    Topics: Acute Disease; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Electric Co

1992
Rationale for antithrombotic therapy in atrial fibrillation.
    Neurologic clinics, 1992, Volume: 10, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Embolism

1992
[Embolic complications of chronic atrial fibrillation].
    Archives des maladies du coeur et des vaisseaux, 1992, Volume: 85, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Heart Valve Diseases; Humans; Primary Prevention; Pro

1992
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience.
    Annals of internal medicine, 1991, Nov-15, Volume: 115, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Com

1991
Stroke prevention in nonvalvular atrial fibrillation.
    Annals of internal medicine, 1991, Nov-01, Volume: 115, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Meta-Analysis as Topic; Platelet Ag

1991
Thromboembolic complications in atrial fibrillation.
    Stroke, 1990, Volume: 21, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Chronic Disease; Female; Fo

1990
[Platelet antiaggregants in cerebral ischemic pathology].
    La Revue du praticien, 1989, Nov-01, Volume: 39, Issue:25

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Platelet Aggregation Inhibit

1989
Controversies in the management of cerebral vascular disease.
    Neurology, 1988, Volume: 38, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders;

1988
Cerebral embolism.
    Chest, 1986, Volume: 89, Issue:2 Suppl

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Calcinosis; Cardiomyopathy, Hypertrophic; Clinical Tri

1986

Trials

175 trials available for aspirin and Auricular Fibrillation

ArticleYear
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
    Circulation, 2021, 11-30, Volume: 144, Issue:22

    Topics: Administration, Oral; Age Factors; Aged; Aspirin; Atrial Fibrillation; Body Mass Index; Dabigatran;

2021
Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
    Open heart, 2022, Volume: 9, Issue:1

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Hum

2022
Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus.
    BMJ open diabetes research & care, 2022, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Incidence

2022
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
    JAMA cardiology, 2022, 07-01, Volume: 7, Issue:7

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrha

2022
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
    Clinical cardiology, 2023, Volume: 46, Issue:7

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combin

2023
Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
    American heart journal, 2023, Volume: 264

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Embolism; Female; Follow-Up Studies;

2023
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    The New England journal of medicine, 2019, 09-19, Volume: 381, Issue:12

    Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combinat

2019
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
    JAMA neurology, 2020, 01-01, Volume: 77, Issue:1

    Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Carotid Stenosis; Double-Blind Method; Drug Therapy,

2020
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Circulation, 2019, 12-03, Volume: 140, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents;

2019
Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
    Circulation, 2020, 03-03, Volume: 141, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Coronary Thrombosis; Factor X

2020
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    The New England journal of medicine, 2020, 01-09, Volume: 382, Issue:2

    Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopid

2020
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
    The New England journal of medicine, 2020, 01-09, Volume: 382, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Th

2020
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    JACC. Cardiovascular interventions, 2019, 12-09, Volume: 12, Issue:23

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2019
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    JACC. Cardiovascular interventions, 2019, 12-09, Volume: 12, Issue:23

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2019
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Circulation. Cardiovascular interventions, 2020, Volume: 13, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; C

2020
Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology.
    Neurology, 2020, 05-19, Volume: 94, Issue:20

    Topics: Adult; Aspirin; Atrial Fibrillation; Foramen Ovale, Patent; Humans; Platelet Aggregation Inhibitors;

2020
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    American heart journal, 2021, Volume: 231

    Topics: Administration, Oral; Aspirin; Atrial Fibrillation; Atrial Flutter; Bioprosthesis; Brazil; Cause of

2021
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2021, Aug-27, Volume: 17, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Com

2021
New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry.
    Journal of the American Heart Association, 2021, 01-05, Volume: 10, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Coronary Artery Disease; Factor Xa Inhib

2021
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
    American heart journal, 2021, Volume: 236

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Fema

2021
Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial.
    BMJ open, 2021, 03-15, Volume: 11, Issue:3

    Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; China; Humans; Multicenter Studies as Topic; Prospec

2021
Aspirin versus P2Y
    Heart (British Cardiac Society), 2021, Volume: 107, Issue:21

    Topics: Aged; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans;

2021
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.
    Blood, 2017, 06-01, Volume: 129, Issue:22

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female;

2017
Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Czech Republic; Female; Fibrinolytic Agents;

2017
Rationale and Design for a Randomized Comparison of Efficacy and Safety between Aspirin and Clopidogrel in Atrial Fibrillation Patients with Low Stroke Risk: CESAC-AF trial.
    Contemporary clinical trials, 2017, Volume: 60

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Endoscopy, Digestive System; G

2017
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    American heart journal, 2017, Volume: 190

    Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16

    Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy

2017
Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials.
    International journal of cardiology, 2018, Feb-01, Volume: 252

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Female; Follow-Up Studies; He

2018
Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).
    The American journal of cardiology, 2018, 03-01, Volume: 121, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Clopidogrel; Female; Hu

2018
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
    American heart journal, 2018, Volume: 197

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, D

2018
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    American heart journal, 2018, Volume: 197

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Monitoring; Female

2018
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat
    American heart journal, 2018, Volume: 200

    Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrha

2018
Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).
    The American journal of cardiology, 2018, 09-01, Volume: 122, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Female; Heart Failure; Humans; Ma

2018
Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study.
    PloS one, 2018, Volume: 13, Issue:8

    Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Fema

2018
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Circulation research, 2019, Volume: 124, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona

2019
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    European heart journal, 2019, 05-14, Volume: 40, Issue:19

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fib

2019
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    The New England journal of medicine, 2019, 04-18, Volume: 380, Issue:16

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Doub

2019
Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention　- From the TWMU-AF PCI Registry.
    Circulation journal : official journal of the Japanese Circulation Society, 2019, 04-25, Volume: 83, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female;

2019
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    JAMA neurology, 2019, 07-01, Volume: 76, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Intracr

2019
Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial.
    BMC neurology, 2019, May-01, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Viscosity; Female; Huma

2019
Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.
    International journal of cardiology, 2019, 08-15, Volume: 289

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther

2019
Disparities and Temporal Trends in the Use of Anticoagulation in Patients With Ischemic Stroke and Atrial Fibrillation.
    Stroke, 2019, Volume: 50, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Flori

2019
Permanent Percutaneous Carotid Artery Filter to Prevent Stroke in Atrial Fibrillation Patients: The CAPTURE Trial.
    Journal of the American College of Cardiology, 2019, 08-20, Volume: 74, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Artery, Common; Clopidogrel; Embolic Pro

2019
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr

2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2015, Volume: 21, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Costs and Cost Analysis; Female; Humans; Male; Pyrazol

2015
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Fema

2014
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    European heart journal, 2014, Volume: 35, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug

2014
One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry.
    Clinical cardiology, 2014, Volume: 37, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Vessels; Female; Fibrinolytic Agents; Humans; Ma

2014
Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Fibri

2014
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    European heart journal, 2014, Jul-21, Volume: 35, Issue:28

    Topics: Aged; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inh

2014
Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study).
    Stroke, 2014, Volume: 45, Issue:5

    Topics: Aged; Aged, 80 and over; Aging; Anticoagulants; Aspirin; Atrial Fibrillation; Cognition Disorders; F

2014
Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications.
    International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:6

    Topics: Age Factors; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Chi

2014
Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Stroke, 2014, Volume: 45, Issue:7

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; D

2014
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
    European heart journal, 2015, Feb-01, Volume: 36, Issue:5

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Embolism; Female; Fibrinoly

2015
Combined low-dose aspirin and warfarin anticoagulant therapy of postoperative atrial fibrillation following mechanical heart valve replacement.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2014, Volume: 34, Issue:6

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Heart Valve Prosth

2014
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
    Contemporary clinical trials, 2015, Volume: 40

    Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combina

2015
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid

2015
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
    Contemporary clinical trials, 2015, Volume: 43

    Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug

2015
Chocolate Consumption and Risk of Atrial Fibrillation (from the Physicians' Health Study).
    The American journal of cardiology, 2015, Aug-15, Volume: 116, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; beta Carotene; Cacao; Cohort Studies; Diet; Humans; Incidence; M

2015
Postoperative Atrial Fibrillation Is Associated With High On-Aspirin Platelet Reactivity.
    The Annals of thoracic surgery, 2015, Volume: 100, Issue:5

    Topics: Aged; Aspirin; Atrial Fibrillation; Blood Platelets; Coronary Artery Bypass; Coronary Artery Disease

2015
Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Stroke, 2015, Volume: 46, Issue:10

    Topics: Aged; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Factor Xa Inhibitors; Female; Hemorrhage;

2015
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
    Age and ageing, 2016, Volume: 45, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibi

2016
Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure　- Subanalysis of the WARCEF Trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2016, Volume: 80, Issue:3

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Echocardiography; Follow-Up Studies; Heart Failure;

2016
Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase.
    Chinese journal of integrative medicine, 2018, Volume: 24, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Base Sequence; Capsules; Drugs, Chinese Herbal; Endpoint Determi

2018
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Journal of cardiology, 2017, Volume: 69, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin

2017
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Clinical cardiology, 2016, Volume: 39, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D

2016
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.
    American heart journal, 2016, Volume: 178

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain; Brain Infarction; Cerebral Hemorrhage; Embolism; Factor X

2016
Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly.
    Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease;

2008
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.
    Circulation, 2008, Nov-11, Volume: 118, Issue:20

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brazil;

2008
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb

2009
Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Blood Coagulation Tes

2009
[Clopidogrel in the treatment of atrial fibrillation: benefit from addition to aspirin. The results of ACTIVE A trial].
    Kardiologiia, 2009, Volume: 49, Issue:5

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Follow-Up S

2009
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug Administration Sche

2010
Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry).
    The American journal of cardiology, 2010, Apr-15, Volume: 105, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiology; Decision Making; Follow-Up Studies;

2010
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
    European heart journal, 2010, Volume: 31, Issue:17

    Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt

2010
Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation.
    Arquivos brasileiros de cardiologia, 2010, Volume: 95, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Bioprosthesis; Heart Valve Prosthesis; Hemorrhag

2010
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, Mar-03, Volume: 364, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi

2011
Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation.
    Stroke, 2011, Volume: 42, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Humans; International Nor

2011
Warfarin in atrial fibrillation patients with moderate chronic kidney disease.
    Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Canada; Chi-Square Distributi

2011
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial

2011
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
    The Lancet. Neurology, 2012, Volume: 11, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic

2012
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:6

    Topics: Aged; Aspirin; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Creatinine; Double-Blind Me

2012
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre

2013
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K
    Stroke, 2012, Volume: 43, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Contraindic

2012
Sleep duration and risk of atrial fibrillation (from the Physicians' Health Study).
    The American journal of cardiology, 2013, Feb-15, Volume: 111, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; beta Carotene; Confidence Intervals; Cyclooxygenase Inhibitors;

2013
Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study.
    Chinese medical journal, 2012, Volume: 125, Issue:24

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Middle

2012
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Circulation, 2013, Feb-12, Volume: 127, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel

2013
Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Health Status Indic

2013
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
    Journal of the American College of Cardiology, 2002, Aug-07, Volume: 40, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clopidogrel;

2002
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.
    Archives of internal medicine, 2003, Apr-28, Volume: 163, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Decision Support Techniques; Fibrinolytic Ag

2003
Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.
    Circulation, 2003, Jul-01, Volume: 107, Issue:25

    Topics: Aspirin; Atrial Fibrillation; Biomarkers; Drug Therapy, Combination; Endothelium, Vascular; Enzyme-L

2003
Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation.
    Journal of internal medicine, 2003, Volume: 254, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Female;

2003
Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]
    BMC cardiovascular disorders, 2003, Aug-26, Volume: 3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Incidence; International Normalized Rati

2003
Stroke prevention in hospitalized patients with atrial fibrillation: a population-based study.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2003,Winter, Volume: 10, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Utilization; Female; Fibrinolytic Agents; H

2003
Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial.
    Stroke, 2004, Volume: 35, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient;

2004
Aspirin--anticoagulant combination in patients with non valvular atrial fibrillation commentary on the FFAACS study results.
    Cardiac electrophysiology review, 2003, Volume: 7, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; Phenindione; Thromb

2003
Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:5

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain; Brain Ischemia; Female; Humans; Incidence; Magnetic Reson

2004
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study.
    American heart journal, 2004, Volume: 148, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Bleeding Time; Clopidogrel; Drug Therapy, Combin

2004
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
    Circulation, 2004, Sep-21, Volume: 110, Issue:12

    Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; Blood Loss, Surgical; Coh

2004
Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enzyme-Linked Immunosorbent Assay; Female; Heart

2005
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    American heart journal, 2005, Volume: 149, Issue:4

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod

2005
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
    Stroke, 2006, Volume: 37, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Japan

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
    Lancet (London, England), 2006, Jun-10, Volume: 367, Issue:9526

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, C

2006
[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin].
    Zhonghua xin xue guan bing za zhi, 2006, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord

2006
A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial.
    International journal of cardiology, 2007, Apr-25, Volume: 117, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Bloo

2007
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO).
    Age and ageing, 2007, Volume: 36, Issue:2

    Topics: Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female;

2007
[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin].
    Kardiologiia, 2007, Volume: 47, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Echocardiog

2007
[Prevention of embolism due to chronic auricular fibrillation with persantin (dipyridamole) combined with aspirin].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2007, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dipyridamole; Embolism

2007
A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial.
    Quality & safety in health care, 2007, Volume: 16, Issue:3

    Topics: Aged; Anticoagulants; Anxiety; Aspirin; Atrial Fibrillation; Conflict, Psychological; Decision Makin

2007
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
    Lancet (London, England), 2007, Aug-11, Volume: 370, Issue:9586

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Fema

2007
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
    The American journal of cardiology, 2007, Nov-01, Volume: 100, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; F

2007
Stroke prevention: age alone does not rule out warfarin.
    The Journal of family practice, 2007, Volume: 56, Issue:11

    Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrilla

2007
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Journal of the American College of Cardiology, 2007, Nov-27, Volume: 50, Issue:22

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co

2007
Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; Cerebral Hemorrhage; Cerebral In

2008
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) tri
    American heart journal, 2008, Volume: 155, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines;

2008
Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 25, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Ele

2008
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Bipheny

2008
[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
    Il Giornale di chirurgia, 1995, Volume: 16, Issue:3

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders

1995
[Bleeding complications in oral anticoagulant treatment].
    Nordisk medicin, 1995, Volume: 110, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial

1995
[Thromboembolic complications in the course of non-valvular atrial fibrillation].
    La Revue du praticien, 1995, Apr-15, Volume: 45, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Tr

1995
A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1994, Volume: 77, Issue:1

    Topics: Adolescent; Adult; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distribution;

1994
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;

1993
Aspirin and prevention of stroke.
    Lancet (London, England), 1994, Jan-22, Volume: 343, Issue:8891

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Isoindoles; Phenylbutyrates; Platel

1994
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.
    Lancet (London, England), 1994, Mar-19, Volume: 343, Issue:8899

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Follow-Up Studies;

1994
Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement.
    Circulation, 1994, Volume: 90, Issue:5 Pt 2

    Topics: Aortic Valve; Aspirin; Atrial Fibrillation; Bioprosthesis; Female; Follow-Up Studies; Heart Valve Pr

1994
Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators.
    Stroke, 1993, Volume: 24, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemostasis

1993
Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin.
    Stroke, 1993, Volume: 24, Issue:10

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Co

1993
Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
    Neurology, 1996, Volume: 46, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin

1996
Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Archives of internal medicine, 1996, Feb-26, Volume: 156, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular

1996
Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy.
    Archives of internal medicine, 1996, Mar-25, Volume: 156, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe

1996
Warfarin encouraged for stroke prevention in atrial fibrillation.
    Wisconsin medical journal, 1996, Volume: 95, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male;

1996
Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.
    Circulation, 1996, Aug-01, Volume: 94, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Dose-Response Relations

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
    Lancet (London, England), 1996, Sep-07, Volume: 348, Issue:9028

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina

1996
Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy.
    Thrombosis and haemostasis, 1996, Volume: 75, Issue:2

    Topics: Aged; Anticoagulants; Antithrombin III; Aspirin; Atrial Fibrillation; Biomarkers; Blood Coagulation;

1996
Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
    Stroke, 1997, Volume: 28, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Cerebrovascular Disorders; Dr

1997
Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
    Thrombosis and haemostasis, 1997, Volume: 77, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Do

1997
[Preventive treatment of nonrheumatic atrial fibrillation: from the efficacy of clinical trials to the effectiveness of clinical practice].
    Atencion primaria, 1997, Oct-31, Volume: 20, Issue:7

    Topics: Acenocoumarol; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin;

1997
Up to date review of the secondary preventive measures for recurrent ischaemic stroke and transient ischaemic episodes.
    Scottish medical journal, 1998, Volume: 43, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Hu

1998
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.
    Annals of internal medicine, 1998, Apr-15, Volume: 128, Issue:8

    Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Drug Therapy,

1998
Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. The Clinical Quality Improvement Network (CQIN) Investigators.
    The Canadian journal of cardiology, 1998, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combinat

1998
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.
    Archives of internal medicine, 1998, Jul-27, Volume: 158, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord

1998
Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography.
    The American journal of cardiology, 1999, Feb-01, Volume: 83, Issue:3

    Topics: Aged; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillati

1999
Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings.
    Heart (British Cardiac Society), 1999, Volume: 81, Issue:4

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi

1999
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
    Stroke, 1999, Volume: 30, Issue:6

    Topics: Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascula

1999
Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group.
    American heart journal, 1999, Volume: 138, Issue:1 Pt 1

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Administratio

1999
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation.
    Archives of internal medicine, 1999, Jun-28, Volume: 159, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord

1999
Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design.
    Controlled clinical trials, 1999, Volume: 20, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Humans

1999
A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial.
    JAMA, 1999, Aug-25, Volume: 282, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Making; Deci

1999
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.
    BMJ (Clinical research ed.), 1999, Oct-09, Volume: 319, Issue:7215

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coumarins; Female; Follow-Up Studies; Humans; Ma

1999
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study).
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 1999, Volume: 12, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Flow Velocity; Drug Ther

1999
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study).
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 1999, Volume: 12, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Flow Velocity; Contrast Media; Drug Therap

1999
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Cohort Studies; Dose-Re

2000
Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
    Stroke, 2000, Volume: 31, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Dru

2000
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
    Lancet (London, England), 2000, Apr-08, Volume: 355, Issue:9211

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation;

2000
[Risk factors for thromboembolism in patients with atrial fibrillation during treatment with aspirin: a multicenter, cooperative retrospective study. Research Group for Antiarrhythmic Drug Therapy].
    Journal of cardiology, 2000, Volume: 35, Issue:5

    Topics: Age Factors; Analysis of Variance; Aspirin; Atrial Fibrillation; Female; Heart Diseases; Humans; Mal

2000
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha

2000
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation.
    The American journal of medicine, 2000, Volume: 109, Issue:1

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy

2000
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
    Cerebrovascular diseases (Basel, Switzerland), 2001, Volume: 12, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship

2001
Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?
    Stroke, 2001, Dec-01, Volume: 32, Issue:12

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi

2001
Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.
    Stroke, 2002, Volume: 33, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Blood Platelets; Cell Coun

2002
The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study.
    American heart journal, 1992, Volume: 124, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Ma

1992
Aspirin to prevent stroke in nonrheumatic atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    The New England journal of medicine, 1992, Jul-23, Volume: 327, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans

1992
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience.
    Annals of internal medicine, 1991, Nov-15, Volume: 115, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Com

1991
Stroke Prevention in Atrial Fibrillation Study. Final results.
    Circulation, 1991, Volume: 84, Issue:2

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies;

1991
Stroke Prevention in Atrial Fibrillation Study. Final results.
    Circulation, 1991, Volume: 84, Issue:2

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies;

1991
Stroke Prevention in Atrial Fibrillation Study. Final results.
    Circulation, 1991, Volume: 84, Issue:2

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies;

1991
Stroke Prevention in Atrial Fibrillation Study. Final results.
    Circulation, 1991, Volume: 84, Issue:2

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies;

1991
[European atrial fibrillation trial (EAFT). Secondary prevention with anticoagulants and aspirin in patients with non-valvular atrial fibrillation having suffered a transient ischemic attack or a regressive vascular accident].
    Revue medicale de la Suisse romande, 1991, Volume: 111, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Tr

1991
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators.
    Stroke, 1990, Volume: 21, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Multicenter Studies as Topic; Rando

1990
Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
    Archives of internal medicine, 1990, Volume: 150, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Denmark; Female; Humans; Male; Proportional Hazards Models; Rand

1990
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
    The New England journal of medicine, 1990, 11-29, Volume: 323, Issue:22

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage

1990
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
    The New England journal of medicine, 1990, 11-29, Volume: 323, Issue:22

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage

1990
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
    The New England journal of medicine, 1990, 11-29, Volume: 323, Issue:22

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage

1990
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
    The New England journal of medicine, 1990, 11-29, Volume: 323, Issue:22

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage

1990
Progress report of the Stroke Prevention in Atrial Fibrillation Study.
    Stroke, 1990, Volume: 21, Issue:11 Suppl

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Meth

1990
Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.
    The New England journal of medicine, 1990, 03-22, Volume: 322, Issue:12

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders

1990
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
    Lancet (London, England), 1989, Jan-28, Volume: 1, Issue:8631

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as To

1989
Warfarin to prevent thromboembolism in chronic atrial fibrillation.
    Lancet (London, England), 1989, Mar-25, Volume: 1, Issue:8639

    Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Humans; Thromboembolism; Wa

1989
Cerebral embolism.
    Chest, 1986, Volume: 89, Issue:2 Suppl

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Calcinosis; Cardiomyopathy, Hypertrophic; Clinical Tri

1986
Hemorrhagic complications of anticoagulant therapy.
    Seminars in thrombosis and hemostasis, 1986, Volume: 12, Issue:1

    Topics: Administration, Oral; Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorde

1986

Other Studies

650 other studies available for aspirin and Auricular Fibrillation

ArticleYear
[Anti-Platelet and Anti-Coagulant Drugs].
    Brain and nerve = Shinkei kenkyu no shinpo, 2021, Volume: 73, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Pharmaceutical Preparations; Platelet Aggregat

2021
Left atrial appendage closure: a new strategy for cardioembolic events despite oral anticoagulation.
    Panminerva medica, 2023, Volume: 65, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Hemorrhage; Humans; Retrospective St

2023
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
    Journal of thrombosis and thrombolysis, 2022, Volume: 53, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He

2022
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
    PloS one, 2021, Volume: 16, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Female; Fibrinol

2021
Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants.
    Journal of pharmacy practice, 2023, Volume: 36, Issue:3

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Interactions; H

2023
When and How to Combine Antiplatelet and Anticoagulant Drugs?
    Hamostaseologie, 2022, Volume: 42, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Platele

2022
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022, Jul-22, Volume: 18, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Fibrinolyti

2022
Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.
    Journal of the American College of Cardiology, 2022, 05-10, Volume: 79, Issue:18

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Fibrinolytic Agents; Frailty; Humans

2022
In the search of the 'sweet spot' for aspirin discontinuation time in AF patients post PCI.
    International journal of cardiology, 2022, 09-01, Volume: 362

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Platelet A

2022
Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.
    PLoS medicine, 2022, Volume: 19, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi

2022
Non-vitamin K oral anticoagulant compared with aspirin may not significantly reduce the rate of ischaemic stroke in patients with mixed cardiovascular disease in sinus rhythm.
    European journal of preventive cardiology, 2022, 08-22, Volume: 29, Issue:11

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular D

2022
Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation.
    JAMA network open, 2022, 09-01, Volume: 5, Issue:9

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Male; Middle Aged; Venous T

2022
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials.
    The Canadian journal of cardiology, 2023, Volume: 39, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Str

2023
A descriptive cross-sectional study of self-management in patients with nonvalvular atrial fibrillation.
    Medicine, 2022, Oct-07, Volume: 101, Issue:40

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Humans; Self-Management

2022
A rare cause of abdominal pain managed unconventionally: acute renal infarction caused by atrial fibrillation: a case report.
    Journal of medical case reports, 2022, Oct-19, Volume: 16, Issue:1

    Topics: Abdominal Pain; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Diltiazem; Humans;

2022
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
    European heart journal, 2023, 01-21, Volume: 44, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele

2023
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
    European heart journal, 2023, 01-21, Volume: 44, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele

2023
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
    European heart journal, 2023, 01-21, Volume: 44, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele

2023
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
    European heart journal, 2023, 01-21, Volume: 44, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele

2023
Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program.
    Journal of cardiology, 2023, Volume: 82, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Canada; Coronary Artery Disease; Fibrinolytic Ag

2023
Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries.
    Pharmacoepidemiology and drug safety, 2023, Volume: 32, Issue:11

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Retrospectiv

2023
The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi.
    Value in health regional issues, 2023, Volume: 37

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Malawi; Stroke; Warfarin

2023
Genetics and the Quest to Define Sources of Cardiac Embolism.
    Stroke, 2023, Volume: 54, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Humans; Risk Factors; Warfarin

2023
Changes in Antithrombotic Therapy Prescription in Patients with a Combination of Atrial Fibrillation and Myocardial Infarction in a Specialised Inpatient Department from 2016-2019 and Associations with Prognosis.
    Medicina (Kaunas, Lithuania), 2023, Aug-27, Volume: 59, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Inpatients; Myocardial Infarction; Prescr

2023
DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis.
    JACC. Cardiovascular interventions, 2023, Nov-27, Volume: 16, Issue:22

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Female; Hemorrhage; Humans; Ma

2023
[Embolic stroke of undetermined source - ESUS: a new challenge for the cardiologist].
    Giornale italiano di cardiologia (2006), 2023, Volume: 24, Issue:12

    Topics: Aspirin; Atrial Fibrillation; Cardiologists; Embolic Stroke; Heart Failure; Humans; Risk Factors; St

2023
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
    European journal of clinical investigation, 2019, Volume: 49, Issue:10

    Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Comb

2019
Reply: Do We Have Good Reasons to Pay Bleeding Penalty With Lifelong Aspirin After LAAO?
    JACC. Cardiovascular interventions, 2019, 09-09, Volume: 12, Issue:17

    Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Fibrinolytic Agents; Humans; Thrombosis; Treatment O

2019
Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019, Sep-01, Volume: 21, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Tests; Cros

2019
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
    Circulation, 2019, 12-03, Volume: 140, Issue:23

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents;

2019
Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists.
    International journal of clinical pharmacy, 2019, Volume: 41, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort

2019
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosen
    European heart journal, 2019, Oct-14, Volume: 40, Issue:39

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Cholesterol,

2019
Effectiveness of Only Aspirin or Clopidogrel Following Percutaneous Left Atrial Appendage Closure.
    The American journal of cardiology, 2019, 12-15, Volume: 124, Issue:12

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cathe

2019
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment.
    JAMA neurology, 2020, 01-01, Volume: 77, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Computed Tomography Angiography; Humans; Rivaroxaban; Stroke

2020
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment-Reply.
    JAMA neurology, 2020, 01-01, Volume: 77, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Computed Tomography Angiography; Humans; Rivaroxaban; Stroke

2020
Changing Trends in the Landscape of Patients Hospitalized With Acute Myocardial Infarction (2001 to 2011) (from the Worcester Heart Attack Study).
    The American journal of cardiology, 2020, 03-01, Volume: 125, Issue:5

    Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin Receptor Antagon

2020
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
    The American journal of cardiology, 2020, 03-01, Volume: 125, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor

2020
[Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention].
    Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:2 Suppl 1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percut

2020
Haemorrhagic transformation following ischaemic stroke: A retrospective study.
    Scientific reports, 2020, 03-24, Volume: 10, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Hemorrhage; Humans; Intr

2020
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Circulation, 2020, 05-19, Volume: 141, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa

2020
Risk Versus Benefit of Combined Aspirin and Warfarin Therapy in Patients With Atrial Fibrillation.
    Journal of pharmacy practice, 2021, Volume: 34, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Humans; Platelet Aggregation Inhibitor

2021
Antithrombotic therapy: less is more or the more the better?
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2020, 07-01, Volume: 22, Issue:7

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Cor

2020
Impact of Flow Dynamics on Device-Related Thrombosis After Left Atrial Appendage Occlusion.
    The Canadian journal of cardiology, 2020, Volume: 36, Issue:6

    Topics: Aged; Antithrombins; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Comput

2020
Antithrombotic therapy: less is more or the more the better? Authors' reply.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2020, 07-01, Volume: 22, Issue:7

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Cor

2020
Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
    BMC cardiovascular disorders, 2020, 06-01, Volume: 20, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin;

2020
Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement.
    The American journal of cardiology, 2020, 08-15, Volume: 129

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Val

2020
Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry.
    Stroke, 2020, Volume: 51, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Female; Fol

2020
Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation: A Teachable Moment.
    JAMA internal medicine, 2020, 09-01, Volume: 180, Issue:9

    Topics: Accidental Falls; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Com

2020
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
    Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:14

    Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality

2020
Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation.
    Revista da Associacao Medica Brasileira (1992), 2020, Volume: 66, Issue:6

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillatio

2020
Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?
    European journal of internal medicine, 2020, Volume: 79

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans

2020
Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation.
    Journal of cardiovascular translational research, 2021, Volume: 14, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Atrial

2021
Age- and sex-based differences in patients with acute pericarditis.
    European journal of clinical investigation, 2021, Volume: 51, Issue:3

    Topics: Acute Disease; Adult; Age Distribution; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammato

2021
Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion.
    The American journal of cardiology, 2020, 11-01, Volume: 134

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiovascular Diseases; Cl

2020
In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo.
    Annals of internal medicine, 2020, 09-15, Volume: 173, Issue:6

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Patients; Percut

2020
Integrating the ABC-Bleeding Risk Score Into Practice.
    JAMA network open, 2020, 09-01, Volume: 3, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Biomarkers; Humans; Risk Factors

2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
    JAMA network open, 2020, 09-01, Volume: 3, Issue:9

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biomarkers; Cohort Studies; Female;

2020
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study.
    Pharmacoepidemiology and drug safety, 2020, Volume: 29, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Gastrointestinal Hemorrhage; Humans; R

2020
Bilateral, vertical supranuclear gaze palsy following unilateral midbrain infarct.
    BMJ case reports, 2020, Nov-04, Volume: 13, Issue:11

    Topics: Aspirin; Atrial Fibrillation; Betacoronavirus; Blindness; Brain Stem Infarctions; Coronavirus Infect

2020
Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation.
    Scientific reports, 2020, 11-19, Volume: 10, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulan

2020
Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation - a qualitative study.
    BMC health services research, 2020, Nov-25, Volume: 20, Issue:1

    Topics: Administration, Oral; Anticoagulants; Asia; Aspirin; Atrial Fibrillation; Humans; Stroke

2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutio
    American heart journal, 2021, Volume: 233

    Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Computer Security; Dat

2021
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Circulation, 2021, 03-23, Volume: 143, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;

2021
The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study.
    International journal of medical sciences, 2021, Volume: 18, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Embolic Stroke; Female; Follow-Up Studies; Hirud

2021
Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy.
    Clinical neurology and neurosurgery, 2021, Volume: 203

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Dyslipidemias; F

2021
Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    Journal of cardiovascular pharmacology, 2021, 04-01, Volume: 77, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dual An

2021
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
    JAMA internal medicine, 2021, 06-01, Volume: 181, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrh

2021
A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Utilization; Du

2021
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrin

2017
Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:8

    Topics: Acute Disease; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation

2017
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    JACC. Cardiovascular interventions, 2017, 06-12, Volume: 10, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A

2017
A comparison between vitamin K antagonists and new oral anticoagulants.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:11

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as To

2017
Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Myocardial Infarction; Vitamin K

2017
Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography,

2017
Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
    Heart (British Cardiac Society), 2018, Volume: 104, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2018
Assessing Bleeding Risk in Patients Taking Anticoagulants.
    American family physician, 2017, Oct-01, Volume: 96, Issue:7

    Topics: Age Factors; Alcohol Drinking; Anemia; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Suppor

2017
Thromboembolism after WATCHMAN
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2018, Volume: 92, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Clopi

2018
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
    Herz, 2018, Volume: 43, Issue:1

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2018
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:3

    Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atr

2018
REduction of THRomboembolic EVents during Ablation using the laserballoon: The RETHREVA registry.
    Journal of cardiovascular electrophysiology, 2018, Volume: 29, Issue:3

    Topics: Administration, Intravenous; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Dis

2018
Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
    Kardiologia polska, 2018, Volume: 76, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy,

2018
WATCHMAN device-related thrombus successfully treated with apixaban: A case report.
    Medicine, 2017, Volume: 96, Issue:47

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibit

2017
Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2018, 04-06, Volume: 13, Issue:18

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Cathet

2018
Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study.
    JACC. Heart failure, 2018, Volume: 6, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cause of Death; Denmark; Dose-Response Relati

2018
Physicians Addicted to Prescribing Aspirin-a Disorder Of Cardiologists (PAPA-DOC) Syndrome: The Headache of Nonevidence-Based Medicine for Ischemic Heart Disease?
    JACC. Heart failure, 2018, Volume: 6, Issue:2

    Topics: Aspirin; Atrial Fibrillation; Cardiologists; Headache; Heart Failure; Humans; Myocardial Ischemia; P

2018
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.
    BMJ (Clinical research ed.), 2018, 02-14, Volume: 360

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; England; Fe

2018
Antithrombotic Therapy Underutilization in Patients With Atrial Flutter.
    Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial

2018
Non-Vitamin K Antagonist Preferred in Patients With Nonvalvular Atrial Fibrillation and Indication for Aspirin Therapy.
    Circulation, 2018, 03-13, Volume: 137, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Warfari

2018
Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy.
    Medical hypotheses, 2018, Volume: 114

    Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Anticoagulants; Arrhythmias, Cardiac; Aspirin; At

2018
Dual antiplatelet therapy after percutaneous left atrial appendage occlusion: single center experience with the Amplatzer Cardiac Plug.
    Acta cardiologica, 2019, Volume: 74, Issue:1

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Clopidogrel; Drug The

2019
Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.
    Cardiology journal, 2019, Volume: 26, Issue:6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comparative Effectiveness

2019
Aspirin and Prognosis in Heart Failure: A Question of Power.
    JACC. Heart failure, 2018, Volume: 6, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Heart Failure; Humans; Platelet Aggregation Inhibitors; Prognosis

2018
Reply: Aspirin and Prognosis in Heart Failure: A Question of Power.
    JACC. Heart failure, 2018, Volume: 6, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Heart Failure; Humans; Platelet Aggregation Inhibitors; Prognosis

2018
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
    BMC family practice, 2018, 07-18, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sect

2018
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances.
    Blood advances, 2018, 07-24, Volume: 2, Issue:14

    Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Platelet

2018
The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical Practice: Results From WARFARIN-TR Study
    Balkan medical journal, 2019, 01-01, Volume: 36, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Drug Combinations; Fema

2019
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
    Journal of the American College of Cardiology, 2018, 10-09, Volume: 72, Issue:15

    Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronar

2018
Letter by Tong et al Regarding Article, "Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials".
    Circulation, 2018, 09-18, Volume: 138, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Stroke

2018
Response by de Veer et al to Letter Regarding Article, "Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials".
    Circulation, 2018, 09-18, Volume: 138, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Stroke

2018
Sex-Based Differences in Outcomes of Oral Anticoagulation: Does Antiplatelet Therapy Matter?
    Journal of the American College of Cardiology, 2018, 11-13, Volume: 72, Issue:20

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors

2018
Reply: Sex-Based Differences in Outcomes of Oral Anticoagulation: Does Antiplatelet Therapy Matter?
    Journal of the American College of Cardiology, 2018, 11-13, Volume: 72, Issue:20

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors

2018
Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation.
    International journal of cardiology, 2019, Jan-15, Volume: 275

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Dose-Response Relationship, Drug;

2019
Aspirin on Top of Anticoagulation in Patients With Concomitant Stable Coronary Artery Disease and Atrial Fibrillation.
    Circulation, 2019, 01-29, Volume: 139, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Humans; Platelet Aggregation

2019
Evaluating the Effect of a Patient Decision Aid for Atrial Fibrillation Stroke Prevention Therapy.
    The Annals of pharmacotherapy, 2019, Volume: 53, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; British Columbia; Decision Making; Decision Supp

2019
Stroke prevention in atrial fibrillation: Closing the gap.
    American heart journal, 2019, Volume: 210

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misu

2019
Stroke prevention in patients with acute ischemic stroke and atrial fibrillation in Germany - a cross sectional survey.
    BMC neurology, 2019, Feb-12, Volume: 19, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Germany; Humans

2019
Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use.
    Clinical drug investigation, 2019, Volume: 39, Issue:4

    Topics: Administration, Oral; Advisory Committees; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial

2019
[Elderly patients and atrial fibrillation: age alone should not be a contra-indication for anticoagulant treatment].
    Nederlands tijdschrift voor geneeskunde, 2019, 02-22, Volume: 163

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Frail Elderly; Humans

2019
Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events.
    JAMA internal medicine, 2019, 04-01, Volume: 179, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Therapy,

2019
A Main Performer May Come for Percutaneous Coronary Intervention With Atrial Fibrillation in Japanese Patients.
    Circulation journal : official journal of the Japanese Circulation Society, 2019, 04-25, Volume: 83, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Japan; Percutaneous Coronary Intervention; Pra

2019
The Effect of Aspirin as an Irreversible COX1 Inhibitor in Preventing Non-Valvular Atrial Fibrillation After Coronary Bypass Surgery.
    The heart surgery forum, 2019, 03-11, Volume: 22, Issue:2

    Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Cyclooxygenase 1; Cyclooxygenase Inhibit

2019
A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy.
    Cardiovascular intervention and therapeutics, 2020, Volume: 35, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug-Eluting Stents; Dual Anti-Plat

2020
Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS.
    European journal of internal medicine, 2019, Volume: 65

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Therapy, Combination; Fi

2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
    The American journal of cardiology, 2019, 08-15, Volume: 124, Issue:4

    Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2019
Critical appraisal of the AUGUSTUS trial.
    European heart journal. Cardiovascular pharmacotherapy, 2019, 10-01, Volume: 5, Issue:4

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Fact

2019
In AF with recent ACS or PCI, apixaban reduced bleeding vs VKAs; aspirin increased bleeding vs placebo.
    Annals of internal medicine, 2019, 07-16, Volume: 171, Issue:2

    Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Cor

2019
Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption.
    Arquivos de neuro-psiquiatria, 2019, 07-29, Volume: 77, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brazil; Clopidogrel; Cross-Sectional Studies; Fe

2019
Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
    European heart journal, 2019, 09-21, Volume: 40, Issue:36

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Electric Countershock; Female; Follow-Up Studies; H

2019
Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry.
    Journal of cardiology, 2013, Volume: 61, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Female; Humans;

2013
Amplatzer left atrial appendage occlusion: single center 10-year experience.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Aug-01, Volume: 82, Issue:2

    Topics: Aged; Aged, 80 and over; Anesthesia, Local; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac

2013
PCI patients taking oral anticoagulants may not need aspirin.
    BMJ (Clinical research ed.), 2013, Feb-20, Volume: 346

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Clopidogrel; Drug Therapy, Combination

2013
Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy.
    Journal of cardiovascular electrophysiology, 2013, Volume: 24, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Echocardiography, Transesophageal;

2013
[Atrial fibrillation. Apixaban reduces stroke risk].
    MMW Fortschritte der Medizin, 2013, Mar-07, Volume: 155, Issue:4

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug

2013
Non-valvular atrial fibrillation in the elderly; preliminary results from the National AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) Study.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Electrocardiography; Female; Humans; Internat

2013
Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electrocardiography; F

2013
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Journal of the American College of Cardiology, 2013, Sep-10, Volume: 62, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2013
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet

2013
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Platelet Aggregation Inhibitors

2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
    International journal of clinical practice, 2013, Volume: 67, Issue:8

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis

2013
Improving cardiovascular disease management in Australia: NPS MedicineWise.
    The Medical journal of Australia, 2013, Aug-05, Volume: 199, Issue:3

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Cardiovascular Diseases; Datab

2013
[Your patient needs antithrombotic drugs, 7. Averting the risk of stroke: with whom and how?].
    MMW Fortschritte der Medizin, 2013, Jul-25, Volume: 155, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; F

2013
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
    Heart and vessels, 2014, Volume: 29, Issue:5

    Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co

2014
Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Factor Xa Inhibitors; Fondaparinux;

2013
[Triple therapy for patients with stent and atrial fibrillation? Yes!].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:39

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combinat

2013
[Triple therapy for patients with stent and atrial fibrillation? No!].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:39

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggre

2013
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therap

2014
Atrial fibrillation patients do not benefit from acetylsalicylic acid.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Female; Gastr

2014
Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system.
    International journal of cardiology, 2013, Dec-10, Volume: 170, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Cross-Sec

2013
Acetylsalicylic acid for stroke prevention in atrial fibrillation: a conspiracy that needs to end?
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibitors;

2014
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
    Cardiovascular intervention and therapeutics, 2014, Volume: 29, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera

2014
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Circulation, 2014, Apr-15, Volume: 129, Issue:15

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies;

2014
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
    European heart journal, 2014, Jul-21, Volume: 35, Issue:28

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inh

2014
Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Neurology, 2014, 02-25, Volume: 82, Issue:8

    Topics: Academies and Institutes; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Practice Guidelines

2014
Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Utilization; Female; Follow-Up

2014
Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists.
    Clinical cardiology, 2014, Volume: 37, Issue:2

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Fibrino

2014
Autonomic modulation in a patient with syncope and paroxysmal atrial-fibrillation.
    Autonomic neuroscience : basic & clinical, 2014, Volume: 183

    Topics: Adult; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Follow-Up Studies; Heart Rate; Humans; M

2014
Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.
    Health expectations : an international journal of public participation in health care and health policy, 2015, Volume: 18, Issue:6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Female; Fib

2015
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Journal of medical economics, 2014, Volume: 17, Issue:8

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparati

2014
Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    The American journal of medicine, 2014, Volume: 127, Issue:10

    Topics: Age Distribution; Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Com

2014
Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Thrombosis research, 2014, Volume: 134, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Female

2014
Aspirin use and risk of atrial fibrillation in the Physicians' Health Study.
    Journal of the American Heart Association, 2014, Jun-30, Volume: 3, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Cohort Studies; Humans;

2014
Aspirin still overprescribed for stroke prevention in atrial fibrillation.
    European heart journal, 2014, Jun-07, Volume: 35, Issue:22

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Stroke; Unnecessary Procedures

2014
Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation.
    Yonsei medical journal, 2014, Volume: 55, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Female; Hemorrhage; Humans; K

2014
Letter by Zito et Al regarding article, "warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham atrial fibrillation treatment of the aged study)".
    Stroke, 2014, Volume: 45, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cognition Disorders; Female; Fibrinolytic Agents; Huma

2014
Response to letter regarding article, "warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (birmingham atrial fibrillation treatment of the aged study)".
    Stroke, 2014, Volume: 45, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cognition Disorders; Female; Fibrinolytic Agents; Huma

2014
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles

2014
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:5

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor

2014
Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
    Clinical drug investigation, 2014, Volume: 34, Issue:10

    Topics: Aged; Aspirin; Atrial Fibrillation; Belgium; Cost-Benefit Analysis; Factor Xa Inhibitors; Female; He

2014
New ways to assess stroke risk and tame an abnormal heartbeat. Cardiology groups update guidelines to treat atrial fibrillation.
    The Johns Hopkins medical letter health after 50, 2014, Volume: 26, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Middle Aged; Practi

2014
Diffuse alveolar hemorrhage secondary to apixaban administration.
    Chest, 2014, Volume: 146, Issue:3

    Topics: Aged; Aspirin; Atrial Fibrillation; Continuous Positive Airway Pressure; Female; Fibrinolytic Agents

2014
New guidelines update treatment of atrial fibrillation. Changes include adding new clot-preventing drugs and using less aspirin.
    Harvard heart letter : from Harvard Medical School, 2014, Volume: 24, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Practice Guid

2014
Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Hemor

2014
Intracranial hemorrhage during dual antiplatelet therapy after percutaneous left atrial appendage closure.
    Cerebrovascular diseases (Basel, Switzerland), 2014, Volume: 38, Issue:1

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans

2014
Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2014, Volume: 33, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Disease Progression; Health Res

2014
Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis.
    Journal of Korean medical science, 2014, Volume: 29, Issue:9

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chromatography, High Pressure Liquid; Cytochrome

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician.
    European heart journal, 2015, Feb-01, Volume: 36, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Male; Stroke

2015
[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?].
    Herz, 2014, Volume: 39, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Cardiovascular Surgical Procedures; Coronary Artery Disease; Drug Admi

2014
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
    The Medical journal of Australia, 2014, Nov-17, Volume: 201, Issue:10

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti

2014
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
    Stroke, 2015, Volume: 46, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Huma

2015
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Stroke, 2015, Volume: 46, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2015
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
    Clinical therapeutics, 2014, Nov-01, Volume: 36, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Databases, Factual; Decision Support

2014
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr

2015
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Journal of the American College of Cardiology, 2014, Dec-16, Volume: 64, Issue:23

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Female; Follow-Up Studi

2014
Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
    Chest, 2015, Volume: 148, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; China; Cohort St

2015
[Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation].
    Zhonghua xin xue guan bing za zhi, 2014, Volume: 42, Issue:10

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; China; Female; H

2014
Increased IL-17A in atrial fibrillation correlates with neutrophil to lymphocyte ratio.
    Iranian journal of immunology : IJI, 2014, Volume: 11, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Chemokine CCL5; Chemoki

2014
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra

2015
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra

2015
Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
    Journal of the American College of Cardiology, 2015, Feb-10, Volume: 65, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Ticlopidine; Vitamin K

2015
Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
    Journal of the American College of Cardiology, 2015, Feb-10, Volume: 65, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Ticlopidine; Vitamin K

2015
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Coronary artery disease, 2015, Volume: 26, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distributi

2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
    Journal of the American College of Cardiology, 2015, Apr-14, Volume: 65, Issue:14

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Cohort

2015
Patients with atrial fibrillation and a CHA2DS2-VASc score of 1: are they at low or high stroke risk?
    Journal of the American College of Cardiology, 2015, Apr-14, Volume: 65, Issue:14

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Stroke

2015
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
    Neurological research, 2015, Volume: 37, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti

2015
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
    Chest, 2015, Volume: 148, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido

2015
Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care.
    International journal of cardiology, 2015, Volume: 187

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Drug Prescrip

2015
Account should also have been taken of the harm versus benefit of aspirin use.
    International journal of cardiology, 2015, Volume: 187

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Platelet

2015
Is long-term warfarin therapy necessary in Chinese patients with atrial fibrillation after bioprosthetic mitral valve replacement and left atrial appendage obliteration?
    The heart surgery forum, 2015, Feb-27, Volume: 18, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Bioprosthesis

2015
Dual or triple therapy in patients with atrial fibrillation and drug-eluting stents?
    Coronary artery disease, 2015, Volume: 26, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Female; Fibrinolytic Agents;

2015
INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.
    International journal of clinical pharmacy, 2015, Volume: 37, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Fe

2015
Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Female; Fibrinolytic Agents; Hong Kong;

2015
[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Harefuah, 2015, Volume: 154, Issue:5

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors

2015
Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
    Journal of the American Heart Association, 2015, Jul-17, Volume: 4, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Coagulation; California; Comorbidity; D

2015
Antithrombotic Therapy Practices in Older Adults Residing in the Long-Term Care Setting.
    Southern medical journal, 2015, Volume: 108, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Body Mass Index; Drug Therapy

2015
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
    Journal of the American College of Cardiology, 2015, Jul-28, Volume: 66, Issue:4

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Female;

2015
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Decision Support Techni

2015
Medication Extraction from Electronic Clinical Notes in an Integrated Health System: A Study on Aspirin Use in Patients with Nonvalvular Atrial Fibrillation.
    Clinical therapeutics, 2015, Volume: 37, Issue:9

    Topics: Algorithms; Aspirin; Atrial Fibrillation; California; Delivery of Health Care, Integrated; Electroni

2015
Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
    JAMA internal medicine, 2015, Volume: 175, Issue:10

    Topics: Acenocoumarol; Administration, Oral; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation

2015
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    The American journal of medicine, 2015, Volume: 128, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Humans;

2015
Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
    Journal of the American College of Cardiology, 2015, Aug-11, Volume: 66, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe

2015
Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2016, Volume: 41, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibril

2016
[Anticoagulants to more people can prevent many cases of stroke].
    Lakartidningen, 2015, Sep-08, Volume: 112

    Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Humans; Medication Adhe

2015
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel;

2015
Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis.
    BMC cardiovascular disorders, 2015, Sep-29, Volume: 15

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Genetic Predisposition to Disea

2015
Hemoptysis due to aspirin treatment alternative to warfarin therapy in a patient with atrial fibrillation.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:20

    Topics: Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Interactions; Female; Hemoptys

2015
Inappropriate combination of warfarin and aspirin.
    Anatolian journal of cardiology, 2016, Volume: 16, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Drug Therapy, Combinati

2016
Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
    The American journal of medicine, 2016, Volume: 129, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbi

2016
Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2016, Volume: 18, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hong Kong; Hospitaliz

2016
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigat

2016
[Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?].
    Revue medicale suisse, 2015, Oct-14, Volume: 11, Issue:490

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Drug Therapy, Combination; Hemorrhag

2015
[A rare differential diagnosis of acute lower gastrointestinal bleeding: Small-bowel diverticulosis].
    MMW Fortschritte der Medizin, 2015, Oct-08, Volume: 157, Issue:17

    Topics: Accidental Falls; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-S

2015
Triple Antithrombotic Therapy - Always One Too Many?
    Circulation journal : official journal of the Japanese Circulation Society, 2016, Volume: 80, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agents; Humans

2016
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    The American journal of medicine, 2016, Volume: 129, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity;

2016
Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Female; Humans;

2016
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2016, Volume: 18, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Surgical Procedures; Clopido

2016
Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey.
    Scientific reports, 2016, Feb-12, Volume: 6

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Balkan Peni

2016
Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation.
    The American journal of cardiology, 2016, Apr-01, Volume: 117, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Canada; Female; Fibrinolytic Agents; Guideline A

2016
Web Exclusives. The Consult Guys--CHADS, SHMADS: What's All This About Anticoagulation?
    Annals of internal medicine, 2016, 02-16, Volume: 164, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Middle Aged; Prac

2016
Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study.
    Thrombosis research, 2016, Volume: 140

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Human

2016
Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.
    Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:2

    Topics: Aspirin; Atrial Fibrillation; Clinical Laboratory Techniques; Coronary Artery Disease; Fibrinolysis;

2016
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk.
    Cardiovascular research, 2016, 06-01, Volume: 110, Issue:3

    Topics: Animals; Aspirin; Atrial Fibrillation; Bleeding Time; Carotid Artery Diseases; Case-Control Studies;

2016
Ask the doctors. I am a 78-year-old woman and have atrial fibrillation. My physician prescribed me Coumadin. Last month aspirin was added to my regimen. Is it okay to take both of these drugs together?
    Harvard heart letter : from Harvard Medical School, 2013, Volume: 23, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Female; Humans; Warfarin

2013
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
    Internal medicine journal, 2016, Volume: 46, Issue:7

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutte

2016
Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry.
    International journal of cardiology, 2016, Jun-01, Volume: 212

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans;

2016
Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
    Journal of medical economics, 2016, Volume: 19, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovas

2016
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Feb-01, Volume: 89, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2017
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
    Minerva cardioangiologica, 2016, Volume: 64, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Rivaroxaban; Str

2016
Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke.
    Journal of the American College of Cardiology, 2016, 06-28, Volume: 67, Issue:25

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female

2016
Aspirin in Atrial Fibrillation: The Clot Thickens.
    Journal of the American College of Cardiology, 2016, 06-28, Volume: 67, Issue:25

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Thrombosis; Warfarin

2016
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    The American journal of medicine, 2016, Volume: 129, Issue:11

    Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabig

2016
Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation.
    The Canadian journal of cardiology, 2016, Volume: 32, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Contraindic

2016
Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    JAMA cardiology, 2016, 05-01, Volume: 1, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; I

2016
Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Biomarkers; Blood Glucose; Blood Pressure; Br

2016
Atrial fibrillation: Stroke prevention in atrial fibrillation: can we do better?
    Nature reviews. Cardiology, 2016, Volume: 13, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke

2016
[Acute subdural hematoma in a patient in treatment with apixaban and acetylsalicylic acid].
    Medicina clinica, 2016, Oct-07, Volume: 147, Issue:7

    Topics: Aged, 80 and over; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Factor Xa Inhibitors; He

2016
Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus.
    Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:8

    Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Clopidogrel; Combined Modal

2016
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
    World neurosurgery, 2016, Volume: 95

    Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra

2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    American heart journal, 2016, Volume: 179

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Therapy, Combination; Embolism

2016
Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:1

    Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Diseas

2017
Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.
    Applied health economics and health policy, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Australia; Cost-Benefit Analysis; Fema

2017
High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study).
    The American journal of cardiology, 2016, Dec-15, Volume: 118, Issue:12

    Topics: Aged; Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Black or African American; C-Reactive P

2016
Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies;

2017
Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017, Volume: 17, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Computer Simulation; Cost-Benefit Analysis; Drug Costs

2017
[Current status of warfarin therapy in Chinese patients with nonvalvular atrial fibrillation: a single center analysis].
    Zhonghua xin xue guan bing za zhi, 2016, Nov-24, Volume: 44, Issue:11

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; China; Hospitali

2016
Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, Apr-20, Volume: 12, Issue:17

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiac Surgical Procedures; Endovascular Pro

2017
Atrial Fibrillation and PCI - Do We Still Need Aspirin?
    The New England journal of medicine, 2016, 12-22, Volume: 375, Issue:25

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

2016
Left Atrial Appendage Closure in Patients with Atrial Fibrillation and Previous Intracerebral Hemorrhage.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cerebral Amyloid Angiopathy

2017
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
    Archives of cardiovascular diseases, 2017, Volume: 110, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl

2017
Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy-based Survey.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 121, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics; Anticoagulants; Aspirin; Atrial Fibrillat

2017
Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation;

2017
Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?
    Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Femal

2008
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Chest, 2008, Volume: 133, Issue:6 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Fibrino

2008
[The importance of oral anticoagulation in patients with atrial fibrillation for stroke prevention].
    Fortschritte der Neurologie-Psychiatrie, 2008, Volume: 76, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Stroke; Warfa

2008
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Chest, 2008, Volume: 134, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As

2008
Freedom from complications related to dual ball-and-cage mechanical valve prostheses despite thirty years without anticoagulation.
    Interactive cardiovascular and thoracic surgery, 2008, Volume: 7, Issue:6

    Topics: Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Endocarditis, Bacterial; Epistaxis; Hear

2008
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
    Journal of the American College of Cardiology, 2008, Sep-02, Volume: 52, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Humans; Incidence; Platelet Aggregation Inhibit

2008
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
    Medizinische Klinik (Munich, Germany : 1983), 2008, Sep-15, Volume: 103, Issue:9

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspir

2008
[Anticoagulation in atrial fibrillation].
    Hamostaseologie, 2008, Volume: 28, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagula

2008
Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan.
    Clinical therapeutics, 2008, Volume: 30, Issue:9

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; Fibrinolytic Agents;

2008
Patient with hypofibrinolysis-mediated thromboembolism converted to a hypercoagulable/hyperfibrinolytic state via ventricular assist device placement.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2008, Volume: 27, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Transesophageal; Female; Fibrinolysi

2008
Diagnosis and treatment of pulmonary arterial hypertension and atrial fibrillation in an adult chimpanzee (Pan troglodytes).
    Journal of the American Association for Laboratory Animal Science : JAALAS, 2008, Volume: 47, Issue:5

    Topics: Animals; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Diureti

2008
Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study.
    BMC health services research, 2008, Oct-27, Volume: 8

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Focus Groups; Humans; Male; Middle Aged;

2008
[Prevention of thrombolitic compications with atrial fibrillation].
    Georgian medical news, 2008, Issue:163

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Throm

2008
eComment: Freedom from complications related to dual ball-and-cage mechanical valve prostheses despite thirty years without anticoagulation.
    Interactive cardiovascular and thoracic surgery, 2008, Volume: 7, Issue:6

    Topics: Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Endocarditis, Bacterial; Epistaxis; Hear

2008
[The BAFTA study].
    Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Randomized Controlled Trials as Topic; Stroke;

2008
[Indications of vitamin K antagonists and aspirin in the atrial fibrillation of the elderly].
    La Revue de medecine interne, 2009, Volume: 30, Issue:8

    Topics: Aged; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Thromboembolism; Vitami

2009
The choice of aspirin dose for primary prevention of embolic complications of nonvalvular atrial fibrillation in elderly people.
    Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; H

2009
Indirect comparison: relative risk fallacies and odds solution.
    Journal of clinical epidemiology, 2009, Volume: 62, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Aspirin; Atrial Fibrillat

2009
Atrial fibrillation: Ways to refine your care.
    The Journal of family practice, 2009, Volume: 58, Issue:2

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; C

2009
Atrial fibrillation and mild cognitive impairment: what correlation?
    Minerva cardioangiologica, 2009, Volume: 57, Issue:2

    Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin;

2009
Atrial fibrillation and stroke risk prevention in real-life clinical practice.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clini

2009
How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Drug

2009
[Factors influencing development of atrial fibrillation after implantation of cardiac pacemaker for sinus node dysfunction].
    Medicina (Kaunas, Lithuania), 2009, Volume: 45, Issue:3

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Data

2009
Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.
    Circulation, 2009, Apr-28, Volume: 119, Issue:16

    Topics: Adult; Antioxidants; Aspirin; Atrial Fibrillation; Blood Pressure; Cohort Studies; Diastole; Female;

2009
[Atrial fibrillation].
    Praxis, 2009, Jan-07, Volume: 98, Issue:1

    Topics: Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Electrocardiography

2009
[Therapy of atrial fibrillation. Heart rate or rhythm control, marcumar or acetylsalicylic acid?].
    MMW Fortschritte der Medizin, 2009, Feb-26, Volume: 151, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Humans; Patient Education as Topic;

2009
The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I

2009
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin.
    The Lancet. Neurology, 2009, Volume: 8, Issue:6

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracra

2009
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
    American heart journal, 2009, Volume: 157, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Heart Diseases; Humans; M

2009
Prevention of stroke in patients with atrial fibrillation.
    The Medical letter on drugs and therapeutics, 2009, Jun-01, Volume: 51, Issue:1313

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans;

2009
[Oral anticoagulant use in patients with atrial fibrillation].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Hypertension; International Norm

2009
Myocardial perfusion imaging and cardiovascular outcomes in a cancer population.
    Texas Heart Institute journal, 2009, Volume: 36, Issue:3

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiovascular Agents; Cardiovascular Diseases; Fem

2009
Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    The American journal of geriatric pharmacotherapy, 2009, Volume: 7, Issue:3

    Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dementia; F

2009
[ASS plus clopidogrel in contraindication for marcumar].
    MMW Fortschritte der Medizin, 2009, Apr-16, Volume: 151, Issue:16

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat

2009
Who is ineligible for warfarin in atrial fibrillation?
    Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans;

2009
Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments.
    Revista espanola de cardiologia, 2009, Volume: 62, Issue:9

    Topics: Aged; Aspirin; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation In

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Contraindications; Drug Therapy, Combinat

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet A

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2009
Clopidogrel plus aspirin in atrial fibrillation.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Pla

2009
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
    The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri

2009
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic;

2009
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinica

2009
Spontaneous spinal epidural haematoma in a geriatric patient on aspirin.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:1

    Topics: Age Factors; Aged, 80 and over; Aspirin; Atrial Fibrillation; Decompression, Surgical; Female; Hemat

2010
By the way, doctor. I am currently on Coumadin because I had atrial fibrillation after my bypass, Plavix because of my stent, and a baby aspirin. Why do I need to take three blood thinners?
    Harvard health letter, 2009, Volume: 34, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiopulmonary Bypass; Clopidogrel; Humans; Platelet

2009
Aspirin gets a backup against atrial fibrillation.
    Harvard heart letter : from Harvard Medical School, 2009, Volume: 19, Issue:11

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation I

2009
Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves.
    Chest, 2009, Volume: 136, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Heart Valve Prosthes

2009
The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Journal of cardiovascular electrophysiology, 2010, Volume: 21, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Fol

2010
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini

2009
Dabigatran versus warfarin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, Dec-31, Volume: 361, Issue:27

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination;

2009
Dabigatran versus warfarin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, Dec-31, Volume: 361, Issue:27

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination;

2009
[Abdominal tumor after persistent coughing and uncontrolled anticoagulation].
    Praxis, 2010, Jan-06, Volume: 99, Issue:1

    Topics: Abdomen, Acute; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coloni

2010
Anticoagulation intensity for elderly atrial fibrillation patients: should we use a conventional INR target (2.0 to 3.0) or a lower range?
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; International Normalized Ratio; Stroke;

2010
Warfarin versus aspirin: using CHADS2 to guide therapy for stroke prevention in nonvalvular atrial fibrillation.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2009, Volume: 24, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Female; Fibr

2009
Stroke in heart failure: atrial fibrillation revisited?
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2010, Volume: 19, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Failure; Hemorrhage; Humans; Patient Selection;

2010
Letter by Barrios et al regarding article, "Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women".
    Circulation, 2010, Feb-09, Volume: 121, Issue:5

    Topics: Adult; Antioxidants; Aspirin; Atrial Fibrillation; Blood Pressure; Cohort Studies; Diastole; Female;

2010
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, May-01, Volume: 75, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor

2010
Prevention and treatment of cardioembolic stroke: a case study.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2009, Volume: 24, Issue:12

    Topics: Aged; Aspirin; Atrial Fibrillation; Embolism; Female; Fibrinolytic Agents; Humans; Risk Factors; Str

2009
Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Humans; Hypoglycemic Agents; J

2010
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
    Der Nervenarzt, 2010, Volume: 81, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel;

2010
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Circulation journal : official journal of the Japanese Circulation Society, 2010, Volume: 74, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis

2010
Anticoagulation versus aspirin for geriatric patients with atrial fibrillation: is there still any doubt?
    Journal of the American Geriatrics Society, 2010, Volume: 58, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Europe; Frail Elderly; Humans

2010
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
    MMW Fortschritte der Medizin, 2010, Mar-25, Volume: 152, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar

2010
Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
    The Medical journal of Australia, 2010, May-03, Volume: 192, Issue:9

    Topics: Algorithms; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Vessels; Drug Therapy, Combination;

2010
Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2010, Volume: 15, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents;

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin.
    Preventive cardiology, 2010,Fall, Volume: 13, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Female; Fibrinolytic Ag

2010
Effect of anticoagulation on endothermal ablation of the great saphenous vein.
    Journal of vascular surgery, 2011, Volume: 53, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Drug Thera

2011
Calcified ball-like left ventricular thrombus embolized during echocardiography follow-up.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2010, Oct-08, Volume: 10, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Cardiomegaly; Dyspnea; Echocardiography; Embolization, Therapeutic; He

2010
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards.
    European journal of internal medicine, 2010, Volume: 21, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Guideline Adhere

2010
Ischaemic stroke--prevention is better than cure.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:1

    Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo

2010
Long term treatment of atrial fibrillation in elderly patients: a decision analysis.
    International journal of cardiology, 2012, Feb-23, Volume: 155, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Decision Support Techniques;

2012
Poor tolerance of beta-blockers by elderly patients with heart failure.
    Clinical interventions in aging, 2010, Nov-26, Volume: 5

    Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin Receptor Antagonists; Aortic Valve Steno

2010
Ask the doctor. I am a 79-year-old man with atrial fibrillation that is well controlled by Pacerone. I also take warfarin and aspirin to prevent stroke. I plan to have a tooth pulled next month and wonder if is is safe to go off the blood thinners. Ho
    Harvard heart letter : from Harvard Medical School, 2010, Volume: 21, Issue:3

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Heal

2010
Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data.
    Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:3

    Topics: Aged; Aspirin; Atrial Fibrillation; Cohort Studies; Community Pharmacy Services; Databases, Factual;

2011
Atrial fibrillation, is warfarin the only option for stroke prevention?
    JPMA. The Journal of the Pakistan Medical Association, 2011, Volume: 61, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp

2011
Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulati

2011
Finding a balance in long-term anticoagulation therapy.
    The American journal of managed care, 2010, Volume: 16, Issue:10 Suppl

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Practice Guidelines as Topic; Stroke; Time Fac

2010
A pharmacoeconomic perspective on stroke prevention in atrial fibrillation.
    The American journal of managed care, 2010, Volume: 16, Issue:10 Suppl

    Topics: Aspirin; Atrial Fibrillation; Drug Monitoring; Fibrinolytic Agents; Humans; Practice Guidelines as T

2010
Dual antiplatelet therapy and the risk of bleeding.
    Archives of internal medicine, 2011, Apr-25, Volume: 171, Issue:8

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag

2011
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
    International journal of stroke : official journal of the International Stroke Society, 2011, Volume: 6, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp

2011
Persistent iatrogenic atrial septal defect after pulmonary vein isolation by cryoballoon: an under-recognized complication.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:10

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Catheterization; Cryos

2011
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.
    JAMA, 2011, May-25, Volume: 305, Issue:20

    Topics: Aspirin; Atrial Fibrillation; Cause of Death; Female; Follow-Up Studies; Health Personnel; Heart Fai

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, 06-16, Volume: 364, Issue:24

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Pyrazoles; Pyridones; Stroke; Warfarin

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, 06-16, Volume: 364, Issue:24

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi

2011
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Drug Evaluation; Fem

2011
Atrial fibrillation treatment update.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2011, Volume: 64, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Heart Rate; Humans; Platelet Aggregation Inhibitors; Prac

2011
[The AVERROES study].
    Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Follow-Up Studies; Humans; Italy; Platelet Aggregation Inhibitors; Pyr

2011
Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry.
    Stroke, 2011, Volume: 42, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Femal

2011
The use of dabigatran immediately after atrial fibrillation ablation.
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2012
Thrombus formation on a left atrial appendage closure device.
    Circulation, 2011, Oct-04, Volume: 124, Issue:14

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design;

2011
Development of a tool to improve the quality of decision making in atrial fibrillation.
    BMC medical informatics and decision making, 2011, Oct-06, Volume: 11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Hemorrhage; Humans; Patie

2011
Selecting the optimal stroke prevention therapy in atrial fibrillation.
    Annals of internal medicine, 2011, Nov-01, Volume: 155, Issue:9

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhib

2011
Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: an 86-year-old woman with peptic ulcer disease.
    JAMA, 2011, Dec-07, Volume: 306, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Interaction

2011
Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.
    Age and ageing, 2012, Volume: 41, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Decision Trees; Hemorrhag

2012
Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now.
    International journal of clinical pharmacy, 2012, Volume: 34, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Femal

2012
Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    The American journal of cardiology, 2012, Apr-01, Volume: 109, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Cohort St

2012
Warfarin use in nursing home residents: results from the 2004 national nursing home survey.
    The American journal of geriatric pharmacotherapy, 2012, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cross-Sectional

2012
Advances in prevention and health services delivery 2010-2011.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Delivery of Health Care; Humans; Platelet Aggregation

2012
[Pharmacoeconomic analysis of dabigatran etexilate effectiveness in patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation T

2012
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective

2012
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective

2012
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective

2012
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Prevention of stroke in atrial fibrillation: cautious optimism.
    The Lancet. Neurology, 2012, Volume: 11, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male;

2012
Cross-sectional study of treatment strategies on atrial fibrillation.
    Arquivos brasileiros de cardiologia, 2012, Volume: 98, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrilla

2012
Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation.
    Internal medicine journal, 2012, Volume: 42, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Femal

2012
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
    Internal medicine journal, 2011, Volume: 41, Issue:10

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai

2011
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
    Internal medicine journal, 2011, Volume: 41, Issue:10

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai

2011
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
    Internal medicine journal, 2011, Volume: 41, Issue:10

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai

2011
Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage.
    Internal medicine journal, 2011, Volume: 41, Issue:10

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Comorbidity; Contrai

2011
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
    The American journal of cardiology, 2012, Jul-01, Volume: 110, Issue:1

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla

2012
What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
    The journal of the Royal College of Physicians of Edinburgh, 2012, Volume: 42 Suppl 18

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemor

2012
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet A

2012
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
    American heart journal, 2012, Volume: 163, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat

2012
The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation.
    Platelets, 2013, Volume: 24, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Agg

2013
Clopidogrel in atrial fibrillation: is there any justification now in the era of new anticoagulants?
    The American journal of cardiology, 2012, Jul-01, Volume: 110, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Practice Guideli

2012
A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.
    BMC cardiovascular disorders, 2012, Jun-26, Volume: 12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, F

2012
Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Cost-Benefit Analysis; Drug C

2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    The American journal of medicine, 2012, Volume: 125, Issue:9

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh

2012
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo

2012
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
    Circulation, 2012, Sep-04, Volume: 126, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi

2012
Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation.
    Circulation, 2012, Aug-14, Volume: 126, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Making; Female; Fibrinolytic Agents; He

2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
    The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,

2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
    The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,

2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
    The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,

2012
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
    The New England journal of medicine, 2012, Aug-16, Volume: 367, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure,

2012
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
    American heart journal, 2012, Volume: 164, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor

2012
[Risks in atrial fibrillation and simultaneous renal failure].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:38

    Topics: Aspirin; Atrial Fibrillation; Cerebral Infarction; Comorbidity; Fibrinolytic Agents; Humans; Kidney

2012
Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"!
    American journal of therapeutics, 2012, Volume: 19, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antithrombins; Aspirin; Atrial Fibrillation; Ben

2012
[Expert answer. Coronary artery patients with atrial fibrillation on anticoagulation treatment may need antithrombotic treatment. What kind is there?].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2012, Volume: 40, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co

2012
Atrial fibrillation and chronic kidney disease.
    The New England journal of medicine, 2012, 11-29, Volume: 367, Issue:22

    Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie

2012
Atrial fibrillation and chronic kidney disease.
    The New England journal of medicine, 2012, 11-29, Volume: 367, Issue:22

    Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie

2012
Atrial fibrillation and chronic kidney disease.
    The New England journal of medicine, 2012, 11-29, Volume: 367, Issue:22

    Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie

2012
Acute management of atrial fibrillation: Part II. Prevention of thromboembolic complications.
    American family physician, 2002, Jul-15, Volume: 66, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Heparin; Humans; Thromboembolis

2002
[Prevention of arterial thromboembolisms in patients with atrial fibrillation].
    Herz, 2002, Volume: 27, Issue:4

    Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Int

2002
Stroke prevention in elderly patients with atrial fibrillation.
    Singapore medical journal, 2002, Volume: 43, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Platele

2002
Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing.
    Age and ageing, 2002, Volume: 31, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Clinical Audit; Cr

2002
[A case of familial restrictive cardiomyopathy].
    Klinicheskaia meditsina, 2002, Volume: 80, Issue:9

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Atenolol; Atrial Fibrillation

2002
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy.
    European heart journal, 2002, Volume: 23, Issue:22

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Cross-Sectional Studies; E

2002
[Anticoagulation in permanent atrial fibrillation after 75 years of age].
    La Revue de medecine interne, 2002, Volume: 23, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hu

2002
Stroke prevention in patients with atrial fibrillation.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2003, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Prescriptions; Female; F

2003
[Embolism prevention in atrial fibrillation with heparin?].
    Deutsche medizinische Wochenschrift (1946), 2002, Dec-13, Volume: 127, Issue:50

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Heparin; Heparin, Low-Molecul

2002
Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment?
    Family practice, 2003, Volume: 20, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coumarins; Cross-Sectional Studies; Evidence-Bas

2003
Warfarin, aspirin, or both after myocardial infarction.
    The New England journal of medicine, 2003, Jan-16, Volume: 348, Issue:3

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans;

2003
The underutilization of cardiac medications of proven benefit, 1990 to 2002.
    Journal of the American College of Cardiology, 2003, Jan-01, Volume: 41, Issue:1

    Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atr

2003
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:3

    Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp

2003
Atrial fibrillation, stroke, and acute antithrombotic therapy.
    Stroke, 2003, Volume: 34, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized

2003
Bedside calculation of stroke risk in patients with atrial fibrillation.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Mar-01, Volume: 60, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Computers, Handheld; Hemorrh

2003
[Anticoagulation and antiaggregation in cardiac patients].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo

2003
Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation.
    American heart journal, 2003, Volume: 145, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Tran

2003
Efficacy of antithrombotic therapy for atrial fibrillation in the oldest old.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Fib

2003
Towards better management of chronic atrial fibrillation.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2003, Volume: 9, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Humans; Warfarin

2003
Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2003, Volume: 9, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Chronic Disease; Contraindications; Fe

2003
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis.
    Stroke, 2003, Volume: 34, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cohort Studies; Decision Su

2003
Aspirin for cardiovascular disease prevention.
    The Medical journal of Australia, 2003, Aug-04, Volume: 179, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Coronary Disease; Heart Valve Prosthesis; Humans; Myocardial Infarctio

2003
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic

2003
Atrial fibrillation and stroke prevention.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Thromboembolism; Warfarin

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
[How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
    Deutsche medizinische Wochenschrift (1946), 2003, Oct-17, Volume: 128, Issue:42

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemo

2003
[Adequate anticoagulation in atrial fibrillation].
    Der Internist, 2003, Volume: 44, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Humans; Intracranial E

2003
Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.
    Clinical cardiology, 2004, Volume: 27, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography; Female; Fibrinoly

2004
Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation.
    Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Long-Ter

2004
Ximelagatran or warfarin in atrial fibrillation?
    Lancet (London, England), 2004, Feb-28, Volume: 363, Issue:9410

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combination; H

2004
Ximelagatran or warfarin in atrial fibrillation?
    Lancet (London, England), 2004, Feb-28, Volume: 363, Issue:9410

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Humans; Randomized Controlle

2004
Community-based study of atrial fibrillation and stroke prevention.
    Irish medical journal, 2004, Volume: 97, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel;

2004
Consensus statement for the prevention of vascular disease.
    Australian family physician, 2004, Volume: 33, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Australia; Diabetes Complications; Diabetes Mellitus; Family Pra

2004
[Management of stroke in a ward of internal medicine. Limits and prospects].
    Recenti progressi in medicina, 2004, Volume: 95, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia;

2004
Anticoagulation in atrial fibrillation.
    Medicine and health, Rhode Island, 2004, Volume: 87, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Electric Countershock; Fibri

2004
Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients.
    International journal of cardiology, 2004, Volume: 96, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Femal

2004
[Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Aspirin].
    Kardiologiia, 2004, Volume: 44, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Warfarin

2004
Late incidence and determinants of stroke after aortic and mitral valve replacement.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral

2004
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
    Age and ageing, 2004, Volume: 33, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Fibrill

2004
Physicians' attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation.
    Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel;

2004
Ask the doctor. Does low-dose Coumadin plus aspirin prevent blood clots?
    Harvard heart letter : from Harvard Medical School, 2004, Volume: 15, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; International Norma

2004
Anticoagulation interruptus: not without risk.
    Circulation, 2004, Sep-21, Volume: 110, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri

2004
A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude to Health; Case-Control Studies; Female

2004
Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study).
    The American journal of cardiology, 2004, Oct-01, Volume: 94, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Gastrointestin

2004
Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation.
    Journal of the American College of Cardiology, 2004, Oct-19, Volume: 44, Issue:8

    Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug;

2004
[Stroke and other tromboembolic complications in atrial fibrillation. Part I. Prevalence and risk factors].
    Kardiologiia, 2004, Volume: 44, Issue:3

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Chronic Disease; Cros

2004
Anticoagulation to prevent strokes in older people with atrial fibrillation: assembling individualized risk and benefit information.
    Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:11

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Long-Term Care;

2004
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.
    Annals of internal medicine, 2004, Nov-16, Volume: 141, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Stu

2004
Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment.
    Age and ageing, 2005, Volume: 34, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Monitoring; Humans; Internatio

2005
Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.
    Age and ageing, 2005, Volume: 34, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death;

2005
[Primary prevention of thrombosis for patients with atrial fibrillation].
    Rinsho shinkeigaku = Clinical neurology, 2004, Volume: 44, Issue:11

    Topics: Aged; Aspirin; Atrial Fibrillation; Humans; Intracranial Thrombosis; Japan; Practice Guidelines as T

2004
Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR.
    American heart journal, 2005, Volume: 149, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clopidogrel; Drug

2005
[Secondary prevention of stroke].
    No to shinkei = Brain and nerve, 2004, Volume: 56, Issue:11

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Complications; Guideline Adherence; Humans; H

2004
[Stroke prevention in atrial fibrillation -- transfer of study results to the practice].
    Wiener klinische Wochenschrift, 2004, Dec-30, Volume: 116, Issue:24

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla

2004
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    JAMA, 2005, Feb-09, Volume: 293, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Chr

2005
Atrial fibrillation: when the heart loses its rhythm. You may not even feel it happening, but if the atria of the heart don't beat correctly you could be in danger of a stroke.
    Harvard health letter, 2005, Volume: 30, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Function, Left; Atrial Function, Right; Humans;

2005
Strategies for stroke prevention in atrial fibrillation.
    Heart rhythm, 2005, Volume: 2, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Balloon Occlusion; Electric Countershock; Heart Atria;

2005
Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke.
    The American journal of geriatric pharmacotherapy, 2004, Volume: 2, Issue:4

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Follow-Up S

2004
Choosing between warfarin (Coumadin) and aspirin therapy for patients with atrial fibrillation.
    American family physician, 2005, Jun-15, Volume: 71, Issue:12

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Female; Hu

2005
Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation.
    Journal of internal medicine, 2005, Volume: 258, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents;

2005
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
    Prescrire international, 2005, Volume: 14, Issue:78

    Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemo

2005
[Prophylaxis of stroke].
    Praxis, 2005, Jul-27, Volume: 94, Issue:30-31

    Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi

2005
Do complaints of amaurosis fugax and blurred vision after transcatheter device closure of atrial septal defect indicate microemboli to retinal vessels?
    International journal of cardiology, 2005, Sep-15, Volume: 104, Issue:1

    Topics: Adult; Aged; Amaurosis Fugax; Anticoagulants; Aspirin; Atrial Fibrillation; Catheters, Indwelling; E

2005
Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation.
    Pharmacotherapy, 2005, Volume: 25, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Aspirin; Atrial Fibrillation;

2005
Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study.
    Stroke, 2005, Volume: 36, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Pressur

2005
Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention.
    Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:11

    Topics: Aged; Aged, 80 and over; Algorithms; Aspirin; Atrial Fibrillation; Contraindications; Cooperative Be

2005
Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task.
    International journal of cardiology, 2006, Jun-16, Volume: 110, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Humans; Platelet Aggregation Inh

2006
Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?
    International journal of clinical practice, 2006, Volume: 60, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Thromboembolism; Warfarin

2006
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
    Medical science monitor : international medical journal of experimental and clinical research, 2006, Volume: 12, Issue:3

    Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibril

2006
Viewpoint.
    Circulation, 2006, Mar-07, Volume: 113, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Patient Participation; Premedication; Thrombos

2006
Low-dose aspirin for stroke prevention.
    Stroke, 2006, Volume: 37, Issue:6

    Topics: Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Platelet Aggregation Inhibit

2006
[Even in 60-year-old atrial fibrillation is not uncommon. Advances in long-term treatment].
    MMW Fortschritte der Medizin, 2006, Apr-13, Volume: 148, Issue:15

    Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillat

2006
Aspirin for prevention of stroke in atrial fibrillation.
    Stroke, 2006, Volume: 37, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Stroke; Throm

2006
[Comparative study of warfarin and aspirin for stroke prevention in elderly patients with atrial fibrillation].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2006, Volume: 26, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; China; Female; Humans; Male; Retrospective Studi

2006
Cardiology groups' antithrombotic guidelines challenge ACCP's.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Sep-15, Volume: 63, Issue:18

    Topics: Aspirin; Atrial Fibrillation; Cardiology; Fibrinolytic Agents; Patient Selection; Platelet Aggregati

2006
[Old patient with atrial fibrillation: do you too hesitate to use anticoagulants?].
    MMW Fortschritte der Medizin, 2006, Sep-21, Volume: 148, Issue:38

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla

2006
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    American heart journal, 2006, Volume: 152, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat

2006
Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
    Chest, 2006, Volume: 130, Issue:6

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2006
Prevention of vascular events in atrial fibrillation.
    Lancet (London, England), 2007, Jan-13, Volume: 369, Issue:9556

    Topics: Accidental Falls; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggreg

2007
Prevention of vascular events in atrial fibrillation.
    Lancet (London, England), 2007, Jan-13, Volume: 369, Issue:9556

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Pro

2007
New guidelines for atrial fibrillation focus on stroke risk.
    Heart advisor, 2006, Volume: 9, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Practice Guidelines as Topic; Risk Factor

2006
Platelet adhesion in atrial fibrillation.
    Thrombosis research, 2007, Volume: 120, Issue:4

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Case-Control Studies; Cross-Sectional Studies; Fema

2007
Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation.
    Age and ageing, 2007, Volume: 36, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fi

2007
Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Stroke, 2007, Volume: 38, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat

2007
Newly detected atrial fibrillation and compliance with antithrombotic guidelines.
    Archives of internal medicine, 2007, Feb-12, Volume: 167, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Agents;

2007
Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.
    Chest, 2007, Volume: 131, Issue:3

    Topics: Aged; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Blood Platelets; Cardiovascular Disea

2007
Atrial fibrillation in pregnancy.
    European journal of obstetrics, gynecology, and reproductive biology, 2008, Volume: 138, Issue:1

    Topics: Adult; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Electrocardiography; Female; Flecainide

2008
Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation?
    Stroke, 2007, Volume: 38, Issue:5

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug T

2007
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    Pharmacotherapy, 2007, Volume: 27, Issue:5

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio

2007
Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm.
    Journal of the American College of Cardiology, 2007, May-15, Volume: 49, Issue:19

    Topics: Aged; Anticoagulants; Antigens, CD; Aspirin; Atrial Fibrillation; Blood Platelets; Case-Control Stud

2007
Study suggests limiting use of aspirin plus warfarin.
    Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Drug Therapy, Combination; Humans; W

2007
National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing.
    British journal of clinical pharmacology, 2007, Volume: 64, Issue:5

    Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cyclooxygen

2007
Stroke prevention in atrial fibrillation--things can only get better.
    British journal of clinical pharmacology, 2007, Volume: 64, Issue:5

    Topics: Aged, 80 and over; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Platelet

2007
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
    Der Internist, 2007, Volume: 48, Issue:8

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny

2007
I've had atrial fibrillation without associated heart disease for 40 years. I'm unable to take Coumadin, so for many years I've taken one 325 mg aspirin daily for its anticoagulation effect. How do you compare aspirin's benefits with Coumadin's?
    DukeMedicine healthnews, 2007, Volume: 13, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Treatment Outcome; Warfarin

2007
Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction.
    International journal of cardiology, 2008, Sep-26, Volume: 129, Issue:2

    Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Atrial

2008
Stroke prevention in elderly patients with atrial fibrillation.
    Lancet (London, England), 2007, Aug-11, Volume: 370, Issue:9586

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi

2007
Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2007, Volume: 50, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Male; Middle Aged; Plat

2007
Polypharmacy as part of comprehensive geriatric assessment: disclosure of false diagnosis of atrial fibrillation by drug revision.
    Journal of the American Geriatrics Society, 2007, Volume: 55, Issue:9

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Artifacts; Aspirin; Atrial Fibrillation; Diagnostic Errors

2007
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
    Internal and emergency medicine, 2007, Volume: 2, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly

2007
Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation.
    Annals of internal medicine, 2007, Oct-16, Volume: 147, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans;

2007
[A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Follow-Up Stud

2007
Post-stenting antithrombotic drug therapy in patients with atrial fibrillation.
    The American journal of medicine, 2007, Volume: 120, Issue:11

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Humans; Practice Guidelines as Topic

2007
[When the thyroid gland causes arrhythmia].
    MMW Fortschritte der Medizin, 2007, Oct-04, Volume: 149, Issue:40

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Female; Humans; Hyperthyroidism; Male;

2007
[Anticoagulation treatment in real-life practice of patient with nonvalvular atrial fibrillation in Beijing city].
    Zhonghua yi xue za zhi, 2007, Sep-04, Volume: 87, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; China; Female; Humans;

2007
Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2008, Volume: 10, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Bias; Humans; In

2008
Distribution of etiologies in patients above and below age 45 with first-ever ischemic stroke.
    Acta neurologica Scandinavica, 2008, Volume: 117, Issue:5

    Topics: Adult; Age Distribution; Aging; Anticoagulants; Aspirin; Atrial Fibrillation; Embolism; Female; Fora

2008
Warfarin trumps aspirin for stroke prevention in elderly.
    Harvard heart letter : from Harvard Medical School, 2007, Volume: 18, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Warfarin

2007
[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation].
    Kardiologiia, 2007, Volume: 47, Issue:6

    Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Female; F

2007
"Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents.
    Journal of the American College of Cardiology, 2008, Feb-26, Volume: 51, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Pyridines

2008
Withholding warfarin therapy for atrial fibrillation patients in the perioperative period.
    Plastic and reconstructive surgery, 2008, Volume: 121, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Enoxaparin; Humans; Perioperative Care; Stroke;

2008
Did we really need another comparison of warfarin with aspirin? An assessment of the BAFTA trial.
    Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Humans; Platelet Aggregation

2007
The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited.
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Brain Ischemia; Cerebral He

2008
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
    European heart journal, 2008, Volume: 29, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electri

2008
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
    The American journal of cardiology, 2008, Apr-15, Volume: 101, Issue:8

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagu

2008
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
    JAMA, 1995, Dec-20, Volume: 274, Issue:23

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; California; Cerebrovascular Disorders; Cost-Bene

1995
Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions.
    The Western journal of medicine, 1995, Volume: 163, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

1995
Stroke prevention.
    Postgraduate medical journal, 1995, Volume: 71, Issue:834

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dementia, Vascular; Humans; Hypertens

1995
Anticoagulants for atrial fibrillation.
    Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged;

1993
Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation.
    Journal of the American College of Cardiology, 1993, Volume: 22, Issue:7

    Topics: Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Catheter Ablation; Cerebrovascular Disorders;

1993
Aspirin and prevention of stroke.
    Lancet (London, England), 1994, Jan-22, Volume: 343, Issue:8891

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Recurrence

1994
Aspirin and prevention of stroke.
    Lancet (London, England), 1994, Jan-22, Volume: 343, Issue:8891

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Monitoring; Humans; Pr

1994
Aspirin or warfarin for non-rheumatic atrial fibrillation?
    Lancet (London, England), 1994, Mar-19, Volume: 343, Issue:8899

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Warfarin

1994
Stroke Prevention in Atrial Fibrillation II Study.
    Lancet (London, England), 1994, Jun-11, Volume: 343, Issue:8911

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascular Disorders; Humans; Warfarin

1994
[Atrial fibrillation: anticoagulants or not?].
    Schweizerische medizinische Wochenschrift, 1994, Sep-03, Volume: 124, Issue:35

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Humans; Intracranial Embo

1994
Anticoagulation update.
    South Dakota journal of medicine, 1994, Volume: 47, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; H

1994
Atrial fibrillation and stroke. Revisiting the dilemmas.
    Stroke, 1994, Volume: 25, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To

1994
Aspirin in elderly atrial fibrillation patients.
    Stroke, 1994, Volume: 25, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male

1994
Left atrial thrombi despite anticoagulant and antiplatelet therapy.
    Clinical cardiology, 1994, Volume: 17, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Dilatation, Pathologic; Echocardiography; Echocardiography, Tran

1994
Warfarin in chronic atrial fibrillation.
    Lancet (London, England), 1993, May-29, Volume: 341, Issue:8857

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Humans; Thromboembolism; W

1993
Atrial fibrillation, stroke, and antithrombotic treatment.
    American heart journal, 1994, Volume: 127, Issue:4 Pt 1

    Topics: Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; M

1994
Survey of use of anticoagulation in patients with atrial fibrillation.
    BMJ (Clinical research ed.), 1993, Oct-23, Volume: 307, Issue:6911

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord

1993
Primary and secondary prevention of stroke in patients with nonrheumatic atrial fibrillation.
    European neurology, 1994, Volume: 34, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Intracranial

1994
Guidelines for medical treatment for stroke prevention. American College of Physicians.
    Annals of internal medicine, 1994, Jul-01, Volume: 121, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard

1994
Prompt i.v. anticoagulation of cerebral embolus based on clinical information alone: a case report.
    Connecticut medicine, 1993, Volume: 57, Issue:8

    Topics: Aged; Anticoagulants; Aphasia; Aspirin; Atrial Fibrillation; Female; Hemiplegia; Heparin; Humans; In

1993
Response to Dr. Arthur's Koffler's case report.
    Connecticut medicine, 1993, Volume: 57, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Intracranial Embolism and Thrombosis;

1993
[Isolated atrial fibrillation. Risk of embolism and its prevention].
    Presse medicale (Paris, France : 1983), 1993, Sep-18, Volume: 22, Issue:27

    Topics: Aged; Aspirin; Atrial Fibrillation; Humans; Intracranial Embolism and Thrombosis; Risk Factors; Warf

1993
Anticoagulation in patients with atrial fibrillation. No consensus among doctors.
    BMJ (Clinical research ed.), 1993, Dec-04, Volume: 307, Issue:6917

    Topics: Aspirin; Atrial Fibrillation; Family Practice; Humans; Retrospective Studies; Risk Factors; Thromboe

1993
Anticoagulation in patients with atrial fibrillation. Use of warfarin dependent on local services.
    BMJ (Clinical research ed.), 1993, Dec-04, Volume: 307, Issue:6917

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Family Practice; Health Promotion; Hu

1993
Anticoagulation in patients with atrial fibrillation. Atrial fibrillation associated with aging.
    BMJ (Clinical research ed.), 1993, Dec-04, Volume: 307, Issue:6917

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin

1993
Treatment of atrial fibrillation in a district general hospital.
    British heart journal, 1994, Volume: 71, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Digoxin; Echocardiography; Electric Co

1994
Anticoagulation for atrial fibrillation and stroke prevention.
    Neuroepidemiology, 1993, Volume: 12, Issue:5

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Denmark;

1993
Stroke and atrial fibrillation: to anticoagulate or not.
    Clinical cardiology, 1993, Volume: 16, Issue:7

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male; Randomized Cont

1993
Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators.
    Neurology, 1993, Volume: 43, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Male;

1993
Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation.
    JAMA, 1996, Mar-27, Volume: 275, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cost-Benefit Analysis; Huma

1996
Primary prevention of stroke.
    The New England journal of medicine, 1996, Apr-25, Volume: 334, Issue:17

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

1996
Prevention of cardioembolic stroke with anticoagulant therapy.
    Annals of neurology, 1996, Volume: 39, Issue:3

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascula

1996
Effects of aspirin on status of thrombin generation in atrial fibrillation.
    The American journal of cardiology, 1996, Mar-01, Volume: 77, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Platelets; Female; Fibrinolysis; Humans

1996
Is aspirin safe for patients with heart failure?
    Heart (British Cardiac Society), 1996, Volume: 75, Issue:2

    Topics: Aspirin; Atrial Fibrillation; Humans; Thrombolytic Therapy; Warfarin

1996
[Atrial fibrillation and apoplexy--risks and prevention].
    Nordisk medicin, 1996, Volume: 111, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Controlled Clinical T

1996
[Atrial fibrillation].
    Praxis, 1996, Apr-30, Volume: 85, Issue:18

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; E

1996
Cerebrovascular events in adult patients with cyanotic congenital heart disease.
    Journal of the American College of Cardiology, 1996, Volume: 28, Issue:3

    Topics: Adult; Aged; Anemia, Iron-Deficiency; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular

1996
Anticoagulation for cardioversion of atrial fibrillation.
    Archives of internal medicine, 1996, Sep-09, Volume: 156, Issue:16

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Heparin; Humans; M

1996
Atrial fibrillation and stroke prevention in the community.
    Age and ageing, 1996, Volume: 25, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications; Cr

1996
[Atrial fibrillation, carotid stenosis and stroke].
    Revista de neurologia, 1996, Volume: 24, Issue:125

    Topics: Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Cerebrovascular Disorders; Cyclooxygenase Inh

1996
Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.
    Archives of internal medicine, 1996, Nov-11, Volume: 156, Issue:20

    Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord

1996
An aggressive approach in converting resistant atrial fibrillation.
    American heart journal, 1996, Volume: 132, Issue:6

    Topics: Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock;

1996
Foundation project promotes stroke prevention.
    Journal of the Mississippi State Medical Association, 1997, Volume: 38, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Foundations; Humans; Male; Mi

1997
[Should every patient with atrial fibrillation get anticoagulants?].
    Praxis, 1997, Feb-11, Volume: 86, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Embolism; Humans; Middle Aged

1997
Therapeutic options in atrial flutter and fibrillation.
    Hospital practice (1995), 1997, May-15, Volume: 32, Issue:5

    Topics: Aged; Algorithms; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive

1997
Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals.
    Neurology, 1997, Volume: 48, Issue:6

    Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia

1997
[Recurrent infarct during aspirin therapy].
    Der Internist, 1997, Volume: 38, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Dose-Response Relationship, Drug;

1997
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
    Lancet (London, England), 1997, Aug-09, Volume: 350, Issue:9075

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Platelet

1997
From clinical trials to clinical practice: oral anticoagulation among patients with non-rheumatic, atrial fibrillation.
    European journal of clinical pharmacology, 1997, Volume: 53, Issue:1

    Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial

1997
Chronic atrial fibrillation: optimizing anticoagulation.
    QJM : monthly journal of the Association of Physicians, 1997, Volume: 90, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Humans; In

1997
Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe.
    Stroke, 1998, Volume: 29, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Endar

1998
Hypertrophic obstructive cardiomyopathy due to a novel T-to-A transition at codon 624 in the beta-myosin heavy chain (beta-MHC) gene possibly related to the sudden death.
    International journal of cardiology, 1997, Dec-19, Volume: 62, Issue:3

    Topics: Amyl Nitrite; Asparagine; Aspirin; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Codon; Death,

1997
ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. American Society of Health-System Pharmacists.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Feb-15, Volume: 55, Issue:4

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; C

1998
Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care.
    The American journal of cardiology, 1998, Mar-12, Volume: 81, Issue:5A

    Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cost-Benefit Analysi

1998
Anticoagulation for nonvalvular atrial fibrillation: effects of type of practice on physicians' self-reported behavior.
    The American journal of medicine, 1998, Volume: 104, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Baltimore; Drug Utilization; Humans; Maryland; Practic

1998
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
    Clinical therapeutics, 1998, Volume: 20 Suppl B

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa

1998
[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy].
    Journal of cardiology, 1998, Volume: 31, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dipyridamole; Female; Heart Diseases; Humans; Male; Mi

1998
[Atrial fibrillation and anticoagulant therapy].
    Ugeskrift for laeger, 1998, May-18, Volume: 160, Issue:21

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged;

1998
[Consensus on antithrombotic prophylaxis of vascular events in patients with manifested atherosclerotic vascular disease].
    Nederlands tijdschrift voor geneeskunde, 1998, Mar-28, Volume: 142, Issue:13

    Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cou

1998
Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation.
    Stroke, 1998, Volume: 29, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cohort Studies; Cost-

1998
Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators.
    Journal of the American College of Cardiology, 1998, Volume: 31, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Echocardiography, Trans

1998
Warfarin versus aspirin in paroxysmal atrial fibrillation.
    Journal of the American College of Cardiology, 1998, Volume: 31, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Humans; Platelet Activation; Platel

1998
Atrial fibrillation and anticoagulation in patients with permanent pacemakers: implications for stroke prevention.
    Pacing and clinical electrophysiology : PACE, 1998, Volume: 21, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Electrocardiography;

1998
[Anticoagulation and non-rheumatic auricular fibrillation].
    Atencion primaria, 1998, May-15, Volume: 21, Issue:8

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Humans; Mi

1998
Risk of stroke in patients with atrial fibrillation.
    The Journal of family practice, 1998, Volume: 47, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cohort Studies; Dose-

1998
Warfarin, aspirin, and atrial fibrillation.
    Harvard heart letter : from Harvard Medical School, 1998, Volume: 8, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

1998
Asymptomatic embolization in subjects with atrial fibrillation not taking anticoagulants: a prospective study.
    Stroke, 1998, Volume: 29, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography; Female; Hum

1998
Patients with atrial fibrillation at low risk of stroke.
    JAMA, 1998, Sep-09, Volume: 280, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Ri

1998
Patients with atrial fibrillation at low risk of stroke.
    JAMA, 1998, Sep-09, Volume: 280, Issue:10

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Ri

1998
[Atrial fibrillation of non-valvular origin and anti-coagulation: a promising opportunity for the prevention of cerebral infarct... if there is participation of those working in primary care].
    Revista de neurologia, 1998, Volume: 27, Issue:157

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Humans; Primary Health Care

1998
[Idiopathic atrial flutter].
    Deutsche medizinische Wochenschrift (1946), 1998, Oct-02, Volume: 123, Issue:40

    Topics: Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Atrial Flutter; Cerebrovascular Disorders; Hum

1998
Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation.
    American heart journal, 1999, Volume: 137, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications;

1999
Thromboprophylaxis for atrial fibrillation.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To

1999
Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin.
    Journal of the American Geriatrics Society, 1999, Volume: 47, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic

1999
Atrial fibrillation: prevalence and management in an acute general medical unit.
    Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation

1999
Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
    Annals of internal medicine, 1999, Apr-20, Volume: 130, Issue:8

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorder

1999
Finding what you seek: analyzing therapies for nonvalvular atrial fibrillation.
    Annals of internal medicine, 1999, Apr-20, Volume: 130, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Fibr

1999
[Anticoagulation in aged patients with chronic non-rheumatic atrial fibrillation].
    Medicina clinica, 1999, Mar-27, Volume: 112, Issue:11

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascul

1999
Warfarin vs aspirin and AFASAK 2.
    Archives of internal medicine, 1999, May-10, Volume: 159, Issue:9

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; F

1999
Alternate-day dosing of aspirin in atrial fibrillation: A critical evaluation.
    American heart journal, 1999, Volume: 138, Issue:1 Pt 1

    Topics: Aspirin; Atrial Fibrillation; Drug Administration Schedule; Fibrinolytic Agents; Humans; Platelet Ag

1999
Temporal trends in the use of anticoagulants among older adults with atrial fibrillation.
    Archives of internal medicine, 1999, Jul-26, Volume: 159, Issue:14

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy; Electro

1999
Antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls.
    The Journal of family practice, 1999, Volume: 48, Issue:7

    Topics: Accidental Falls; Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Support Te

1999
Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy?
    Journal of the American Geriatrics Society, 1999, Volume: 47, Issue:8

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; C

1999
Additional risk factors in atrial fibrillation patients not receiving warfarin.
    Age and ageing, 1999, Volume: 28, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dr

1999
Anticoagulation in atrial fibrillation in older people.
    Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications; Hu

1999
Atrial fibrillation: the epidemic of the new millennium.
    Annals of internal medicine, 1999, Oct-05, Volume: 131, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fibrinolytic Agents;

1999
[The thromboembolic risk of atrial fibrillation].
    Revue medicale de Bruxelles, 1999, Volume: 20, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coumarins; Echocardiography; Electric Countershock; He

1999
Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young.
    Heart (British Cardiac Society), 1999, Volume: 82, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Male; Risk Assessment; Stroke; W

1999
Use of antithrombotic measures for stroke prevention in atrial fibrillation.
    Heart (British Cardiac Society), 1999, Volume: 82, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Fibrinolytic

1999
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
    Stroke, 1999, Volume: 30, Issue:12

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Biomarkers; F

1999
Secular trends in the management of hypertension and atrial fibrillation in patients presenting with stroke.
    QJM : monthly journal of the Association of Physicians, 2000, Volume: 93, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillatio

2000
Aspirin for atrial fibrillation.
    The Journal of family practice, 2000, Volume: 49, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Humans; Middle Aged; Pa

2000
Preventing stroke in patients with atrial fibrillation.
    The Journal of family practice, 2000, Volume: 49, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Evidence-Based Medicine; Female; Humans; Male; P

2000
Re: The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3,575 hospitalized patients with atrial fibrillation. 1998;14:695-702.
    The Canadian journal of cardiology, 2000, Volume: 16, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Heart Diseases; Humans; Pra

2000
Evaluating quality of care for patients with heart failure.
    Circulation, 2000, Mar-28, Volume: 101, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin

2000
Risk stratification in the management of atrial fibrillation in the community.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 1999, Volume: 49, Issue:441

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Family Practice; Female; Fibrinolytic Agents;

1999
Underutilization of antithrombotic therapy in atrial fibrillation.
    Journal of the Royal Society of Medicine, 2000, Volume: 93, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Female; Fibrinolytic Ag

2000
Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction.
    The American journal of cardiology, 2000, Apr-15, Volume: 85, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Humans; Incidence; Intracranial Embolism

2000
Using anticoagulation or aspirin to prevent stroke. Aspirin is the logical choice for non-rheumatic atrial fibrillation.
    BMJ (Clinical research ed.), 2000, Apr-08, Volume: 320, Issue:7240

    Topics: Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Platelet Aggregation Inhibitors; Stroke

2000
[What anticoagulant therapy should be used for what form of atrial fibrillation?].
    Deutsche medizinische Wochenschrift (1946), 2000, Apr-20, Volume: 125 Suppl 1

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Controlled Clinical Trials as Topic

2000
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation.
    Annals of internal medicine, 2000, May-16, Volume: 132, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio

2000
Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease;

2000
Anticoagulation for chronic atrial fibrillation.
    JAMA, 2000, Jun-14, Volume: 283, Issue:22

    Topics: Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Echocardiography, T

2000
Non-rheumatic atrial fibrillation and stroke.
    Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Risk Assessment; Risk Factors; Stroke; Warfari

1999
Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
    Circulation, 2000, Jul-04, Volume: 102, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Fibrinolytic Agents; Heart Valve

2000
Antithrombotic therapy in atrial fibrillation.
    Journal of the Royal Society of Medicine, 2000, Volume: 93, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Protocols; Fibrinolytic Agents; Humans;

2000
Prescribing patterns for the use of antithrombotics in the management of atrial fibrillation in Zimbabwe.
    The Central African journal of medicine, 1999, Volume: 45, Issue:11

    Topics: Adult; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Fibrinolytic Agents; Humans; M

1999
Sex differences and similarities in the management and outcome of stroke patients.
    Stroke, 2000, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity;

2000
Ask the doctor. Recently I read that aspirin can actually increase a person's risk for a stroke by causing bleeding in the brain. I have atrial fibrillation and my doctor wants me to take a blood thinner - if not warfarin, then at least aspirin. I've alre
    Harvard heart letter : from Harvard Medical School, 2000, Volume: 11, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Humans; Platelet Aggregation Inhi

2000
Heparin versus aspirin in ischaemic stroke.
    Lancet (London, England), 2000, Aug-05, Volume: 356, Issue:9228

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Disease Progression; Fibrinolytic Agents; Heparin, Low

2000
Care is required with cost effectiveness approach.
    BMJ (Clinical research ed.), 2000, Aug-12, Volume: 321, Issue:7258

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Humans; Stroke

2000
Antiplatelet drugs in cardiovascular prevention: stroke: acute phase and secondary prevention.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Anticoagulants; Arrhythmia, Sinus; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Dipyridamole

2000
Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; E

2000
Which acute stroke patients with atrial fibrillation are prescribed warfarin therapy? Results from one-year's experience in Dundee.
    Scottish medical journal, 2000, Volume: 45, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Contraindications; Female; Hospitalization; H

2000
Implementation of antithrombotic management in atrial fibrillation.
    Postgraduate medical journal, 2000, Volume: 76, Issue:902

    Topics: Aged; Aged, 80 and over; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Fibrinoly

2000
Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy.
    Journal of general internal medicine, 2000, Volume: 15, Issue:10

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Humans; Multimedia; Plate

2000
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Feb-06, Volume: 164, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2001
Atrial fibrillation and anticoagulation.
    Medicine and health, Rhode Island, 2001, Volume: 84, Issue:3

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Drug Therapy,

2001
Prevention of cerebral thromboembolism by low-dose anticoagulant therapy in atrial fibrillation with mitral regurgitation.
    Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Circulation; Echocardiography; F

2001
Better stroke prevention.
    Health news (Waltham, Mass.), 2001, Volume: 7, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; Platelet Aggregatio

2001
By the way, doctor... Drugs for atrial fibrillation. I had atrial fibrillation and was zapped back into sinus rhythm several weeks ago. It seems like I'm going to have to take either aspirin or Coumadin. Which is better, and why?
    Harvard health letter, 2001, Volume: 26, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Warfarin

2001
Balancing risk in atrial fibrillation.
    The Practitioner, 2001, Volume: 245, Issue:1622

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Risk Factors; Thromboembolism; Warfarin

2001
Long term anticoagulation or antiplatelet treatment. Inclusion criteria determine results of review.
    BMJ (Clinical research ed.), 2001, Jul-28, Volume: 323, Issue:7306

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Meta-Analysis as Topic; Platelet Aggrega

2001
Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.
    BMJ (Clinical research ed.), 2001, Jul-28, Volume: 323, Issue:7306

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Meta-Analysis as Topic; Platelet Aggrega

2001
Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants;

2001
Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice.
    Internal medicine journal, 2001, Volume: 31, Issue:6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, Factual; Fema

2001
Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper.
    Quality in health care : QHC, 2001, Volume: 10 Suppl 1

    Topics: Aged; Anticoagulants; Aortic Valve Stenosis; Aspirin; Atrial Fibrillation; Communication; Decision M

2001
Atrial fibrillation and flutter: aeromedical considerations. New strategies for management and intervention.
    European heart journal supplements : journal of the European Society of Cardiology, 1999, Volume: 1 Suppl D

    Topics: Aerospace Medicine; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flu

1999
Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications.
    European heart journal, 2001, Volume: 22, Issue:20

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Defibrillators, Implantable; Echocardiogr

2001
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.
    BMJ (Clinical research ed.), 2001, Nov-24, Volume: 323, Issue:7323

    Topics: Adult; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Attitude of Health Personn

2001
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
    Stroke, 2001, Dec-01, Volume: 32, Issue:12

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation;

2001
[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
    Haematologica, 2001, Volume: 86, Issue:9 Suppl

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Diabetes

2001
Atrial fibrillation and anticoagulation.
    Medicine and health, Rhode Island, 2001, Volume: 84, Issue:12

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi

2001
Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation.
    Archives of internal medicine, 2002, Mar-11, Volume: 162, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Decisio

2002
Antiplatelet aggregating versus anticoagulant agents in preventing early recurrent stroke among patients with atrial fibrillation.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Dalteparin; Platelet Aggrega

2001
The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2002, Volume: 9, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Embolism; Hemorrha

2002
Thromboembolic complications after mitral valve replacement with Hancock xenograft.
    The Journal of thoracic and cardiovascular surgery, 1978, Volume: 75, Issue:5

    Topics: Adolescent; Adult; Aged; Animals; Aortic Valve; Aspirin; Atrial Fibrillation; Blood Vessel Prosthesi

1978
Does lone atrial fibrillation constitute a risk of embolization, and how should we manage it?
    Le Journal medical libanais. The Lebanese medical journal, 1992, Volume: 40, Issue:2

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Humans; Risk F

1992
[Drug treatments of atrial fibrillation].
    Archives des maladies du coeur et des vaisseaux, 1992, Volume: 85 Spec No 4

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; H

1992
Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction.
    Internal medicine (Tokyo, Japan), 1992, Volume: 31, Issue:6

    Topics: Adult; Aged; Arteriosclerosis; Aspirin; Atrial Fibrillation; Carotid Artery Diseases; Cerebral Infar

1992
Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1992, Volume: 3, Issue:4

    Topics: Aged; Antithrombin III; Aspirin; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Peptide Fra

1992
Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.
    BMJ (Clinical research ed.), 1992, Dec-12, Volume: 305, Issue:6867

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Co

1992
Anticoagulants for atrial fibrillation.
    The Medical journal of Australia, 1992, Jul-20, Volume: 157, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged;

1992
From the National Institutes of Health.
    JAMA, 1991, Dec-04, Volume: 266, Issue:21

    Topics: Acute Disease; Acyclovir; Administration, Oral; Antibodies, Viral; Aspirin; Atrial Fibrillation; Cer

1991
Stroke prevention in atrial fibrillation trial.
    Circulation, 1991, Volume: 84, Issue:2

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Research

1991
Atrial fibrillation and embolic stroke.
    Archives of internal medicine, 1991, Volume: 151, Issue:10

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dipyridamole; Embolism; Humans; Warfa

1991
Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation.
    Archives of internal medicine, 1991, Volume: 151, Issue:10

    Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Cerebrovascu

1991
[Anticoagulants in non-rheumatic atrium fibrillation].
    Nederlands tijdschrift voor geneeskunde, 1991, Nov-23, Volume: 135, Issue:47

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Humans; Male; Prospective Studies

1991
Atrial fibrillation--risk marker for stroke.
    The New England journal of medicine, 1990, Nov-29, Volume: 323, Issue:22

    Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged; Warfarin

1990
Prevention of stroke in atrial fibrillation.
    The New England journal of medicine, 1990, Aug-16, Volume: 323, Issue:7

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin

1990
[Atrial fibrillation: an indication to prevent stroke].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1989, Aug-10, Volume: 109, Issue:22

    Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin

1989
Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
    Lancet (London, England), 1986, Apr-05, Volume: 1, Issue:8484

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Atrial Fibrillatio

1986
Platelet aggregation behaviour in patients treated with ticlopidine.
    Drugs under experimental and clinical research, 1987, Volume: 13, Issue:1

    Topics: Adult; Aged; Aspirin; Atrial Fibrillation; Bleeding Time; Dipyridamole; Female; Humans; Male; Middle

1987
Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.
    Zeitschrift fur Kardiologie, 1986, Volume: 75 Suppl 2

    Topics: Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Bioprosthesis; Dipyridamole; Drug Therap

1986
Do all patients with mechanical heart valve prostheses need anticoagulant therapy?
    Zeitschrift fur Kardiologie, 1986, Volume: 75 Suppl 2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Bioprosthesis; Dipyridamole; Drug Therapy, Combination

1986
Hyperthyroid crisis.
    JAMA, 1974, Oct-28, Volume: 230, Issue:4

    Topics: Adrenal Cortex Hormones; Aspirin; Atrial Fibrillation; Diarrhea; Fever; Guanethidine; Humans; Iodide

1974
[Peptic ulcer hemorrhage due to anticoagulants].
    Deutsche medizinische Wochenschrift (1946), 1973, Sep-14, Volume: 98, Issue:37

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Transfusion; Coumarins; Digitalis Glycosides; Do

1973